<!DOCTYPE html>
<html lang="en" class="grade-c">
<head>
    <title>Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks | Nature Medicine</title>
    
        
<link rel="alternate" type="application/rss+xml" href="https://www.nature.com/nm.rss"/>


    
        

        <script id="save-data-connection-testing">
            function hasConnection() {
                return navigator.connection || navigator.mozConnection || navigator.webkitConnection || navigator.msConnection;
            }

            function createLink(src) {
                var preloadLink = document.createElement("link");
                preloadLink.rel = "preload";
                preloadLink.href = src;
                preloadLink.as = "font";
                preloadLink.type = "font/woff2";
                preloadLink.crossOrigin = "";
                document.head.insertBefore(preloadLink, document.head.firstChild);
            }

            var connectionDetail = {
                saveDataEnabled: false,
                slowConnection: false
            };

            var connection = hasConnection();
            if (connection) {
                connectionDetail.saveDataEnabled = connection.saveData;
                if (/\slow-2g|2g/.test(connection.effectiveType)) {
                    connectionDetail.slowConnection = true;
                }
            }

            if (!(connectionDetail.saveDataEnabled || connectionDetail.slowConnection)) {
                createLink("/static/fonts/HardingText-Regular-Web-cecd90984f.woff2");
            } else {
                document.documentElement.classList.add('save-data');
            }
        </script>
    

<link rel="preconnect" href="https://cmp.nature.com" crossorigin>

<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="applicable-device" content="pc,mobile">
<meta name="viewport" content="width=device-width,initial-scale=1.0,maximum-scale=5,user-scalable=yes">
<meta name="360-site-verification" content="5a2dc4ab3fcb9b0393241ffbbb490480" />

<script data-test="dataLayer">
    window.dataLayer = [{"content":{"category":{"contentType":"article","legacy":{"webtrendsPrimaryArticleType":"research","webtrendsSubjectTerms":"alzheimers-disease","webtrendsContentCategory":null,"webtrendsContentCollection":null,"webtrendsContentGroup":"Nature Medicine","webtrendsContentGroupType":null,"webtrendsContentSubGroup":"Article","status":null}},"article":{"doi":"10.1038/s41591-026-04206-y"},"attributes":{"cms":null,"deliveryPlatform":"oscar","copyright":{"open":true,"legacy":{"webtrendsLicenceType":"http://creativecommons.org/licenses/by/4.0/"}}},"contentInfo":{"authors":["Kellen K. Petersen","Marta Milà-Alomà","Yan Li","Lianlian Du","Chengjie Xiong","Duygu Tosun","Benjamin Saef","Ziad S. Saad","Lei Du-Cuny","Janaky Coomaraswamy","Yulia Mordashova","Carrie E. Rubel","Emily A. Meyers","Leslie M. Shaw","Jeffrey L. Dage","Nicholas J. Ashton","Henrik Zetterberg","Kyle Ferber","Gallen Triana-Baltzer","Michael Baratta","Erin G. Rosenbaugh","Carlos Cruchaga","Eric McDade","David M. Holtzman","John C. Morris","J. Martin Sabandal","Randall J. Bateman","Anthony W. Bannon","William Z. Potter","Suzanne E. Schindler"],"publishedAt":1771459200,"publishedAtString":"2026-02-19","title":"Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks","legacy":null,"publishedAtTime":null,"documentType":"aplusplus","subjects":"Alzheimer's disease"},"journal":{"pcode":"nm","title":"nature medicine","volume":null,"issue":null,"id":41591,"publishingModel":"Hybrid Access"},"authorization":{"status":true},"features":[{"name":"furtherReadingSection","present":true}],"collection":null},"page":{"category":{"pageType":"article"},"attributes":{"template":"mosaic","featureFlags":[{"name":"download-collection-test","active":false},{"name":"download-issue-test","active":false},{"name":"nature-onwards-journey","active":false}],"testGroup":null},"search":null},"privacy":{},"version":"1.0.0","product":null,"session":null,"user":null,"backHalfContent":true,"country":"IT","hasBody":true,"uneditedManuscript":false,"twitterId":["o3xnx","o43y9","o3ef7"],"baiduId":"d38bce82bcb44717ccc29a90c4b781ea","japan":false}];
    window.dataLayer.push({
        ga4MeasurementId: 'G-ERRNTNZ807',
        ga360TrackingId: 'UA-71668177-1',
        twitterId: ['3xnx', 'o43y9', 'o3ef7'],
        baiduId: 'd38bce82bcb44717ccc29a90c4b781ea',
        ga4ServerUrl: 'https://sgtm.nature.com',
        imprint: 'nature'
    });
</script>


<script>
    (function(w, d) {
        w.config = w.config || {};
        w.config.mustardcut = false;

        
        if (w.matchMedia && w.matchMedia('only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)').matches) {
            w.config.mustardcut = true;
            d.classList.add('js');
            d.classList.remove('grade-c');
            d.classList.remove('no-js');
        }
    })(window, document.documentElement);
</script>
 



     
    
    
        
    
    <style>@media only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark) {  .c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card--major .c-card__title,.c-card__title,.u-h2,.u-h3,h2,h3{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,.u-h3,h3{font-size:min(max(1.125rem,3vw),1.25rem);line-height:1.4rem}.c-reading-companion__figure-title,.u-h4{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}html{line-height:1.15;text-size-adjust:100%;box-sizing:border-box;font-size:100%;height:100%;overflow-y:scroll}body{background:#eee;color:#222;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;line-height:1.76;margin:0;min-height:100%}details,main{display:block}h1{font-size:2em;margin:.67em 0}a,sup{vertical-align:baseline}a{background-color:transparent;color:#069;overflow-wrap:break-word;text-decoration:underline .0625rem;text-decoration-skip-ink:auto;text-underline-offset:.08em;word-break:break-word}b{font-weight:bolder}sup{font-size:75%;line-height:0;position:relative;top:-.5em}img{border:0;height:auto;max-width:100%;vertical-align:middle}button,input,select{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=submit],button{appearance:button}[type=checkbox]{box-sizing:border-box;padding:0}summary{display:list-item}[hidden]{display:none}button{border-radius:0;cursor:pointer;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}h1{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;font-size:min(max(1.5rem,4vw),2rem);letter-spacing:min(max(-.0117156rem,4vw),-.0390625rem);line-height:min(max(1.6rem,4vw),2.25rem)}.c-card--major .c-card__title,.u-h2,.u-h3,h2{font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-card--major .c-card__title,.u-h2,h2,h2.app-access-wall__title{-webkit-font-smoothing:antialiased}.c-card--major .c-card__title,.u-h2,h2{font-size:min(max(1.25rem,3.5vw),1.5rem);font-weight:700;line-height:min(max(1.4rem,3.5vw),1.6rem)}.u-h3{font-size:min(max(1.125rem,3vw),1.25rem)}.c-card__title,.c-reading-companion__figure-title,.u-h3,.u-h4,h4,h5,h6{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,h3{font-family:Harding,Palatino,serif;font-size:min(max(1.125rem,3vw),1.25rem)}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,h3{font-weight:700;-webkit-font-smoothing:antialiased;letter-spacing:-.0117156rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:min(max(1rem,2.5vw),1.125rem);letter-spacing:-.0117156rem}input+label{padding-left:.5em}nav ol,nav ul{list-style:none none}p:empty{display:none}.app-cta-group{display:flex;flex-direction:column;gap:0 16px;width:100%}@media only screen and (min-width:540px){.app-cta-group{align-items:baseline;flex-direction:row}}.app-cta-group>*{flex:1 1 auto}@media only screen and (min-width:540px){.app-cta-group>*{flex:0 1 auto}}.c-nature-box{background-color:#fff;border:1px solid #d5d5d5;border-radius:2px;box-shadow:0 0 5px 0 rgba(51,51,51,.1);line-height:1.3;margin-bottom:24px;padding:16px 16px 3px}.c-nature-box__text{font-size:1rem;margin-bottom:16px}.c-nature-box--access-to-pdf{display:none}@media only screen and (min-width:1024px){.c-nature-box--mobile{display:none}}.c-nature-box .c-pdf-download{margin-bottom:16px!important}.c-nature-box svg+.c-article__button-text{margin-left:8px}.c-nature-box--version{background-color:#eee}.c-nature-box__wrapper{transform:translateZ(0)}.c-nature-box__wrapper--placeholder{min-height:165px}.sans-serif{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.article-page{background:#fff}p{overflow-wrap:break-word;word-break:break-word}.c-article-header{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;margin-bottom:40px}.c-article-identifiers{color:#6f6f6f;display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3;list-style:none;padding:0}.c-article-identifiers__item{list-style:none;margin-right:8px;padding-right:8px}.c-article-identifiers__item:last-child{margin-right:0;padding-right:0}.c-article-title{font-size:1.5rem;line-height:1.25;margin:0 0 16px}@media only screen and (min-width:768px){.c-article-title{font-size:1.875rem;line-height:1.2}}.c-article-author-list{display:inline;font-size:1rem;list-style:none;margin:0 8px 0 0;padding:0;width:100%}.c-article-author-list__item{display:inline;padding-right:0}.c-article-author-list svg{margin-left:4px}.c-article-author-list__show-more{display:none;margin-right:4px}.c-article-author-list__button,.js .c-article-author-list__item--hide,.js .c-article-author-list__show-more{display:none}.js .c-article-author-list--long .c-article-author-list__show-more,.js .c-article-author-list--long+.c-article-author-list__button{display:inline}@media only screen and (max-width:539px){.js .c-article-author-list__item--hide-small-screen{display:none}.js .c-article-author-list--short .c-article-author-list__show-more,.js .c-article-author-list--short+.c-article-author-list__button{display:inline}}#uptodate-client,.js .c-article-author-list--expanded .c-article-author-list__show-more{display:none!important}.js .c-article-author-list--expanded .c-article-author-list__item--hide-small-screen{display:inline!important}.c-article-author-list__button,.c-button-author-list{background:#ebf1f5;border:4px solid #ebf1f5;border-radius:20px;color:#666;font-size:.875rem;line-height:1.4;padding:2px 11px 2px 8px;text-decoration:none}.c-article-author-list__button svg,.c-button-author-list svg{margin:1px 4px 0 0}.c-article-author-list__button:hover,.c-button-author-list:hover{background:#069;border-color:transparent;color:#fff}.c-article-info-details{font-size:1rem;margin-bottom:8px;margin-top:16px}.c-article-info-details__cite-as{border-left:1px solid #6f6f6f;margin-left:8px;padding-left:8px}.c-article-metrics-bar{display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3}.c-article-metrics-bar__wrapper{margin:16px 0}.c-article-metrics-bar__item{align-items:baseline;border-right:1px solid #6f6f6f;margin-right:8px}.c-article-metrics-bar__item:last-child{border-right:0}.c-article-metrics-bar__count{font-weight:700;margin:0}.c-article-metrics-bar__label{color:#626262;font-style:normal;font-weight:400;margin:0 10px 0 5px}.c-article-metrics-bar__details{margin:0}.c-article-main-column{font-family:Harding,Palatino,serif;margin-right:8.6%;width:60.2%}@media only screen and (max-width:1023px){.c-article-main-column{margin-right:0;width:100%}}.c-article-extras{float:left;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;width:31.2%}@media only screen and (max-width:1023px){.c-article-extras{display:none}}.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{border-bottom:2px solid #d5d5d5;font-size:1.25rem;margin:0;padding-bottom:8px}@media only screen and (min-width:768px){.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{font-size:1.5rem;line-height:1.24}}.c-article-associated-content__container .c-article-associated-content__title{margin-bottom:8px}.c-article-body p{margin-bottom:24px;margin-top:0}.c-article-section{clear:both}.c-article-section__content{margin-bottom:40px;padding-top:8px}@media only screen and (max-width:1023px){.c-article-section__content{padding-left:0}}.c-article-authors-search{margin-bottom:24px;margin-top:0}.c-article-authors-search__item,.c-article-authors-search__title{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.c-article-authors-search__title{color:#626262;font-size:1.05rem;font-weight:700;margin:0;padding:0}.c-article-authors-search__item{font-size:1rem}.c-article-authors-search__text{margin:0}.c-code-block{border:1px solid #fff;font-family:monospace;margin:0 0 24px;padding:20px}.c-code-block__heading{font-weight:400;margin-bottom:16px}.c-code-block__line{display:block;overflow-wrap:break-word;white-space:pre-wrap}.c-article-share-box__no-sharelink-info{font-size:.813rem;font-weight:700;margin-bottom:24px;padding-top:4px}.c-article-share-box__only-read-input{border:1px solid #d5d5d5;box-sizing:content-box;display:inline-block;font-size:.875rem;font-weight:700;height:24px;margin-bottom:8px;padding:8px 10px}.c-article-share-box__button--link-like{background-color:transparent;border:0;color:#069;cursor:pointer;font-size:.875rem;margin-bottom:8px;margin-left:10px}.c-article-editorial-summary__container{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem}.c-article-editorial-summary__container .c-article-editorial-summary__content p:last-child{margin-bottom:0}.c-article-editorial-summary__container .c-article-editorial-summary__content--less{max-height:9.5rem;overflow:hidden}.c-article-editorial-summary__container .c-article-editorial-summary__button.active,.c-article-editorial-summary__container .c-article-editorial-summary__button.hover,.c-article-editorial-summary__container .c-article-editorial-summary__button:active,.c-article-editorial-summary__container .c-article-editorial-summary__button:hover{text-decoration:underline;text-decoration-skip-ink:auto}.c-article-editorial-summary__container .c-article-editorial-summary__button{background-color:#fff;border:0;color:#069;font-size:.875rem;margin-bottom:16px}.c-article-associated-content__container .c-article-associated-content__collection-label{font-size:.875rem;line-height:1.4}.c-article-associated-content__container .c-article-associated-content__collection-title{line-height:1.3}.c-reading-companion{clear:both;min-height:389px}.c-reading-companion__sticky{max-width:389px}.c-reading-companion__scroll-pane{margin:0;min-height:200px;overflow:hidden auto}.c-reading-companion__tabs{display:flex;flex-flow:row;font-size:1rem;list-style:none;margin:0 0 8px;padding:0}.c-reading-companion__tabs>li{flex-grow:1}.c-reading-companion__tab{background-color:#eee;border:1px solid #d5d5d5;border-image:initial;border-left-width:0;color:#0067c5;font-size:1rem;padding:8px 8px 8px 15px;text-align:left;width:100%}.c-reading-companion__tabs li:first-child .c-reading-companion__tab{border-left-width:1px}.c-reading-companion__tab--active{background-color:#fff;border-bottom:1px solid #fff;color:#222;font-weight:700}.c-reading-companion__sections-list{list-style:none;padding:0}.c-reading-companion__figures-list,.c-reading-companion__references-list{list-style:none;min-height:389px;padding:0}.c-reading-companion__references-list--numeric{list-style:decimal inside}.c-reading-companion__sections-list{margin:0 0 8px;min-height:50px}.c-reading-companion__section-item{font-size:1rem;padding:0}.c-reading-companion__section-item a{display:block;line-height:1.5;overflow:hidden;padding:8px 0 8px 16px;text-overflow:ellipsis;white-space:nowrap}.c-reading-companion__figure-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:16px 8px 16px 0}.c-reading-companion__figure-item:first-child{border-top:none;padding-top:8px}.c-reading-companion__reference-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:8px 8px 8px 16px}.c-reading-companion__reference-item:first-child{border-top:none}.c-reading-companion__reference-item a{word-break:break-word}.c-reading-companion__reference-citation{display:inline}.c-reading-companion__reference-links{font-size:.813rem;font-weight:700;list-style:none;margin:8px 0 0;padding:0;text-align:right}.c-reading-companion__reference-links>a{display:inline-block;padding-left:8px}.c-reading-companion__reference-links>a:first-child{display:inline-block;padding-left:0}.c-reading-companion__figure-title{display:block;margin:0 0 8px}.c-reading-companion__figure-links{display:flex;justify-content:space-between;margin:8px 0 0}.c-reading-companion__figure-links>a{align-items:center;display:flex}.c-reading-companion__figure-full-link svg{height:.8em;margin-left:2px}.c-reading-companion__panel{border-top:none;display:none;margin-top:0;padding-top:0}.c-cod,.c-reading-companion__panel--active{display:block}.c-cod{font-size:1rem;width:100%}.c-cod__form{background:#ebf0f3}.c-cod__prompt{font-size:1.125rem;line-height:1.3;margin:0 0 24px}.c-cod__label{display:block;margin:0 0 4px}.c-cod__row{display:flex;margin:0 0 16px}.c-cod__row:last-child{margin:0}.c-cod__input{border:1px solid #d5d5d5;border-radius:2px;flex:1 1 auto;margin:0;padding:13px}.c-cod__input--submit{background-color:#069;border:1px solid #069;color:#fff;flex-shrink:1;margin-left:8px;transition:background-color .2s ease-out,color .2s ease-out}.c-cod__input--submit-single{flex-basis:100%;flex-shrink:0;margin:0}.c-cod__input--submit:focus,.c-cod__input--submit:hover{background-color:#fff;color:#069}.c-pdf-download__link .u-icon{padding-top:2px}.c-pdf-download{display:flex;margin-bottom:24px;max-height:48px}@media only screen and (min-width:540px){.c-pdf-download{max-height:none}}@media only screen and (min-width:1024px){.c-pdf-download{max-height:48px}}.c-pdf-download__link{display:flex;flex:1 1 0%}.c-pdf-download__link:hover{text-decoration:none}.c-pdf-download__text{padding-right:4px}@media only screen and (max-width:539px){.c-pdf-download__text{text-transform:capitalize}}@media only screen and (min-width:540px){.c-pdf-download__text{padding-right:8px}}.c-context-bar--sticky .c-pdf-download{display:block;margin-bottom:0;white-space:nowrap}@media only screen and (max-width:539px){.c-pdf-download .u-sticky-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}}.c-pdf-container{display:flex;justify-content:flex-end}@media only screen and (max-width:539px){.c-pdf-container .c-pdf-download{display:flex;flex-basis:100%}}.c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:16px}.c-article-extras .c-pdf-container .c-pdf-download{width:100%}.c-article-extras .c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:0}@media only screen and (min-width:540px){.c-context-bar--sticky .c-pdf-download__link{align-items:center;flex:1 1 183px}}@media only screen and (max-width:320px){.c-context-bar--sticky .c-pdf-download__link{padding:16px}}.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:none}@media only screen and (max-width:1023px){.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:block}}.c-recommendations-column-switch .c-meta{margin-top:auto}.c-context-bar{box-shadow:0 0 10px 0 rgba(51,51,51,.2);position:relative;width:100%}.c-context-bar__container{margin:0 auto;max-width:1280px;padding:0 16px}.c-context-bar__title{display:none}.app-researcher-popup__link.hover,.app-researcher-popup__link.visited,.app-researcher-popup__link:hover,.app-researcher-popup__link:visited,.c-article-metrics__heading a,.c-article-metrics__posts .c-card__title a{color:inherit}.c-article-authors-search__list{align-items:center;display:flex;flex-wrap:wrap;gap:16px;justify-content:center}@media only screen and (min-width:320px){.c-article-authors-search__list{justify-content:normal}}.c-article-authors-search__text{align-items:center;display:flex;flex-flow:column wrap;font-size:14px;justify-content:center}@media only screen and (min-width:320px){.c-article-authors-search__text{flex-direction:row;font-size:16px}}.c-article-authors-search__links-text{font-weight:700;margin-right:8px;text-align:center}@media only screen and (min-width:320px){.c-article-authors-search__links-text{text-align:left}}.c-article-authors-search__list-item--left{flex:1 1 100%}@media only screen and (min-width:320px){.c-article-authors-search__list-item--left{flex-basis:auto}}.c-article-authors-search__list-item--right{flex:1 1 auto}.c-article-identifiers{margin:0}.c-article-identifiers__item{border-right:2px solid #cedbe0;color:#222;font-size:14px}@media only screen and (min-width:320px){.c-article-identifiers__item{font-size:16px}}.c-article-identifiers__item:last-child{border-right:none}.c-article-metrics__posts .c-card__title{font-size:1.05rem}.c-article-metrics__posts .c-card__title+span{color:#6f6f6f;font-size:1rem}.app-author-list{color:#222;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;line-height:1.4;list-style:none;margin:0;padding:0}.app-author-list>li,.c-breadcrumbs>li,.c-footer__links>li,.js .app-author-list,.u-list-comma-separated>li,.u-list-inline>li{display:inline}.app-author-list>li:not(:first-child):not(:last-child):before{content:", "}.app-author-list>li:not(:only-child):last-child:before{content:" & "}.app-author-list--compact{font-size:.875rem;line-height:1.4}.app-author-list--truncated>li:not(:only-child):last-child:before{content:" ... "}.js .app-author-list__hide{display:none;visibility:hidden}.js .app-author-list__hide:first-child+*{margin-block-start:0}.c-ad{text-align:center}@media only screen and (min-width:320px){.c-ad{padding:8px}}.c-ad--728x90{background-color:#ccc;display:none}.c-ad--728x90 .c-ad__inner{min-height:calc(1.5em + 94px)}@media only screen and (min-width:768px){.js .c-ad--728x90{display:none}.js .u-show-following-ad+.c-ad--728x90{display:block}}.c-ad__label{color:#333;font-weight:400;line-height:1.5;margin-bottom:4px}.c-ad__label,.c-meta{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem}.c-meta{color:inherit;line-height:1.4;list-style:none;margin:0;padding:0}.c-meta--large{font-size:1rem}.c-meta--large .c-meta__item{margin-bottom:8px}.c-meta__item{display:inline-block;margin-bottom:4px}.c-meta__item:not(:last-child){border-right:1px solid #d5d5d5;margin-right:4px;padding-right:4px}@media only screen and (max-width:539px){.c-meta__item--block-sm-max{display:block}.c-meta__item--block-sm-max:not(:last-child){border-right:none;margin-right:0;padding-right:0}}@media only screen and (min-width:1024px){.c-meta__item--block-at-lg{display:block}.c-meta__item--block-at-lg:not(:last-child){border-right:none;margin-right:0;padding-right:0}}.c-meta__type{font-weight:700;text-transform:none}.c-skip-link{background:#069;color:#fff;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;inset:0 0 auto;padding:8px;position:absolute;text-align:center;transform:translateY(-100%);z-index:9999}@media (prefers-reduced-motion:reduce){.c-skip-link{transition:top .3s ease-in-out}}@media print{.c-skip-link{display:none}}.c-skip-link:link{color:#fff}.c-status-message{align-items:center;box-sizing:border-box;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;position:relative;width:100%}.c-card__summary>p:last-child,.c-status-message :last-child{margin-bottom:0}.c-status-message--boxed{background-color:#fff;border:1px solid #eee;border-radius:2px;line-height:1.4;padding:16px}.c-status-message__heading{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;font-weight:700}.c-status-message__icon{display:inline-block;fill:currentcolor;flex:0 0 auto;height:1.5em;margin-right:8px;transform:translate(0);vertical-align:text-top;width:1.5em}.c-status-message__icon--top{align-self:flex-start}.c-status-message--info .c-status-message__icon{color:#003f8d}.c-status-message--boxed.c-status-message--info{border-bottom:4px solid #003f8d}.c-status-message--error .c-status-message__icon{color:#c40606}.c-status-message--boxed.c-status-message--error{border-bottom:4px solid #c40606}.c-status-message--success .c-status-message__icon{color:#00b8b0}.c-status-message--boxed.c-status-message--success{border-bottom:4px solid #00b8b0}.c-status-message--warning .c-status-message__icon{color:#edbc53}.c-status-message--boxed.c-status-message--warning{border-bottom:4px solid #edbc53}.c-breadcrumbs{color:#000;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;list-style:none;margin:0;padding:0}.c-breadcrumbs__link{color:#666}svg.c-breadcrumbs__chevron{fill:#888;height:10px;margin:4px 4px 0;width:10px}@media only screen and (max-width:539px){.c-breadcrumbs .c-breadcrumbs__item{display:none}.c-breadcrumbs .c-breadcrumbs__item:last-child,.c-breadcrumbs .c-breadcrumbs__item:nth-last-child(2){display:inline}}.c-card{background-color:transparent;border:0;box-shadow:none;display:flex;flex-direction:column;font-size:14px;min-width:0;overflow:hidden;padding:0;position:relative}.c-card--no-shape{background:0 0;border:0;box-shadow:none}.c-card__image{display:flex;justify-content:center;overflow:hidden;padding-bottom:56.25%;position:relative}@supports (aspect-ratio:1/1){.c-card__image{aspect-ratio:var(--card--image-aspect-ratio,16/9);padding-bottom:0}}.c-card__image img{left:0;min-height:100%;min-width:100%;position:absolute}@supports ((-o-object-fit:cover) or (object-fit:cover)){.c-card__image img{height:100%;object-fit:cover;width:100%}}.c-card__body{flex:1 1 auto;padding:16px}.c-card--no-shape .c-card__body{padding:0}.c-card--no-shape .c-card__body:not(:first-child){padding-top:16px}.c-card__title{letter-spacing:-.01875rem;margin-bottom:8px;margin-top:0}[lang=de] .c-card__title{hyphens:auto}.c-card__summary{line-height:1.4}.c-card__summary>p{margin-bottom:5px}.c-card__summary a{text-decoration:underline}.c-card__link:not(.c-card__link--no-block-link):before{content:"";inset:0;position:absolute}.c-card--flush .c-card__body{padding:0}.c-card--major{font-size:1rem}.c-card--dark{background-color:#29303c;border-width:0;color:#e3e4e5}.c-card--dark .c-card__title{color:#fff}.c-card--dark .c-card__link,.c-card--dark .c-card__summary a{color:inherit}.c-header{background-color:#fff;border-bottom:5px solid #000;font-size:1rem;line-height:1.4;margin-bottom:16px}.c-header__row{padding:0;position:relative}.c-header__row:not(:last-child){border-bottom:1px solid #eee}.c-header__split{align-items:center;display:flex;justify-content:space-between}.c-header__logo-container{flex:1 1 0px;line-height:0;margin:8px 24px 8px 0}.c-header__logo{transform:translateZ(0)}.c-header__logo img{max-height:32px}.c-header__container{margin:0 auto;max-width:1280px}@media print{.c-header__menu{display:none}}.c-header__menu{align-items:center;display:flex;flex:0 1 auto;flex-wrap:wrap;font-weight:700;gap:8px;line-height:1.4;list-style:none;margin:0 -4px;padding:0}@media only screen and (max-width:1023px){.c-header__menu--hide-lg-max{display:none;visibility:hidden}}.c-header__menu--global{font-weight:400;justify-content:flex-end}.c-header__menu--global svg{display:none;visibility:hidden}.c-header__menu--global svg:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__menu--global svg{display:block;visibility:visible}}.c-header__menu--journal{font-size:.875rem;margin:8px 0 8px -8px}@media only screen and (min-width:540px){.c-header__menu--journal{flex-wrap:nowrap;font-size:1rem}}.c-header__item{padding-bottom:0;padding-top:0;position:static}.c-header__item--pipe{border-left:2px solid #eee;padding-left:8px}.c-header__item--padding{padding-bottom:8px;padding-top:8px}@media only screen and (min-width:540px){.c-header__item--dropdown-menu{position:relative}}@media only screen and (min-width:1024px){.c-header__item--hide-lg{display:none;visibility:hidden}}@media only screen and (max-width:767px){.c-header__item--hide-md-max{display:none;visibility:hidden}.c-header__item--hide-md-max:first-child+*{margin-block-start:0}}.c-header__link{align-items:center;color:inherit;display:inline-flex;gap:4px;padding:8px;white-space:nowrap}.c-header__link svg{transition-duration:.2s}.c-header__show-text{display:none;visibility:hidden}.has-tethered .c-header__heading--js-hide:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__show-text{display:inline;visibility:visible}}.c-header__show-text-sm{display:inline;visibility:visible}@media only screen and (min-width:540px){.c-header__show-text-sm{display:none;visibility:hidden}.c-header__show-text-sm:first-child+*{margin-block-start:0}}@media print{.c-header__dropdown{display:none}}.c-header__dropdown{background-color:#000;border-bottom:1px solid #2f2f2f;color:#eee;font-size:.875rem;line-height:1.2;padding:16px 0}.c-header__heading{display:inline-block;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.25rem;font-weight:400;line-height:1.4;margin-bottom:8px}.c-header__heading--keyline{border-top:1px solid;border-color:#2f2f2f;margin-top:16px;padding-top:16px;width:100%}.c-header__list{display:flex;flex-wrap:wrap;gap:0 16px;list-style:none;margin:0 -8px}.c-header__flush{margin:0 -8px}.c-header__visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.c-header__search-form{margin-bottom:8px}.c-header__search-layout{display:flex;flex-wrap:wrap;gap:16px}.c-header__search-layout>:first-child{flex:999 1 auto}.c-header__search-layout>*{flex:1 1 auto}.c-header__search-layout--max-width{max-width:720px}.c-header__search-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #fff;border-radius:2px;color:#fff;cursor:pointer;display:flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.15;margin:0;padding:8px 16px;position:relative;text-decoration:none;transition:.25s,color .25s,border-color .25s;width:100%}.c-header__input,.c-header__select{border:1px solid;border-radius:3px;box-sizing:border-box;font-size:1rem;padding:8px 16px;width:100%}.c-header__select{appearance:none;background-image:url("data:image/svg+xml,%3Csvg height='16' viewBox='0 0 16 16' width='16' xmlns='http://www.w3.org/2000/svg'%3E%3Cpath d='m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z' fill='%23333' fill-rule='evenodd' transform='matrix(0 1 -1 0 11 3)'/%3E%3C/svg%3E");background-position:right .7em top 50%;background-repeat:no-repeat;background-size:1em;box-shadow:0 1px 0 1px rgba(0,0,0,.04);display:block;margin:0;max-width:100%;min-width:150px}@media only screen and (min-width:540px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:auto;right:0}}@media only screen and (min-width:768px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:0;right:auto}}.c-header__dropdown.has-tethered{border-bottom:0;border-radius:0 0 2px 2px;left:0;position:absolute;top:100%;transform:translateY(5px);width:100%;z-index:1}@media only screen and (min-width:540px){.c-header__dropdown.has-tethered{transform:translateY(8px);width:auto}}@media only screen and (min-width:768px){.c-header__dropdown.has-tethered{min-width:225px}}.c-header__dropdown--full-width.has-tethered{padding:32px 0 24px;transform:none;width:100%}.has-tethered .c-header__heading--js-hide{display:none;visibility:hidden}.has-tethered .c-header__list--js-stack{flex-direction:column}.has-tethered .c-header__item--keyline,.has-tethered .c-header__list~.c-header__list .c-header__item:first-child{border-top:1px solid #d5d5d5;margin-top:8px;padding-top:8px}.c-header__item--snid-account-widget{display:flex}.c-header__container{padding:0 4px}.c-header__list{padding:0 12px}.c-header__menu .c-header__link{font-size:14px}.c-header__item--snid-account-widget .c-header__link{padding:8px}.c-header__menu--journal{margin-left:0}@media only screen and (min-width:540px){.c-header__container{padding:0 16px}.c-header__menu--journal{margin-left:-8px}.c-header__menu .c-header__link{font-size:16px}.c-header__link--search{gap:13px}}.u-button{align-items:center;background-color:transparent;background-image:none;border-radius:2px;cursor:pointer;display:inline-flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.3;margin:0;padding:8px;position:relative;text-decoration:none;transition:.25s,color .25s,border-color .25s;width:auto}.u-button svg,.u-button--primary svg{fill:currentcolor}.u-button{border:1px solid #069;color:#069}.u-button--primary{background-color:#069;background-image:none;border:1px solid #069;color:#fff}.u-button--full-width{display:flex;width:100%}.u-display-none{display:none}.js .u-js-hide,.u-hide{display:none;visibility:hidden}.u-hide:first-child+*{margin-block-start:0}.u-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}@media print{.u-hide-print{display:none}}@media only screen and (min-width:1024px){.u-hide-at-lg{display:none;visibility:hidden}.u-hide-at-lg:first-child+*{margin-block-start:0}}.u-clearfix:after,.u-clearfix:before{content:"";display:table}.u-clearfix:after{clear:both}.u-color-open-access{color:#b74616}.u-float-left{float:left}.u-icon{display:inline-block;fill:currentcolor;height:1em;transform:translate(0);vertical-align:text-top;width:1em}.u-full-height{height:100%}.u-list-reset{list-style:none;margin:0;padding:0}.u-container{margin:0 auto;max-width:1280px;padding:0 16px}.u-justify-content-space-between{justify-content:space-between}.u-mt-32{margin-top:32px}.u-mb-8{margin-bottom:8px}.u-mb-16{margin-bottom:16px}.u-mb-24{margin-bottom:24px}.u-mb-32{margin-bottom:32px}.u-mb-48{margin-bottom:48px}.u-pa-16{padding:16px}html *,html :after,html :before{box-sizing:inherit}.c-article-section__title,.c-article-title{font-weight:700}.c-card__title{line-height:1.4em}.c-article__button{background-color:#069;border:1px solid #069;border-radius:2px;color:#fff;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;margin-bottom:16px;padding:13px;transition:background-color .2s ease-out,color .2s ease-out}.c-article__button,.c-article__button:hover{text-decoration:none}.c-article__button--inverted,.c-article__button:hover{background-color:#fff;color:#069}.c-article__button--inverted:hover{background-color:#069;color:#fff}.c-header__link{text-decoration:inherit}.grade-c-hide{display:block}.c-pdf-download__link{padding:13px 24px} } </style>




    
        <link data-test="critical-css-handler" data-inline-css-source="critical-css" rel="stylesheet" href="/static/css/enhanced-article-nature-branded-3ddc847771.css" media="print" onload="this.media='only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)';this.onload=null">
    
    <noscript>
        <link rel="stylesheet" type="text/css" href="/static/css/enhanced-article-nature-branded-3ddc847771.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)">
    </noscript>

<link rel="stylesheet" type="text/css" href="/static/css/article-print-58da41a5fd.css" media="print">
    



<link rel="apple-touch-icon" sizes="180x180" href=/static/images/favicons/nature/apple-touch-icon-f39cb19454.png>
<link rel="icon" type="image/png" sizes="48x48" href=/static/images/favicons/nature/favicon-48x48-b52890008c.png>
<link rel="icon" type="image/png" sizes="32x32" href=/static/images/favicons/nature/favicon-32x32-3fe59ece92.png>
<link rel="icon" type="image/png" sizes="16x16" href=/static/images/favicons/nature/favicon-16x16-951651ab72.png>
<link rel="manifest" href=/static/manifest.json crossorigin="use-credentials">
<link rel="mask-icon" href=/static/images/favicons/nature/safari-pinned-tab-619cea1bcb.svg color="#000000">
<link rel="shortcut icon" href=/static/images/favicons/nature/favicon.ico>
<meta name="msapplication-TileColor" content="#000000">
<meta name="msapplication-config" content=/static/browserconfig.xml>
<meta name="theme-color" content="#000000">
<meta name="application-name" content="Nature">



<script>
    (function () {
        if ( typeof window.CustomEvent === "function" ) return false;
        function CustomEvent ( event, params ) {
            params = params || { bubbles: false, cancelable: false, detail: null };
            var evt = document.createEvent( 'CustomEvent' );
            evt.initCustomEvent( event, params.bubbles, params.cancelable, params.detail );
            return evt;
        }

        CustomEvent.prototype = window.Event.prototype;

        window.CustomEvent = CustomEvent;
    })();
</script>


<script>
    (function (w, d, s) {
        var urlParams = new URLSearchParams(w.location.search);
        if (urlParams.get('gptAdsTest') !== null) {
            d.addEventListener('sncc:initialise', function (e) {
                var t = d.createElement(s);
                var h = d.getElementsByTagName(s)[0];
                t.src = 'https://' + (e.detail.C03 ? 'securepubads.g.doubleclick' : 'pagead2.googlesyndication') + '.net/tag/js/gpt.js';
                t.async = false;
                t.onload = function () {
                    var n = d.createElement(s);
                    n.src = 'https://fed-libs.nature.com/production/gpt-ads-gtm.min.js';
                    n.async = false;
                    h.insertAdjacentElement('afterend', n);
                };
                h.insertAdjacentElement('afterend', t);
            })
        }
    })(window, document, 'script');
</script>
    
<!-- Google Tag Manager -->
<script data-test="gtm-head">
    window.initGTM = function() {
        if (window.config.mustardcut) {
            (function (w, d, s, l, i) {
                w[l] = w[l] || [];
                w[l].push({'gtm.start': new Date().getTime(), event: 'gtm.js'});
                var f = d.getElementsByTagName(s)[0],
                        j = d.createElement(s),
                        dl = l != 'dataLayer' ? '&l=' + l : '';
                j.async = true;
                j.src = 'https://sgtm.nature.com/gtm.js?id=' + i + dl;
                f.parentNode.insertBefore(j, f);
            })(window, document, 'script', 'dataLayer', 'GTM-MRVXSHQ');
        }
    }
</script>
<!-- End Google Tag Manager -->

    <script>
    (function(w,d,t) {
        function cc() {
            var h = w.location.hostname;
            if (h === 'preview-www.nature.com') return;
            var e = d.createElement(t),
                s = d.getElementsByTagName(t)[0];
            e.setAttribute('crossorigin', 'anonymous');
            if (h === 'nature.com' || h.endsWith('.nature.com')) {
                e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-102.js';
                e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
            } else {
                e.src = '/static/js/cookie-consent-es5-bundle-0b812e7bd9.js';
                e.setAttribute('data-consent', h);
            }
            s.insertAdjacentElement('afterend', e);
        }
        cc();
    })(window,document,'script');
</script>


<script id="js-position0">
    (function(w, d) {
        w.idpVerifyPrefix = 'https://verify.nature.com';
        w.ra21Host = 'https://wayf.springernature.com';
        var moduleSupport = (function() {
            return 'noModule' in d.createElement('script');
        })();

        if (w.config.mustardcut === true) {
            w.loader = {
                index: 0,
                registered: [],
                scripts: [
                    
                        {src: '/static/js/global-article-es6-bundle-3c95024fee.js', test: 'global-article-js', module: true},
                        {src: '/static/js/global-article-es5-bundle-2038893a49.js', test: 'global-article-js', nomodule: true},
                        {src: '/static/js/shared-es6-bundle-3aa6baa481.js', test: 'shared-js', module: true},
                        {src: '/static/js/shared-es5-bundle-8fc015859c.js', test: 'shared-js', nomodule: true},
                        {src: '/static/js/header-150-es6-bundle-a3d441cf1b.js', test: 'header-150-js', module: true},
                        {src: '/static/js/header-150-es5-bundle-5080ac4398.js', test: 'header-150-js', nomodule: true}
                    
                ].filter(function (s) {
                    if (s.src === null) return false;
                    if (moduleSupport && s.nomodule) return false;
                    return !(!moduleSupport && s.module);
                }),

                register: function (value) {
                    this.registered.push(value);
                },

                ready: function () {
                    if (this.registered.length === this.scripts.length) {
                        this.registered.forEach(function (fn) {
                            if (typeof fn === 'function') {
                                setTimeout(fn, 0); 
                            }
                        });
                        this.ready = function () {};
                    }
                },

                insert: function (s) {
                    var t = d.getElementById('js-position' + this.index);
                    if (t && t.insertAdjacentElement) {
                        t.insertAdjacentElement('afterend', s);
                    } else {
                        d.head.appendChild(s);
                    }
                    ++this.index;
                },

                createScript: function (script, beforeLoad) {
                    var s = d.createElement('script');
                    s.id = 'js-position' + (this.index + 1);
                    s.setAttribute('data-test', script.test);
                    if (beforeLoad) {
                        s.defer = 'defer';
                        s.onload = function () {
                            if (script.noinit) {
                                loader.register(true);
                            }
                            if (d.readyState === 'interactive' || d.readyState === 'complete') {
                                loader.ready();
                            }
                        };
                    } else {
                        s.async = 'async';
                    }
                    s.src = script.src;
                    return s;
                },

                init: function () {
                    this.scripts.forEach(function (s) {
                        loader.insert(loader.createScript(s, true));
                    });

                    d.addEventListener('DOMContentLoaded', function () {
                        loader.ready();
                        var conditionalScripts;
                        
                            conditionalScripts = [
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es6-bundle-9055a10868.js', test: 'pan-zoom-js',  module: true },
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es5-bundle-9055a10868.js', test: 'pan-zoom-js',  nomodule: true },
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es6-bundle-cccbca52af.js', test: 'math-js', module: true},
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es5-bundle-cccbca52af.js', test: 'math-js', nomodule: true}
                            ];
                        

                        if (conditionalScripts) {
                            conditionalScripts.filter(function (script) {
                                return !!document.querySelector(script.match) && !((moduleSupport && script.nomodule) || (!moduleSupport && script.module));
                            }).forEach(function (script) {
                                loader.insert(loader.createScript(script));
                            });
                        }
                    }, false);
                }
            };
            loader.init();
        }
    })(window, document);
</script>










<meta name="robots" content="noarchive">
<meta name="access" content="Yes">


<link rel="search" href="https://www.nature.com/search">
<link rel="search" href="https://www.nature.com/opensearch/opensearch.xml" type="application/opensearchdescription+xml" title="nature.com">
<link rel="search" href="https://www.nature.com/opensearch/request" type="application/sru+xml" title="nature.com">





    
    <script type="application/ld+json">{"mainEntity":{"headline":"Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks","description":"Predicting not just if, but also when, cognitively unimpaired individuals are likely to develop onset of Alzheimerʼs disease (AD) symptoms would be useful to clinical trials and, eventually, clinical practice. Although clock models based on amyloid and tau positron emission tomography have shown promise in predicting the onset of AD symptoms, a model based on plasma biomarkers would be more accessible. Using longitudinal plasma %p-tau217 (the ratio of phosphorylated to non-phosphorylated tau at position 217) from two independent cohorts (n = 258 and n = 345), clock models were used to estimate the age at plasma %p-tau217 positivity. The estimated age at plasma %p-tau217 positivity was associated with the age at onset of AD symptoms (adjusted R2 of 0.337−0.612) with a median absolute error of 3.0−3.7 years. Notably, the time from %p-tau217 positivity to onset of AD symptoms was markedly shorter in older individuals. Similar models were constructed with data from one p-tau217/Aβ42 immunoassay and four plasma p-tau217 immunoassays. These findings suggest that the time until onset of AD symptoms can be estimated using a single blood test within a margin of error that is acceptable for use in clinical trials. Plasma p-tau217 tests used to develop clocks that predict when cognitively unimpaired individuals would develop symptoms of Alzheimerʼs disease.","datePublished":"2026-02-19T00:00:00Z","dateModified":"2026-02-19T00:00:00Z","pageStart":"1","pageEnd":"10","license":"http://creativecommons.org/licenses/by/4.0/","sameAs":"https://doi.org/10.1038/s41591-026-04206-y","keywords":["Alzheimer's disease","Biomedicine","general","Cancer Research","Metabolic Diseases","Infectious Diseases","Molecular Medicine","Neurosciences"],"image":["https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig1_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig2_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig3_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig4_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig5_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig6_HTML.png"],"isPartOf":{"name":"Nature Medicine","issn":["1546-170X","1078-8956"],"@type":["Periodical"]},"publisher":{"name":"Nature Publishing Group US","logo":{"url":"https://www.springernature.com/app-sn/public/images/logo-springernature.png","@type":"ImageObject"},"@type":"Organization"},"author":[{"name":"Kellen K. Petersen","url":"http://orcid.org/0000-0003-3195-3456","affiliation":[{"name":"Washington University in St. Louis","address":{"name":"Department of Neurology, Washington University in St. Louis, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Marta Milà-Alomà","affiliation":[{"name":"Northern California Institute for Research and Education","address":{"name":"Northern California Institute for Research and Education, San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of California, San Francisco","address":{"name":"Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Yan Li","url":"http://orcid.org/0000-0003-1340-6694","affiliation":[{"name":"Washington University in St. Louis","address":{"name":"Department of Neurology, Washington University in St. Louis, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Lianlian Du","url":"http://orcid.org/0000-0002-1662-0883","affiliation":[{"name":"University of Wisconsin-Madison School of Medicine and Public Health","address":{"name":"Wisconsin Alzheimer’s Institute, University of Wisconsin-Madison School of Medicine and Public Health, Madison, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Wisconsin-Madison School of Medicine and Public Health","address":{"name":"Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Rush Alzheimer’s Disease Center","address":{"name":"Rush Alzheimer’s Disease Center, Chicago, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Rush University Medical Center","address":{"name":"Department of Neurological Sciences, Rush University Medical Center, Chicago, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Chengjie Xiong","affiliation":[{"name":"Knight Alzheimer Disease Research Center","address":{"name":"Knight Alzheimer Disease Research Center, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Washington University School of Medicine","address":{"name":"Division of Biostatistics, Washington University School of Medicine, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Duygu Tosun","url":"http://orcid.org/0000-0001-8644-7724","affiliation":[{"name":"Northern California Institute for Research and Education","address":{"name":"Northern California Institute for Research and Education, San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of California, San Francisco","address":{"name":"Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Benjamin Saef","affiliation":[{"name":"Washington University in St. Louis","address":{"name":"Department of Neurology, Washington University in St. Louis, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Ziad S. Saad","affiliation":[{"name":"Johnson & Johnson","address":{"name":"Precision Measures, Johnson & Johnson, San Diego, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Lei Du-Cuny","affiliation":[{"name":"AbbVie Deutschland GmbH & Co. KG","address":{"name":"AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Janaky Coomaraswamy","affiliation":[{"name":"Takeda Pharmaceutical Company Ltd.","address":{"name":"Takeda Pharmaceutical Company Ltd., Cambridge, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Yulia Mordashova","affiliation":[{"name":"AbbVie Deutschland GmbH & Co. KG","address":{"name":"AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Carrie E. Rubel","affiliation":[{"name":"Biogen","address":{"name":"Biogen, Cambridge, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Emily A. Meyers","url":"http://orcid.org/0000-0002-0886-6218","affiliation":[{"name":"Alzheimer’s Association","address":{"name":"Alzheimer’s Association, Chicago, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Leslie M. Shaw","affiliation":[{"name":"University of Pennsylvania","address":{"name":"Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Jeffrey L. Dage","url":"http://orcid.org/0000-0002-2192-1699","affiliation":[{"name":"Indiana University School of Medicine","address":{"name":"Department of Neurology, Indiana University School of Medicine, Indianapolis, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Indiana University School of Medicine","address":{"name":"Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Nicholas J. Ashton","affiliation":[{"name":"The Sahlgrenska Academy at University of Gothenburg","address":{"name":"Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden","@type":"PostalAddress"},"@type":"Organization"},{"name":"Banner Alzheimer’s Institute","address":{"name":"Banner Alzheimer’s Institute, Phoenix, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Banner Sun Health Research Institute","address":{"name":"Banner Sun Health Research Institute, Sun City, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Henrik Zetterberg","url":"http://orcid.org/0000-0003-3930-4354","affiliation":[{"name":"The Sahlgrenska Academy at University of Gothenburg","address":{"name":"Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden","@type":"PostalAddress"},"@type":"Organization"},{"name":"Sahlgrenska University Hospital","address":{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden","@type":"PostalAddress"},"@type":"Organization"},{"name":"UK Dementia Research Institute Fluid Biomarkers Laboratory, UK DRI at UCL","address":{"name":"UK Dementia Research Institute Fluid Biomarkers Laboratory, UK DRI at UCL, London, UK","@type":"PostalAddress"},"@type":"Organization"},{"name":"Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology","address":{"name":"Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK","@type":"PostalAddress"},"@type":"Organization"},{"name":"Hong Kong Center for Neurodegenerative Diseases","address":{"name":"Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Wisconsin-Madison","address":{"name":"Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Kyle Ferber","affiliation":[{"name":"Biogen","address":{"name":"Biogen, Cambridge, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Gallen Triana-Baltzer","affiliation":[{"name":"Johnson & Johnson","address":{"name":"Precision Measures, Johnson & Johnson, San Diego, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Michael Baratta","affiliation":[{"name":"Takeda Pharmaceutical Company Ltd.","address":{"name":"Takeda Pharmaceutical Company Ltd., Cambridge, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Erin G. Rosenbaugh","affiliation":[{"name":"Foundation for the National Institutes of Health","address":{"name":"Foundation for the National Institutes of Health, North Bethesda, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Carlos Cruchaga","url":"http://orcid.org/0000-0002-0276-2899","affiliation":[{"name":"Knight Alzheimer Disease Research Center","address":{"name":"Knight Alzheimer Disease Research Center, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Washington University School of Medicine","address":{"name":"Department of Psychiatry, Washington University School of Medicine, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Washington University","address":{"name":"NeuroGenomics and Informatics Center, Washington University, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Hope Center for Neurologic Diseases","address":{"name":"Hope Center for Neurologic Diseases, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Eric McDade","url":"http://orcid.org/0000-0002-6764-3866","affiliation":[{"name":"Washington University in St. Louis","address":{"name":"Department of Neurology, Washington University in St. Louis, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Knight Alzheimer Disease Research Center","address":{"name":"Knight Alzheimer Disease Research Center, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"David M. Holtzman","url":"http://orcid.org/0000-0002-3400-0856","affiliation":[{"name":"Washington University in St. Louis","address":{"name":"Department of Neurology, Washington University in St. Louis, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Knight Alzheimer Disease Research Center","address":{"name":"Knight Alzheimer Disease Research Center, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Hope Center for Neurologic Diseases","address":{"name":"Hope Center for Neurologic Diseases, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"John C. Morris","affiliation":[{"name":"Washington University in St. Louis","address":{"name":"Department of Neurology, Washington University in St. Louis, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Knight Alzheimer Disease Research Center","address":{"name":"Knight Alzheimer Disease Research Center, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"J. Martin Sabandal","affiliation":[{"name":"Foundation for the National Institutes of Health","address":{"name":"Foundation for the National Institutes of Health, North Bethesda, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Randall J. Bateman","url":"http://orcid.org/0000-0002-7729-1702","affiliation":[{"name":"Washington University in St. Louis","address":{"name":"Department of Neurology, Washington University in St. Louis, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Knight Alzheimer Disease Research Center","address":{"name":"Knight Alzheimer Disease Research Center, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Hope Center for Neurologic Diseases","address":{"name":"Hope Center for Neurologic Diseases, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Tracy Family SILQ Center for Neurodegenerative Biology","address":{"name":"Tracy Family SILQ Center for Neurodegenerative Biology, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Anthony W. Bannon","affiliation":[{"name":"AbbVie","address":{"name":"AbbVie, North Chicago, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"William Z. Potter","@type":"Person"},{"name":"Suzanne E. Schindler","url":"http://orcid.org/0000-0002-1680-1465","affiliation":[{"name":"Washington University in St. Louis","address":{"name":"Department of Neurology, Washington University in St. Louis, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Knight Alzheimer Disease Research Center","address":{"name":"Knight Alzheimer Disease Research Center, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Hope Center for Neurologic Diseases","address":{"name":"Hope Center for Neurologic Diseases, St. Louis, USA","@type":"PostalAddress"},"@type":"Organization"}],"email":"schindlers@neuro.wustl.edu","@type":"Person"}],"isAccessibleForFree":true,"@type":"ScholarlyArticle"},"@context":"https://schema.org","@type":"WebPage"}</script>





    
    <link rel="canonical" href="https://www.nature.com/articles/s41591-026-04206-y">
    
    
    <meta name="journal_id" content="41591"/>
    <meta name="dc.title" content="Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks"/>
    <meta name="dc.source" content="Nature Medicine 2026"/>
    <meta name="dc.format" content="text/html"/>
    <meta name="dc.publisher" content="Nature Publishing Group"/>
    <meta name="dc.date" content="2026-02-19"/>
    <meta name="dc.type" content="OriginalPaper"/>
    <meta name="dc.language" content="En"/>
    <meta name="dc.copyright" content="2026 The Author(s)"/>
    <meta name="dc.rights" content="2026 The Author(s)"/>
    <meta name="dc.rightsAgent" content="journalpermissions@springernature.com"/>
    <meta name="dc.description" content="Predicting not just if, but also when, cognitively unimpaired individuals are likely to develop onset of Alzheimer&#700;s disease (AD) symptoms would be useful to clinical trials and, eventually, clinical practice. Although clock models based on amyloid and tau positron emission tomography have shown promise in predicting the onset of AD symptoms, a model based on plasma biomarkers would be more accessible. Using longitudinal plasma %p-tau217 (the ratio of phosphorylated to non-phosphorylated tau at position 217) from two independent cohorts (n&#8201;=&#8201;258 and n&#8201;=&#8201;345), clock models were used to estimate the age at plasma %p-tau217 positivity. The estimated age at plasma %p-tau217 positivity was associated with the age at onset of AD symptoms (adjusted R2 of 0.337&#8722;0.612) with a median absolute error of 3.0&#8722;3.7&#8201;years. Notably, the time from %p-tau217 positivity to onset of AD symptoms was markedly shorter in older individuals. Similar models were constructed with data from one p-tau217/A&#946;42 immunoassay and four plasma p-tau217 immunoassays. These findings suggest that the time until onset of AD symptoms can be estimated using a single blood test within a margin of error that is acceptable for use in clinical trials. Plasma p-tau217 tests used to develop clocks that predict when cognitively unimpaired individuals would develop symptoms of Alzheimer&#700;s disease."/>
    <meta name="prism.issn" content="1546-170X"/>
    <meta name="prism.publicationName" content="Nature Medicine"/>
    <meta name="prism.publicationDate" content="2026-02-19"/>
    <meta name="prism.section" content="OriginalPaper"/>
    <meta name="prism.startingPage" content="1"/>
    <meta name="prism.endingPage" content="10"/>
    <meta name="prism.copyright" content="2026 The Author(s)"/>
    <meta name="prism.rightsAgent" content="journalpermissions@springernature.com"/>
    <meta name="prism.url" content="https://www.nature.com/articles/s41591-026-04206-y"/>
    <meta name="prism.doi" content="doi:10.1038/s41591-026-04206-y"/>
    <meta name="citation_pdf_url" content="https://www.nature.com/articles/s41591-026-04206-y.pdf"/>
    <meta name="citation_fulltext_html_url" content="https://www.nature.com/articles/s41591-026-04206-y"/>
    <meta name="citation_journal_title" content="Nature Medicine"/>
    <meta name="citation_journal_abbrev" content="Nat Med"/>
    <meta name="citation_publisher" content="Nature Publishing Group"/>
    <meta name="citation_issn" content="1546-170X"/>
    <meta name="citation_title" content="Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks"/>
    <meta name="citation_online_date" content="2026/02/19"/>
    <meta name="citation_firstpage" content="1"/>
    <meta name="citation_lastpage" content="10"/>
    <meta name="citation_article_type" content="Article"/>
    <meta name="citation_fulltext_world_readable" content=""/>
    <meta name="citation_language" content="en"/>
    <meta name="dc.identifier" content="doi:10.1038/s41591-026-04206-y"/>
    <meta name="DOI" content="10.1038/s41591-026-04206-y"/>
    <meta name="size" content="220731"/>
    <meta name="citation_doi" content="10.1038/s41591-026-04206-y"/>
    <meta name="citation_springer_api_url" content="http://api.springer.com/xmldata/jats?q=doi:10.1038/s41591-026-04206-y&amp;api_key="/>
    <meta name="description" content="Predicting not just if, but also when, cognitively unimpaired individuals are likely to develop onset of Alzheimer&#700;s disease (AD) symptoms would be useful to clinical trials and, eventually, clinical practice. Although clock models based on amyloid and tau positron emission tomography have shown promise in predicting the onset of AD symptoms, a model based on plasma biomarkers would be more accessible. Using longitudinal plasma %p-tau217 (the ratio of phosphorylated to non-phosphorylated tau at position 217) from two independent cohorts (n&#8201;=&#8201;258 and n&#8201;=&#8201;345), clock models were used to estimate the age at plasma %p-tau217 positivity. The estimated age at plasma %p-tau217 positivity was associated with the age at onset of AD symptoms (adjusted R2 of 0.337&#8722;0.612) with a median absolute error of 3.0&#8722;3.7&#8201;years. Notably, the time from %p-tau217 positivity to onset of AD symptoms was markedly shorter in older individuals. Similar models were constructed with data from one p-tau217/A&#946;42 immunoassay and four plasma p-tau217 immunoassays. These findings suggest that the time until onset of AD symptoms can be estimated using a single blood test within a margin of error that is acceptable for use in clinical trials. Plasma p-tau217 tests used to develop clocks that predict when cognitively unimpaired individuals would develop symptoms of Alzheimer&#700;s disease."/>
    <meta name="dc.creator" content="Petersen, Kellen K."/>
    <meta name="dc.creator" content="Mil&#224;-Alom&#224;, Marta"/>
    <meta name="dc.creator" content="Li, Yan"/>
    <meta name="dc.creator" content="Du, Lianlian"/>
    <meta name="dc.creator" content="Xiong, Chengjie"/>
    <meta name="dc.creator" content="Tosun, Duygu"/>
    <meta name="dc.creator" content="Saef, Benjamin"/>
    <meta name="dc.creator" content="Saad, Ziad S."/>
    <meta name="dc.creator" content="Du-Cuny, Lei"/>
    <meta name="dc.creator" content="Coomaraswamy, Janaky"/>
    <meta name="dc.creator" content="Mordashova, Yulia"/>
    <meta name="dc.creator" content="Rubel, Carrie E."/>
    <meta name="dc.creator" content="Meyers, Emily A."/>
    <meta name="dc.creator" content="Shaw, Leslie M."/>
    <meta name="dc.creator" content="Dage, Jeffrey L."/>
    <meta name="dc.creator" content="Ashton, Nicholas J."/>
    <meta name="dc.creator" content="Zetterberg, Henrik"/>
    <meta name="dc.creator" content="Ferber, Kyle"/>
    <meta name="dc.creator" content="Triana-Baltzer, Gallen"/>
    <meta name="dc.creator" content="Baratta, Michael"/>
    <meta name="dc.creator" content="Rosenbaugh, Erin G."/>
    <meta name="dc.creator" content="Cruchaga, Carlos"/>
    <meta name="dc.creator" content="McDade, Eric"/>
    <meta name="dc.creator" content="Holtzman, David M."/>
    <meta name="dc.creator" content="Morris, John C."/>
    <meta name="dc.creator" content="Sabandal, J. Martin"/>
    <meta name="dc.creator" content="Bateman, Randall J."/>
    <meta name="dc.creator" content="Bannon, Anthony W."/>
    <meta name="dc.creator" content="Potter, William Z."/>
    <meta name="dc.creator" content="Schindler, Suzanne E."/>
    <meta name="dc.subject" content="Alzheimer&#39;s disease"/>
    <meta name="citation_reference" content="citation_journal_title=Alzheimers Dement.; citation_title=Revised criteria for diagnosis and staging of Alzheimer&#8217;s disease: Alzheimer&#8217;s Association Workgroup; citation_author=CR Jack Jr; citation_volume=20; citation_publication_date=2024; citation_pages=5143-5169; citation_doi=10.1002/alz.13859; citation_id=CR1"/>
    <meta name="citation_reference" content="citation_journal_title=Neurology; citation_title=Brain &#946;-amyloid load approaches a plateau; citation_author=CR Jack Jr; citation_volume=80; citation_publication_date=2013; citation_pages=890-896; citation_doi=10.1212/WNL.0b013e3182840bbe; citation_id=CR2"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Clinical and biomarker changes in dominantly inherited Alzheimer&#8217;s disease; citation_author=RJ Bateman; citation_volume=367; citation_publication_date=2012; citation_pages=795-804; citation_doi=10.1056/NEJMoa1202753; citation_id=CR3"/>
    <meta name="citation_reference" content="citation_journal_title=Brain; citation_title=Tau PET in autosomal dominant Alzheimer&#8217;s disease: relationship with cognition, dementia and other biomarkers; citation_author=BA Gordon; citation_volume=142; citation_publication_date=2019; citation_pages=1063-1076; citation_doi=10.1093/brain/awz019; citation_id=CR4"/>
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline; citation_author=R Ossenkoppele; citation_volume=28; citation_publication_date=2022; citation_pages=2381-2387; citation_doi=10.1038/s41591-022-02049-x; citation_id=CR5"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Lecanemab in early Alzheimer&#8217;s disease; citation_author=CH Dyck; citation_volume=388; citation_publication_date=2023; citation_pages=9-21; citation_doi=10.1056/NEJMoa2212948; citation_id=CR6"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA; citation_title=Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial; citation_author=JR Sims; citation_volume=330; citation_publication_date=2023; citation_pages=512-527; citation_doi=10.1001/jama.2023.13239; citation_id=CR7"/>
    <meta name="citation_reference" content="citation_journal_title=Sci. Transl. Med.; citation_title=Testing the right target and right drug at the right stage; citation_author=RA Sperling, CR Jack Jr, PS Aisen; citation_volume=3; citation_publication_date=2011; citation_pages=111cm133; citation_doi=10.1126/scitranslmed.3002609; citation_id=CR8"/>
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=Stop Alzheimer&#8217;s before it starts; citation_author=E McDade, RJ Bateman; citation_volume=547; citation_publication_date=2017; citation_pages=153-155; citation_doi=10.1038/547153a; citation_id=CR9"/>
    <meta name="citation_reference" content="citation_journal_title=Neurology; citation_title=Predicting symptom onset in sporadic Alzheimer disease with amyloid PET; citation_author=SE Schindler; citation_volume=97; citation_publication_date=2021; citation_pages=e1823-e1834; citation_doi=10.1212/WNL.0000000000012775; citation_id=CR10"/>
    <meta name="citation_reference" content="citation_journal_title=Ann. Neurol.; citation_title=Longitudinal assessment of A&#946; and cognition in aging and Alzheimer disease; citation_author=VL Villemagne; citation_volume=69; citation_publication_date=2011; citation_pages=181-192; citation_doi=10.1002/ana.22248; citation_id=CR11"/>
    <meta name="citation_reference" content="citation_journal_title=Alzheimers Dement.; citation_title=Factors associated with age at tau pathology onset and time from tau onset to dementia in Alzheimer&#39;s disease; citation_author=MB Heston; citation_volume=21; citation_publication_date=2025; citation_pages=e70551; citation_doi=10.1002/alz.70551; citation_id=CR12"/>
    <meta name="citation_reference" content="citation_journal_title=Ann. Neurol.; citation_title=Timing of changes in Alzheimer&#39;s disease plasma biomarkers as assessed by amyloid and tau PET clocks; citation_author=M Mila-Aloma; citation_volume=98; citation_publication_date=2025; citation_pages=508-523; citation_doi=10.1002/ana.27285; citation_id=CR13"/>
    <meta name="citation_reference" content="citation_journal_title=Stat. Med.; citation_title=Constructing longitudinal disease progression curves using sparse, short-term individual data with an application to Alzheimer&#8217;s disease; citation_author=CA Budgeon; citation_volume=36; citation_publication_date=2017; citation_pages=2720-2734; citation_doi=10.1002/sim.7300; citation_id=CR14"/>
    <meta name="citation_reference" content="citation_journal_title=Alzheimers Dement.; citation_title=Amyloid duration is associated with preclinical cognitive decline and tau PET; citation_author=RL Koscik; citation_volume=12; citation_publication_date=2020; citation_id=CR15"/>
    <meta name="citation_reference" content="citation_journal_title=Ann. Neurol.; citation_title=Timing of biomarker changes in sporadic Alzheimer&#8217;s disease in estimated years from symptom onset; citation_author=Y Li; citation_volume=95; citation_publication_date=2024; citation_pages=951-965; citation_doi=10.1002/ana.26891; citation_id=CR16"/>
    <meta name="citation_reference" content="citation_journal_title=Brain; citation_title=Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts; citation_author=TJ Betthauser; citation_volume=145; citation_publication_date=2022; citation_pages=4065-4079; citation_doi=10.1093/brain/awac213; citation_id=CR17"/>
    <meta name="citation_reference" content="citation_journal_title=Alzheimers Dement.; citation_title=The AHEAD 3-45 study: design of a prevention trial for Alzheimer&#8217;s disease; citation_author=MS Rafii; citation_volume=19; citation_publication_date=2023; citation_pages=1227-1233; citation_doi=10.1002/alz.12748; citation_id=CR18"/>
    <meta name="citation_reference" content="citation_journal_title=Alzheimers Dement.; citation_title=Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer&#8217;s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup; citation_author=GD Rabinovici; citation_volume=21; citation_publication_date=2025; citation_doi=10.1002/alz.14338; citation_id=CR19"/>
    <meta name="citation_reference" content="citation_journal_title=Neuron; citation_title=Blood-based biomarkers for Alzheimer&#8217;s disease: current state and future use in a transformed global healthcare landscape; citation_author=H Hampel; citation_volume=111; citation_publication_date=2023; citation_pages=2781-2799; citation_doi=10.1016/j.neuron.2023.05.017; citation_id=CR20"/>
    <meta name="citation_reference" content="citation_journal_title=Alzheimers Dement.; citation_title=Predicting continuous amyloid PET values with CSF and plasma A&#946;42/A&#946;40; citation_author=JK Wisch; citation_volume=15; citation_publication_date=2023; citation_id=CR21"/>
    <meta name="citation_reference" content="citation_journal_title=Alzheimers Dement.; citation_title=Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer&#39;s disease; citation_author=V Devanarayan; citation_volume=20; citation_publication_date=2024; citation_pages=5617-5628; citation_doi=10.1002/alz.14073; citation_id=CR22"/>
    <meta name="citation_reference" content="citation_journal_title=Alzheimers Dement.; citation_title=Head-to-head comparison of leading blood tests for Alzheimer&#8217;s disease pathology; citation_author=SE Schindler; citation_volume=20; citation_publication_date=2024; citation_pages=8074-8096; citation_doi=10.1002/alz.14315; citation_id=CR23"/>
    <meta name="citation_reference" content="Barthelemy, N. R. et al. Highly accurate blood test for Alzheimer&#8217;s disease is similar or superior to clinical cerebrospinal fluid tests. Nat. Med. 30, 1085&#8211;1095 (2024)."/>
    <meta name="citation_reference" content="citation_journal_title=Brain; citation_title=A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests; citation_author=N Warmenhoven; citation_volume=148; citation_publication_date=2025; citation_pages=416-431; citation_doi=10.1093/brain/awae346; citation_id=CR25"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA; citation_title=Blood biomarkers to detect Alzheimer disease in primary care and secondary care; citation_author=S Palmqvist; citation_volume=332; citation_publication_date=2024; citation_pages=1245-1257; citation_doi=10.1001/jama.2024.13855; citation_id=CR26"/>
    <meta name="citation_reference" content="Meyer, M. R. et al. Clinical validation of the PrecivityAD2 blood test: a mass spectrometry-based test with algorithm combining %p-tau217 and A&#946;42/40 ratio to identify presence of brain amyloid. Alzheimers Dement. 20, 3179&#8211;3192 (2024)."/>
    <meta name="citation_reference" content="Janelidze, S. et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer&#8217;s disease. Brain 146, 1592&#8211;1601 (2023)."/>
    <meta name="citation_reference" content="citation_journal_title=Alzheimers Dement.; citation_title=Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid-positive early Alzheimer&#8217;s disease; citation_author=V Devanarayan; citation_volume=21; citation_publication_date=2025; citation_doi=10.1002/alz.14411; citation_id=CR29"/>
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=Prediction of future Alzheimer&#8217;s disease dementia using plasma phospho-tau combined with other accessible measures; citation_author=S Palmqvist; citation_volume=27; citation_publication_date=2021; citation_pages=1034-1042; citation_doi=10.1038/s41591-021-01348-z; citation_id=CR30"/>
    <meta name="citation_reference" content="citation_journal_title=Nat. Aging; citation_title=Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials; citation_author=R Ossenkoppele; citation_volume=5; citation_publication_date=2025; citation_pages=883-896; citation_doi=10.1038/s43587-025-00835-z; citation_id=CR31"/>
    <meta name="citation_reference" content="Rissman, R. A. et al. Plasma A&#946;42/A&#946;40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer&#8217;s disease. Alzheimers Dement. 20, 1214&#8211;1224 (2024)."/>
    <meta name="citation_reference" content="citation_journal_title=Alzheimers Dement.; citation_title=The diagnosis of dementia due to Alzheimer&#8217;s disease: recommendations from the National Institute on Aging-Alzheimer&#8217;s Association workgroups on diagnostic guidelines for Alzheimer&#8217;s disease; citation_author=GM McKhann; citation_volume=7; citation_publication_date=2011; citation_pages=263-269; citation_doi=10.1016/j.jalz.2011.03.005; citation_id=CR33"/>
    <meta name="citation_reference" content="citation_journal_title=Alzheimers Dement.; citation_title=The diagnosis of mild cognitive impairment due to Alzheimer&#8217;s disease: recommendations from the National Institute on Aging-Alzheimer&#8217;s Association workgroups on diagnostic guidelines for Alzheimer&#8217;s disease; citation_author=MS Albert; citation_volume=7; citation_publication_date=2011; citation_pages=270-279; citation_doi=10.1016/j.jalz.2011.03.008; citation_id=CR34"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA Neurol.; citation_title=Alzheimer disease as a clinical-biological construct&#8212;an international working group recommendation; citation_author=B Dubois; citation_volume=81; citation_publication_date=2024; citation_pages=1304-1311; citation_doi=10.1001/jamaneurol.2024.3770; citation_id=CR35"/>
    <meta name="citation_reference" content="citation_journal_title=Neurology; citation_title=Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis; citation_author=DC Ryman; citation_volume=83; citation_publication_date=2014; citation_pages=253-260; citation_doi=10.1212/WNL.0000000000000596; citation_id=CR36"/>
    <meta name="citation_reference" content="citation_journal_title=Alzheimers Dement.; citation_title=The DIAN-TU Next Generation Alzheimer&#8217;s prevention trial: adaptive design and disease progression model; citation_author=RJ Bateman; citation_volume=13; citation_publication_date=2017; citation_pages=8-19; citation_doi=10.1016/j.jalz.2016.07.005; citation_id=CR37"/>
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer&#8217;s disease; citation_author=K Horie; citation_volume=31; citation_publication_date=2025; citation_pages=2044-2053; citation_doi=10.1038/s41591-025-03617-7; citation_id=CR38"/>
    <meta name="citation_reference" content="citation_journal_title=Brain Commun.; citation_title=Onset ages of cerebrovascular disease and amyloid and effects on cognition in risk-enriched cohorts; citation_author=L Du; citation_volume=7; citation_publication_date=2025; citation_doi=10.1093/braincomms/fcaf158; citation_id=CR39"/>
    <meta name="citation_reference" content="citation_journal_title=J. Alzheimers Dis.; citation_title=Predicting symptom onset in sporadic Alzheimer&#8217;s disease: &#8216;How long do I have?&#8217;; citation_author=SE Schindler; citation_volume=90; citation_publication_date=2022; citation_pages=975-979; citation_doi=10.3233/JAD-215722; citation_id=CR40"/>
    <meta name="citation_reference" content="citation_journal_title=Alzheimers Dement.; citation_title=Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer&#8217;s disease; citation_author=LM Shaw; citation_volume=14; citation_publication_date=2018; citation_pages=1505-1521; citation_doi=10.1016/j.jalz.2018.07.220; citation_id=CR41"/>
    <meta name="citation_reference" content="citation_journal_title=Alzheimers Dement.; citation_title=The Alzheimer&#8217;s Association appropriate use recommendations for blood biomarkers in Alzheimer&#8217;s disease; citation_author=O Hansson; citation_volume=18; citation_publication_date=2022; citation_pages=2669-2686; citation_doi=10.1002/alz.12756; citation_id=CR42"/>
    <meta name="citation_reference" content="citation_journal_title=Alzheimers Dement.; citation_title=Alzheimer&#8217;s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer&#8217;s disease within specialized care settings; citation_author=S Palmqvist; citation_volume=21; citation_publication_date=2025; citation_doi=10.1002/alz.70535; citation_id=CR43"/>
    <meta name="citation_reference" content="citation_journal_title=JAMA Neurol.; citation_title=Evaluation of the revised criteria for biological and clinical staging of Alzheimer disease; citation_author=A Pichet Binette; citation_volume=82; citation_publication_date=2025; citation_pages=666-675; citation_doi=10.1001/jamaneurol.2025.1100; citation_id=CR44"/>
    <meta name="citation_reference" content="citation_journal_title=J. Prev. Alzheimers Dis.; citation_title=Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer&#8217;s Association Research Roundtable; citation_author=G Farrar, CJ Weber, GD Rabinovici; citation_volume=12; citation_publication_date=2025; citation_doi=10.1016/j.tjpad.2024.100008; citation_id=CR45"/>
    <meta name="citation_reference" content="citation_journal_title=Alzheimers Dement.; citation_title=Improved protocol for measurement of plasma &#946;-amyloid in longitudinal evaluation of Alzheimer&#8217;s Disease Neuroimaging Initiative study patients; citation_author=MJ Figurski; citation_volume=8; citation_publication_date=2012; citation_pages=250-260; citation_doi=10.1016/j.jalz.2012.01.001; citation_id=CR46"/>
    <meta name="citation_reference" content="citation_journal_title=Alzheimers Dement.; citation_title=ADNI Biomarker Core: a review of progress since 2004 and future challenges; citation_author=LM Shaw; citation_volume=21; citation_publication_date=2025; citation_doi=10.1002/alz.14264; citation_id=CR47"/>
    <meta name="citation_reference" content="citation_journal_title=Neurology; citation_title=The Clinical Dementia Rating (CDR): current version and scoring rules; citation_author=JC Morris; citation_volume=43; citation_publication_date=1993; citation_pages=2412-2414; citation_doi=10.1212/WNL.43.11.2412-a; citation_id=CR48"/>
    <meta name="citation_author" content="Petersen, Kellen K."/>
    <meta name="citation_author_institution" content="Department of Neurology, Washington University in St. Louis, St. Louis, USA"/>
    <meta name="citation_author" content="Mil&#224;-Alom&#224;, Marta"/>
    <meta name="citation_author_institution" content="Northern California Institute for Research and Education, San Francisco, USA"/>
    <meta name="citation_author_institution" content="Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, USA"/>
    <meta name="citation_author" content="Li, Yan"/>
    <meta name="citation_author_institution" content="Department of Neurology, Washington University in St. Louis, St. Louis, USA"/>
    <meta name="citation_author" content="Du, Lianlian"/>
    <meta name="citation_author_institution" content="Wisconsin Alzheimer&#8217;s Institute, University of Wisconsin-Madison School of Medicine and Public Health, Madison, USA"/>
    <meta name="citation_author_institution" content="Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, USA"/>
    <meta name="citation_author_institution" content="Rush Alzheimer&#8217;s Disease Center, Chicago, USA"/>
    <meta name="citation_author_institution" content="Department of Neurological Sciences, Rush University Medical Center, Chicago, USA"/>
    <meta name="citation_author" content="Xiong, Chengjie"/>
    <meta name="citation_author_institution" content="Knight Alzheimer Disease Research Center, St. Louis, USA"/>
    <meta name="citation_author_institution" content="Division of Biostatistics, Washington University School of Medicine, St. Louis, USA"/>
    <meta name="citation_author" content="Tosun, Duygu"/>
    <meta name="citation_author_institution" content="Northern California Institute for Research and Education, San Francisco, USA"/>
    <meta name="citation_author_institution" content="Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, USA"/>
    <meta name="citation_author" content="Saef, Benjamin"/>
    <meta name="citation_author_institution" content="Department of Neurology, Washington University in St. Louis, St. Louis, USA"/>
    <meta name="citation_author" content="Saad, Ziad S."/>
    <meta name="citation_author_institution" content="Precision Measures, Johnson &amp; Johnson, San Diego, USA"/>
    <meta name="citation_author" content="Du-Cuny, Lei"/>
    <meta name="citation_author_institution" content="AbbVie Deutschland GmbH &amp; Co. KG, Ludwigshafen am Rhein, Germany"/>
    <meta name="citation_author" content="Coomaraswamy, Janaky"/>
    <meta name="citation_author_institution" content="Takeda Pharmaceutical Company Ltd., Cambridge, USA"/>
    <meta name="citation_author" content="Mordashova, Yulia"/>
    <meta name="citation_author_institution" content="AbbVie Deutschland GmbH &amp; Co. KG, Ludwigshafen am Rhein, Germany"/>
    <meta name="citation_author" content="Rubel, Carrie E."/>
    <meta name="citation_author_institution" content="Biogen, Cambridge, USA"/>
    <meta name="citation_author" content="Meyers, Emily A."/>
    <meta name="citation_author_institution" content="Alzheimer&#8217;s Association, Chicago, USA"/>
    <meta name="citation_author" content="Shaw, Leslie M."/>
    <meta name="citation_author_institution" content="Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA"/>
    <meta name="citation_author" content="Dage, Jeffrey L."/>
    <meta name="citation_author_institution" content="Department of Neurology, Indiana University School of Medicine, Indianapolis, USA"/>
    <meta name="citation_author_institution" content="Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, USA"/>
    <meta name="citation_author" content="Ashton, Nicholas J."/>
    <meta name="citation_author_institution" content="Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, M&#246;lndal, Sweden"/>
    <meta name="citation_author_institution" content="Banner Alzheimer&#8217;s Institute, Phoenix, USA"/>
    <meta name="citation_author_institution" content="Banner Sun Health Research Institute, Sun City, USA"/>
    <meta name="citation_author" content="Zetterberg, Henrik"/>
    <meta name="citation_author_institution" content="Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, M&#246;lndal, Sweden"/>
    <meta name="citation_author_institution" content="Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#246;lndal, Sweden"/>
    <meta name="citation_author_institution" content="UK Dementia Research Institute Fluid Biomarkers Laboratory, UK DRI at UCL, London, UK"/>
    <meta name="citation_author_institution" content="Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK"/>
    <meta name="citation_author_institution" content="Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China"/>
    <meta name="citation_author_institution" content="Wisconsin Alzheimer&#8217;s Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, USA"/>
    <meta name="citation_author" content="Ferber, Kyle"/>
    <meta name="citation_author_institution" content="Biogen, Cambridge, USA"/>
    <meta name="citation_author" content="Triana-Baltzer, Gallen"/>
    <meta name="citation_author_institution" content="Precision Measures, Johnson &amp; Johnson, San Diego, USA"/>
    <meta name="citation_author" content="Baratta, Michael"/>
    <meta name="citation_author_institution" content="Takeda Pharmaceutical Company Ltd., Cambridge, USA"/>
    <meta name="citation_author" content="Rosenbaugh, Erin G."/>
    <meta name="citation_author_institution" content="Foundation for the National Institutes of Health, North Bethesda, USA"/>
    <meta name="citation_author" content="Cruchaga, Carlos"/>
    <meta name="citation_author_institution" content="Knight Alzheimer Disease Research Center, St. Louis, USA"/>
    <meta name="citation_author_institution" content="Department of Psychiatry, Washington University School of Medicine, St. Louis, USA"/>
    <meta name="citation_author_institution" content="NeuroGenomics and Informatics Center, Washington University, St. Louis, USA"/>
    <meta name="citation_author_institution" content="Hope Center for Neurologic Diseases, St. Louis, USA"/>
    <meta name="citation_author" content="McDade, Eric"/>
    <meta name="citation_author_institution" content="Department of Neurology, Washington University in St. Louis, St. Louis, USA"/>
    <meta name="citation_author_institution" content="Knight Alzheimer Disease Research Center, St. Louis, USA"/>
    <meta name="citation_author" content="Holtzman, David M."/>
    <meta name="citation_author_institution" content="Department of Neurology, Washington University in St. Louis, St. Louis, USA"/>
    <meta name="citation_author_institution" content="Knight Alzheimer Disease Research Center, St. Louis, USA"/>
    <meta name="citation_author_institution" content="Hope Center for Neurologic Diseases, St. Louis, USA"/>
    <meta name="citation_author" content="Morris, John C."/>
    <meta name="citation_author_institution" content="Department of Neurology, Washington University in St. Louis, St. Louis, USA"/>
    <meta name="citation_author_institution" content="Knight Alzheimer Disease Research Center, St. Louis, USA"/>
    <meta name="citation_author" content="Sabandal, J. Martin"/>
    <meta name="citation_author_institution" content="Foundation for the National Institutes of Health, North Bethesda, USA"/>
    <meta name="citation_author" content="Bateman, Randall J."/>
    <meta name="citation_author_institution" content="Department of Neurology, Washington University in St. Louis, St. Louis, USA"/>
    <meta name="citation_author_institution" content="Knight Alzheimer Disease Research Center, St. Louis, USA"/>
    <meta name="citation_author_institution" content="Hope Center for Neurologic Diseases, St. Louis, USA"/>
    <meta name="citation_author_institution" content="Tracy Family SILQ Center for Neurodegenerative Biology, St. Louis, USA"/>
    <meta name="citation_author" content="Bannon, Anthony W."/>
    <meta name="citation_author_institution" content="AbbVie, North Chicago, USA"/>
    <meta name="citation_author" content="Potter, William Z."/>
    <meta name="citation_author" content="Schindler, Suzanne E."/>
    <meta name="citation_author_institution" content="Department of Neurology, Washington University in St. Louis, St. Louis, USA"/>
    <meta name="citation_author_institution" content="Knight Alzheimer Disease Research Center, St. Louis, USA"/>
    <meta name="citation_author_institution" content="Hope Center for Neurologic Diseases, St. Louis, USA"/>
    <meta name="access_endpoint" content="https://www.nature.com/platform/readcube-access"/>
    <meta name="twitter:site" content="@naturemedicine"/>
    <meta name="twitter:card" content="summary_large_image"/>
    <meta name="twitter:image:alt" content="Content cover image"/>
    <meta name="twitter:title" content="Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks"/>
    <meta name="twitter:description" content="Nature Medicine - Plasma p-tau217 tests used to develop clocks that predict when cognitively unimpaired individuals would develop symptoms of Alzheimer&#700;s disease."/>
    <meta name="twitter:image" content="https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig1_HTML.png"/>
    

    
    
    <meta property="og:url" content="https://www.nature.com/articles/s41591-026-04206-y"/>
    <meta property="og:type" content="article"/>
    <meta property="og:site_name" content="Nature"/>
    <meta property="og:title" content="Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks - Nature Medicine"/>
    <meta property="og:description" content="Plasma p-tau217 tests used to develop clocks that predict when cognitively unimpaired individuals would develop symptoms of Alzheimer&#700;s disease."/>
    <meta property="og:image" content="https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig1_HTML.png"/>
    

    <script>
        window.eligibleForRa21 = 'false'; 
    </script>
</head>
<body class="article-page">

<div class="position-relative cleared z-index-50 background-white" data-test="top-containers">
    <a class="c-skip-link" href="#content">Skip to main content</a>



<div class="c-grade-c-banner u-hide">
    <div class="c-grade-c-banner__container">
        
        <p>Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
            the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
            Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
            and JavaScript.</p>

    </div>
</div>

    

    

    
    
        <div class="u-hide u-show-following-ad"></div>

    <aside class="c-ad c-ad--728x90">
        <div class="c-ad__inner" data-container-type="banner-advert">
            <p class="c-ad__label">Advertisement</p>
            
        
            
    <div id="div-gpt-ad-top-1"
         class="div-gpt-ad advert leaderboard js-ad text-center hide-print grade-c-hide"
         data-ad-type="top"
         data-test="top-ad"
         data-pa11y-ignore
         data-gpt
         data-gpt-unitpath="/285/medicine.nature.com/article"
         data-gpt-sizes="728x90"
         data-gpt-targeting="type=article;pos=top;artid=s41591-026-04206-y;doi=10.1038/s41591-026-04206-y;subjmeta=1283,1689,378,631;kwrd=Alzheimer%27s+disease">
        
        <script>
            window.SN = window.SN || {};
            window.SN.libs = window.SN.libs || {};
            window.SN.libs.ads = window.SN.libs.ads || {};
            window.SN.libs.ads.slotConfig = window.SN.libs.ads.slotConfig || {};
            
                window.SN.libs.ads.slotConfig['top'] = {
                    'pos': 'top',
                    'type': 'article',
                    'path': 's41591-026-04206-y'
                };
            
            
            window.SN.libs.ads.slotConfig['kwrd'] = 'Alzheimer%27s+disease';
            
            
            window.SN.libs.ads.slotConfig['subjmeta'] = '1283,1689,378,631';
            
            
        </script>
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=549431045&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-026-04206-y%26doi%3D10.1038/s41591-026-04206-y%26subjmeta%3D1283,1689,378,631%26kwrd%3DAlzheimer%27s+disease">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=549431045&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-026-04206-y%26doi%3D10.1038/s41591-026-04206-y%26subjmeta%3D1283,1689,378,631%26kwrd%3DAlzheimer%27s+disease"
                     alt="Advertisement"
                     width="728"
                     height="90"></a>
        </noscript>
    </div>

        
    
        </div>
    </aside>


    <header class="c-header" id="header" data-header data-track-component="nature-150-split-header" style="border-color:#e40428">
        <div class="c-header__row">
            <div class="c-header__container">
                <div class="c-header__split">
                    
                    
                    <div class="c-header__logo-container">
                        
                        <a href="/nm"
                           data-track="click" data-track-action="home" data-track-label="image">
                            <picture class="c-header__logo">
                                <source srcset="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" media="(min-width: 875px)">
                                <img src="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" height="32" alt="Nature Medicine">
                            </picture>
                        </a>
                    
                    </div>
                    
                    <ul class="c-header__menu c-header__menu--global">
                        <li class="c-header__item c-header__item--padding c-header__item--hide-md-max">
                            <a class="c-header__link" href="https://www.nature.com/siteindex" data-test="siteindex-link"
                               data-track="click" data-track-action="open nature research index" data-track-label="link">
                                <span>View all journals</span>
                            </a>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--pipe">
                            <a class="c-header__link c-header__link--search"
                                href="#search-menu"
                                data-header-expander
                                data-test="search-link" data-track="click" data-track-action="open search tray" data-track-label="button">
                                <svg role="img" aria-hidden="true" focusable="false" height="22" width="22" viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg"><path d="M16.48 15.455c.283.282.29.749.007 1.032a.738.738 0 01-1.032-.007l-3.045-3.044a7 7 0 111.026-1.026zM8 14A6 6 0 108 2a6 6 0 000 12z"/></svg><span>Search</span>
                            </a>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--snid-account-widget c-header__item--pipe">
                            
                                <a href="/nams/svc/myaccount"
    id="my-account"
    class="c-header__link placeholder"
    data-test="login-link" data-track="click" data-track-action="my account" data-track-category="nature-150-split-header" data-track-label="link">
    <span>My Account</span><svg role="img" aria-hidden="true" focusable="false" height="22" width="22" viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg"><path d="M10.238 16.905a7.96 7.96 0 003.53-1.48c-.874-2.514-2.065-3.936-3.768-4.319V9.83a3.001 3.001 0 10-2 0v1.277c-1.703.383-2.894 1.805-3.767 4.319A7.96 7.96 0 009 17c.419 0 .832-.032 1.238-.095zm4.342-2.172a8 8 0 10-11.16 0c.757-2.017 1.84-3.608 3.49-4.322a4 4 0 114.182 0c1.649.714 2.731 2.305 3.488 4.322zM9 18A9 9 0 119 0a9 9 0 010 18z" fill="#333" fill-rule="evenodd"/></svg>
</a>
<a href="https://idp.nature.com/authorize/natureuser?client_id&#x3D;grover&amp;redirect_uri&#x3D;https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-026-04206-y"
    id="login-button"
    style="display: none;"
    class="c-header__link placeholder"
    data-test="login-link" data-track="click" data-track-action="login" data-track-category="nature-150-split-header" data-track-label="link">
    <span>Login</span><svg role="img" aria-hidden="true" focusable="false" height="22" width="22" viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg"><path d="M10.238 16.905a7.96 7.96 0 003.53-1.48c-.874-2.514-2.065-3.936-3.768-4.319V9.83a3.001 3.001 0 10-2 0v1.277c-1.703.383-2.894 1.805-3.767 4.319A7.96 7.96 0 009 17c.419 0 .832-.032 1.238-.095zm4.342-2.172a8 8 0 10-11.16 0c.757-2.017 1.84-3.608 3.49-4.322a4 4 0 114.182 0c1.649.714 2.731 2.305 3.488 4.322zM9 18A9 9 0 119 0a9 9 0 010 18z" fill="#333" fill-rule="evenodd"/></svg>
</a>

                            
                        </li>
                    </ul>
                </div>
            </div>
        </div>
        
            <div class="c-header__row">
                <div class="c-header__container" data-test="navigation-row">
                    <div class="c-header__split">
                        <ul class="c-header__menu c-header__menu--journal">
                            
                                <li class="c-header__item c-header__item--dropdown-menu" data-test="explore-content-button">
                                    <a href="#explore"
                                       class="c-header__link"
                                       data-header-expander
                                       data-test="menu-button--explore"
                                       data-track="click" data-track-action="open explore expander" data-track-label="button">
                                        <span class="c-header__show-text-sm">Content</span>
                                        <span class="c-header__show-text">Explore content</span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"/></svg>
                                    </a>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--dropdown-menu">
                                    <a href="#about-the-journal"
                                       class="c-header__link"
                                       data-header-expander
                                       data-test="menu-button--about-the-journal"
                                       data-track="click" data-track-action="open about the journal expander" data-track-label="button">
                                        <span>About <span class="c-header__show-text">the journal</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"/></svg>
                                    </a>
                                </li>
                                
                                    <li class="c-header__item c-header__item--dropdown-menu" data-test="publish-with-us-button">
                                        <a href="#publish-with-us"
                                           class="c-header__link c-header__link--dropdown-menu"
                                           data-header-expander
                                           data-test="menu-button--publish"
                                           data-track="click" data-track-action="open publish with us expander" data-track-label="button">
                                            <span>Publish <span class="c-header__show-text">with us</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"/></svg>
                                        </a>
                                    </li>
                                
                            
                            
                        </ul>
                        <ul class="c-header__menu c-header__menu--hide-lg-max">
                            
                                <li class="c-header__item" data-test="alert-link">
                                    <a class="c-header__link"
                                       href="https://journal-alerts.springernature.com/subscribe?journal_id&#x3D;41591"
                                       rel="nofollow"
                                       data-track="nav_sign_up_for_alerts"
                                       data-track-action="Sign up for alerts"
                                       data-track-label="link (desktop site header)"
                                       data-track-external>
                                        <span>Sign up for alerts</span><svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#222"/></svg>
                                    </a>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--pipe">
                                    <a class="c-header__link"
                                       href="https://www.nature.com/nm.rss"
                                       data-track="click"
                                       data-track-action="rss feed"
                                       data-track-label="link">
                                            <span>RSS feed</span>
                                    </a>
                                </li>
                            
                        </ul>
                    </div>
                </div>
            </div>
        
    </header>


    
    
        <nav class="u-mb-16" aria-label="breadcrumbs">
            <div class="u-container">
                <ol class="c-breadcrumbs" itemscope itemtype="https://schema.org/BreadcrumbList">
                    <li class="c-breadcrumbs__item" id="breadcrumb0" itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link"
                               href="/" itemprop="item"
                               data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature"><span itemprop="name">nature</span></a><meta itemprop="position" content="1">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10"
                                         xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z"
                                              fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb1" itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link"
                               href="/nm" itemprop="item"
                               data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature medicine"><span itemprop="name">nature medicine</span></a><meta itemprop="position" content="2">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10"
                                         xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z"
                                              fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb2" itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link"
                               href="/nm/articles?type&#x3D;article" itemprop="item"
                               data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:articles"><span itemprop="name">articles</span></a><meta itemprop="position" content="3">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10"
                                         xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z"
                                              fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb3" itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem">
                                    <span itemprop="name">article</span><meta itemprop="position" content="4"></li>
                </ol>
            </div>
        </nav>
    



    

</div>


<div class="u-container u-mt-32 u-mb-32 u-clearfix" id="content" data-component="article-container"  data-container-type="article">
    <main class="c-article-main-column u-float-left js-main-column" data-track-component="article body">
        
            
                <div class="c-context-bar u-hide"
                     id="js-enable-context-bar"
                     data-test="context-bar"
                     data-context-bar
                     aria-hidden="true">
                    <div class="c-context-bar__container" data-track-context="sticky banner">
                        <div class="c-context-bar__title">
                            Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks
                        </div>
                        <div class="c-context-bar__cta-container">
                            
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-026-04206-y.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external download>
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"/></svg>
            </a>
        </div>
    

                            
                        </div>
                    </div>
                </div>
            
        
        <article lang="en">
            
                <div class="c-pdf-button__container u-mb-8 u-hide-at-lg js-context-bar-sticky-point-mobile">
                    <div class="c-pdf-container" data-track-context="article body">
                        
                            
                                <div class="app-cta-group">
                                    
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-026-04206-y.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external download>
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"/></svg>
            </a>
        </div>
    

                                    
                                </div>
                            
                        
                    </div>
                </div>
            
            <div class="c-article-header">
                <header>
                    <ul class="c-article-identifiers" data-test="article-identifier">
                        
        <li class="c-article-identifiers__item" data-test="article-category">Article</li>
    
        <li class="c-article-identifiers__item">
            <a href="https://www.springernature.com/gp/open-science/about/the-fundamentals-of-open-access-and-open-research" data-track="click" data-track-action="open access" data-track-label="link" class="u-color-open-access" data-test="open-access">Open access</a>
        </li>
    
    

                        <li class="c-article-identifiers__item">Published: <time datetime="2026-02-19">19 February 2026</time></li>
                    </ul>

                    <h1 class="c-article-title" data-test="article-title" data-article-title="">Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks</h1>
                    <ul class="c-article-author-list c-article-author-list--long" data-test="authors-list" data-component-authors-activator="authors-list"><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="1_30" data-track-context="researcher popup with no profile" href="#auth-Kellen_K_-Petersen-Aff1" data-author-popup="auth-Kellen_K_-Petersen-Aff1" data-author-search="Petersen, Kellen K.">Kellen K. Petersen</a><span class="u-js-hide"> 
            <a class="js-orcid" href="https://orcid.org/0000-0003-3195-3456"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-3195-3456</a></span><sup class="u-js-hide"><a href="#Aff1">1</a></sup>, </li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="2_30" data-track-context="researcher popup with no profile" href="#auth-Marta-Mil__Alom_-Aff2-Aff3" data-author-popup="auth-Marta-Mil__Alom_-Aff2-Aff3" data-author-search="Milà-Alomà, Marta">Marta Milà-Alomà</a><sup class="u-js-hide"><a href="#Aff2">2</a>,<a href="#Aff3">3</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="3_30" data-track-context="researcher popup with no profile" href="#auth-Yan-Li-Aff1" data-author-popup="auth-Yan-Li-Aff1" data-author-search="Li, Yan">Yan Li</a><span class="u-js-hide"> 
            <a class="js-orcid" href="https://orcid.org/0000-0003-1340-6694"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-1340-6694</a></span><sup class="u-js-hide"><a href="#Aff1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="4_30" data-track-context="researcher popup with no profile" href="#auth-Lianlian-Du-Aff4-Aff5-Aff6-Aff7" data-author-popup="auth-Lianlian-Du-Aff4-Aff5-Aff6-Aff7" data-author-search="Du, Lianlian">Lianlian Du</a><span class="u-js-hide"> 
            <a class="js-orcid" href="https://orcid.org/0000-0002-1662-0883"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-1662-0883</a></span><sup class="u-js-hide"><a href="#Aff4">4</a>,<a href="#Aff5">5</a>,<a href="#Aff6">6</a>,<a href="#Aff7">7</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="5_30" data-track-context="researcher popup with no profile" href="#auth-Chengjie-Xiong-Aff8-Aff9" data-author-popup="auth-Chengjie-Xiong-Aff8-Aff9" data-author-search="Xiong, Chengjie">Chengjie Xiong</a><sup class="u-js-hide"><a href="#Aff8">8</a>,<a href="#Aff9">9</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="6_30" data-track-context="researcher popup with no profile" href="#auth-Duygu-Tosun-Aff2-Aff3" data-author-popup="auth-Duygu-Tosun-Aff2-Aff3" data-author-search="Tosun, Duygu">Duygu Tosun</a><span class="u-js-hide"> 
            <a class="js-orcid" href="https://orcid.org/0000-0001-8644-7724"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-8644-7724</a></span><sup class="u-js-hide"><a href="#Aff2">2</a>,<a href="#Aff3">3</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="7_30" data-track-context="researcher popup with no profile" href="#auth-Benjamin-Saef-Aff1" data-author-popup="auth-Benjamin-Saef-Aff1" data-author-search="Saef, Benjamin">Benjamin Saef</a><sup class="u-js-hide"><a href="#Aff1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="8_30" data-track-context="researcher popup with no profile" href="#auth-Ziad_S_-Saad-Aff10" data-author-popup="auth-Ziad_S_-Saad-Aff10" data-author-search="Saad, Ziad S.">Ziad S. Saad</a><sup class="u-js-hide"><a href="#Aff10">10</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="9_30" data-track-context="researcher popup with no profile" href="#auth-Lei-Du_Cuny-Aff11" data-author-popup="auth-Lei-Du_Cuny-Aff11" data-author-search="Du-Cuny, Lei">Lei Du-Cuny</a><sup class="u-js-hide"><a href="#Aff11">11</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="10_30" data-track-context="researcher popup with no profile" href="#auth-Janaky-Coomaraswamy-Aff12" data-author-popup="auth-Janaky-Coomaraswamy-Aff12" data-author-search="Coomaraswamy, Janaky">Janaky Coomaraswamy</a><sup class="u-js-hide"><a href="#Aff12">12</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="11_30" data-track-context="researcher popup with no profile" href="#auth-Yulia-Mordashova-Aff11" data-author-popup="auth-Yulia-Mordashova-Aff11" data-author-search="Mordashova, Yulia">Yulia Mordashova</a><sup class="u-js-hide"><a href="#Aff11">11</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="12_30" data-track-context="researcher popup with no profile" href="#auth-Carrie_E_-Rubel-Aff13" data-author-popup="auth-Carrie_E_-Rubel-Aff13" data-author-search="Rubel, Carrie E.">Carrie E. Rubel</a><sup class="u-js-hide"><a href="#Aff13">13</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="13_30" data-track-context="researcher popup with no profile" href="#auth-Emily_A_-Meyers-Aff14" data-author-popup="auth-Emily_A_-Meyers-Aff14" data-author-search="Meyers, Emily A.">Emily A. Meyers</a><span class="u-js-hide"> 
            <a class="js-orcid" href="https://orcid.org/0000-0002-0886-6218"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-0886-6218</a></span><sup class="u-js-hide"><a href="#Aff14">14</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="14_30" data-track-context="researcher popup with no profile" href="#auth-Leslie_M_-Shaw-Aff15" data-author-popup="auth-Leslie_M_-Shaw-Aff15" data-author-search="Shaw, Leslie M.">Leslie M. Shaw</a><sup class="u-js-hide"><a href="#Aff15">15</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="15_30" data-track-context="researcher popup with no profile" href="#auth-Jeffrey_L_-Dage-Aff16-Aff17" data-author-popup="auth-Jeffrey_L_-Dage-Aff16-Aff17" data-author-search="Dage, Jeffrey L.">Jeffrey L. Dage</a><span class="u-js-hide"> 
            <a class="js-orcid" href="https://orcid.org/0000-0002-2192-1699"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-2192-1699</a></span><sup class="u-js-hide"><a href="#Aff16">16</a>,<a href="#Aff17">17</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="16_30" data-track-context="researcher popup with no profile" href="#auth-Nicholas_J_-Ashton-Aff18-Aff19-Aff20" data-author-popup="auth-Nicholas_J_-Ashton-Aff18-Aff19-Aff20" data-author-search="Ashton, Nicholas J.">Nicholas J. Ashton</a><sup class="u-js-hide"><a href="#Aff18">18</a>,<a href="#Aff19">19</a>,<a href="#Aff20">20</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="17_30" data-track-context="researcher popup with no profile" href="#auth-Henrik-Zetterberg-Aff18-Aff21-Aff22-Aff23-Aff24-Aff25" data-author-popup="auth-Henrik-Zetterberg-Aff18-Aff21-Aff22-Aff23-Aff24-Aff25" data-author-search="Zetterberg, Henrik">Henrik Zetterberg</a><span class="u-js-hide"> 
            <a class="js-orcid" href="https://orcid.org/0000-0003-3930-4354"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-3930-4354</a></span><sup class="u-js-hide"><a href="#Aff18">18</a>,<a href="#Aff21">21</a>,<a href="#Aff22">22</a>,<a href="#Aff23">23</a>,<a href="#Aff24">24</a>,<a href="#Aff25">25</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="18_30" data-track-context="researcher popup with no profile" href="#auth-Kyle-Ferber-Aff13" data-author-popup="auth-Kyle-Ferber-Aff13" data-author-search="Ferber, Kyle">Kyle Ferber</a><sup class="u-js-hide"><a href="#Aff13">13</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="19_30" data-track-context="researcher popup with no profile" href="#auth-Gallen-Triana_Baltzer-Aff10" data-author-popup="auth-Gallen-Triana_Baltzer-Aff10" data-author-search="Triana-Baltzer, Gallen">Gallen Triana-Baltzer</a><sup class="u-js-hide"><a href="#Aff10">10</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="20_30" data-track-context="researcher popup with no profile" href="#auth-Michael-Baratta-Aff12" data-author-popup="auth-Michael-Baratta-Aff12" data-author-search="Baratta, Michael">Michael Baratta</a><sup class="u-js-hide"><a href="#Aff12">12</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="21_30" data-track-context="researcher popup with no profile" href="#auth-Erin_G_-Rosenbaugh-Aff26" data-author-popup="auth-Erin_G_-Rosenbaugh-Aff26" data-author-search="Rosenbaugh, Erin G.">Erin G. Rosenbaugh</a><sup class="u-js-hide"><a href="#Aff26">26</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="22_30" data-track-context="researcher popup with no profile" href="#auth-Carlos-Cruchaga-Aff8-Aff27-Aff28-Aff29" data-author-popup="auth-Carlos-Cruchaga-Aff8-Aff27-Aff28-Aff29" data-author-search="Cruchaga, Carlos">Carlos Cruchaga</a><span class="u-js-hide"> 
            <a class="js-orcid" href="https://orcid.org/0000-0002-0276-2899"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-0276-2899</a></span><sup class="u-js-hide"><a href="#Aff8">8</a>,<a href="#Aff27">27</a>,<a href="#Aff28">28</a>,<a href="#Aff29">29</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="23_30" data-track-context="researcher popup with no profile" href="#auth-Eric-McDade-Aff1-Aff8" data-author-popup="auth-Eric-McDade-Aff1-Aff8" data-author-search="McDade, Eric">Eric McDade</a><span class="u-js-hide"> 
            <a class="js-orcid" href="https://orcid.org/0000-0002-6764-3866"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-6764-3866</a></span><sup class="u-js-hide"><a href="#Aff1">1</a>,<a href="#Aff8">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="24_30" data-track-context="researcher popup with no profile" href="#auth-David_M_-Holtzman-Aff1-Aff8-Aff29" data-author-popup="auth-David_M_-Holtzman-Aff1-Aff8-Aff29" data-author-search="Holtzman, David M.">David M. Holtzman</a><span class="u-js-hide"> 
            <a class="js-orcid" href="https://orcid.org/0000-0002-3400-0856"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-3400-0856</a></span><sup class="u-js-hide"><a href="#Aff1">1</a>,<a href="#Aff8">8</a>,<a href="#Aff29">29</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="25_30" data-track-context="researcher popup with no profile" href="#auth-John_C_-Morris-Aff1-Aff8" data-author-popup="auth-John_C_-Morris-Aff1-Aff8" data-author-search="Morris, John C.">John C. Morris</a><sup class="u-js-hide"><a href="#Aff1">1</a>,<a href="#Aff8">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="26_30" data-track-context="researcher popup with no profile" href="#auth-J__Martin-Sabandal-Aff26" data-author-popup="auth-J__Martin-Sabandal-Aff26" data-author-search="Sabandal, J. Martin">J. Martin Sabandal</a><sup class="u-js-hide"><a href="#Aff26">26</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="27_30" data-track-context="researcher popup with no profile" href="#auth-Randall_J_-Bateman-Aff1-Aff8-Aff29-Aff30" data-author-popup="auth-Randall_J_-Bateman-Aff1-Aff8-Aff29-Aff30" data-author-search="Bateman, Randall J.">Randall J. Bateman</a><span class="u-js-hide"> 
            <a class="js-orcid" href="https://orcid.org/0000-0002-7729-1702"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-7729-1702</a></span><sup class="u-js-hide"><a href="#Aff1">1</a>,<a href="#Aff8">8</a>,<a href="#Aff29">29</a>,<a href="#Aff30">30</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="28_30" data-track-context="researcher popup with no profile" href="#auth-Anthony_W_-Bannon-Aff31" data-author-popup="auth-Anthony_W_-Bannon-Aff31" data-author-search="Bannon, Anthony W.">Anthony W. Bannon</a><sup class="u-js-hide"><a href="#Aff31">31</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="29_30" data-track-context="researcher popup with no profile" href="#auth-William_Z_-Potter" data-author-popup="auth-William_Z_-Potter" data-author-search="Potter, William Z.">William Z. Potter</a><sup class="u-js-hide"></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="30_30" data-track-context="researcher popup with no profile" href="#auth-Suzanne_E_-Schindler-Aff1-Aff8-Aff29" data-author-popup="auth-Suzanne_E_-Schindler-Aff1-Aff8-Aff29" data-author-search="Schindler, Suzanne E." data-corresp-id="c1">Suzanne E. Schindler<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><span class="u-js-hide"> 
            <a class="js-orcid" href="https://orcid.org/0000-0002-1680-1465"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-1680-1465</a></span><sup class="u-js-hide"><a href="#Aff1">1</a>,<a href="#Aff8">8</a>,<a href="#Aff29">29</a></sup> &amp; </li><li class="c-article-author-list__item"><a data-test="author-name" data-author-popup="group-1" href="#group-1">Alzheimer’s Disease Neuroimaging Initiative (ADNI)</a> &amp; </li><li class="c-article-author-list__item"><a data-test="author-name" data-author-popup="group-2" href="#group-2">On behalf of the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer’s Disease Project Team</a></li></ul><button aria-expanded="false" class="c-article-author-list__button"><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-down-medium"></use></svg><span>Show authors</span></button>

                    

                    <p class="c-article-info-details" data-container-section="info">
                        
    <a data-test="journal-link" href="/nm" data-track="click" data-track-action="journal homepage" data-track-category="article body" data-track-label="link"><i data-test="journal-title">Nature Medicine</i></a>

                         (<span data-test="article-publication-year">2026</span>)<a href="#citeas" class="c-article-info-details__cite-as u-hide-print" data-track="click" data-track-action="cite this article" data-track-label="link">Cite this article</a>
                    </p>
                    
        
        <div class="c-article-metrics-bar__wrapper u-clear-both">
            <ul class="c-article-metrics-bar u-list-reset">
                
                    <li class=" c-article-metrics-bar__item" data-test="access-count">
                        <p class="c-article-metrics-bar__count">42k <span class="c-article-metrics-bar__label">Accesses</span></p>
                    </li>
                
                
                    <li class="c-article-metrics-bar__item" data-test="citation-count">
                        <p class="c-article-metrics-bar__count">1 <span class="c-article-metrics-bar__label">Citations</span></p>
                    </li>
                
                
                    
                        <li class="c-article-metrics-bar__item" data-test="altmetric-score">
                            <p class="c-article-metrics-bar__count">946 <span class="c-article-metrics-bar__label">Altmetric</span></p>
                        </li>
                    
                
                
                    <li class="c-article-metrics-bar__item">
                        <p class="c-article-metrics-bar__details"><a href="/articles/s41591-026-04206-y/metrics" data-track="click" data-track-action="view metrics" data-track-label="link" rel="nofollow">Metrics <span class="u-visually-hidden">details</span></a></p>
                    </li>
                
            </ul>
        </div>
    
                    
                </header>

                
    <div class="u-js-hide" data-component="article-subject-links">
        <h3 class="c-article__sub-heading">Subjects</h3>
        <ul class="c-article-subject-list">
            <li class="c-article-subject-list__subject"><a href="/subjects/alzheimers-disease" data-track="click" data-track-action="view subject" data-track-label="link">Alzheimer&#x27;s disease</a></li>
        </ul>
    </div>

                
    
    

    
    

                
            </div>

        <div class="c-article-body">
            <section aria-labelledby="Abs1" data-title="Abstract" lang="en"><div class="c-article-section" id="Abs1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Abs1">Abstract</h2><div class="c-article-section__content" id="Abs1-content"><p>Predicting not just if, but also when, cognitively unimpaired individuals are likely to develop onset of Alzheimerʼs disease (AD) symptoms would be useful to clinical trials and, eventually, clinical practice. Although clock models based on amyloid and tau positron emission tomography have shown promise in predicting the onset of AD symptoms, a model based on plasma biomarkers would be more accessible. Using longitudinal plasma %p-tau217 (the ratio of phosphorylated to non-phosphorylated tau at position 217) from two independent cohorts (<i>n</i> = 258 and <i>n</i> = 345), clock models were used to estimate the age at plasma %p-tau217 positivity. The estimated age at plasma %p-tau217 positivity was associated with the age at onset of AD symptoms (adjusted <i>R</i><sup>2</sup> of 0.337−0.612) with a median absolute error of 3.0−3.7 years. Notably, the time from %p-tau217 positivity to onset of AD symptoms was markedly shorter in older individuals. Similar models were constructed with data from one p-tau217/Aβ42 immunoassay and four plasma p-tau217 immunoassays. These findings suggest that the time until onset of AD symptoms can be estimated using a single blood test within a margin of error that is acceptable for use in clinical trials.</p></div></div></section>

            
                
            

            
                
                    
        
            <section aria-labelledby="inline-recommendations" data-title="Inline Recommendations" class="c-article-recommendations" data-track-component="inline-recommendations">
                <h3 class="c-article-recommendations-title" id="inline-recommendations">Similar content being viewed by others</h3>
                <div class="c-article-recommendations-list">
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs43587-023-00405-1/MediaObjects/43587_2023_405_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link"
                                           itemprop="url"
                                           href="https://www.nature.com/articles/s43587-023-00405-1"
                                           data-track="select_recommendations_1"
                                           data-track-context="inline recommendations"
                                           data-track-action="click recommendations inline - 1"
                                           data-track-label="10.1038/s43587-023-00405-1">Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">27 April 2023</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs43587-025-00904-3/MediaObjects/43587_2025_904_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link"
                                           itemprop="url"
                                           href="https://www.nature.com/articles/s43587-025-00904-3"
                                           data-track="select_recommendations_2"
                                           data-track-context="inline recommendations"
                                           data-track-action="click recommendations inline - 2"
                                           data-track-label="10.1038/s43587-025-00904-3">Comprehensive evaluation of plasma tau biomarkers for detecting and monitoring Alzheimer’s disease in a multicenter and multiethnic aging population
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                        
                                         <span class="c-article-meta-recommendations__date">23 June 2025</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs43856-025-00768-z/MediaObjects/43856_2025_768_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link"
                                           itemprop="url"
                                           href="https://www.nature.com/articles/s43856-025-00768-z"
                                           data-track="select_recommendations_3"
                                           data-track-context="inline recommendations"
                                           data-track-action="click recommendations inline - 3"
                                           data-track-label="10.1038/s43856-025-00768-z">Alzheimer’s disease biological PET staging using plasma p217+tau
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">27 February 2025</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                </div>
            </section>
        
            <script>
                window.dataLayer = window.dataLayer || [];
                window.dataLayer.push({
                    recommendations: {
                        recommender: 'semantic',
                        model: 'e5',
                        policy_id: null,
                        timestamp: 1772019004,
                        embedded_user: 'null'
                    }
                });
            </script>
        
    
                
                
                <div class="main-content">
                    
                        <section data-title="Main"><div class="c-article-section" id="Sec1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec1">Main</h2><div class="c-article-section__content" id="Sec1-content"><p>AD is the most common cause of dementia and is characterized by amyloid plaques primarily comprised of amyloid-β 42 (Aβ42) and neurofibrillary tangles comprising tau<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Jack Jr, C. R. et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimers Dement. 20, 5143–5169 (2024)." href="/articles/s41591-026-04206-y#ref-CR1" id="ref-link-section-d37439729e1462">1</a></sup>. The burden of amyloid plaques as quantified by amyloid positron emission tomography (PET) increases for about 10−20 years during the preclinical phase of AD when patients are cognitively unimpaired and then plateaus around the time of symptom onset<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 2" title="Jack Jr, C. R. et al. Brain β-amyloid load approaches a plateau. Neurology 80, 890–896 (2013)." href="/articles/s41591-026-04206-y#ref-CR2" id="ref-link-section-d37439729e1466">2</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N. Engl. J. Med. 367, 795–804 (2012)." href="/articles/s41591-026-04206-y#ref-CR3" id="ref-link-section-d37439729e1469">3</a></sup>. By contrast, neurofibrillary tangles as measured by tau PET develop later and increase with symptom severity<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 4" title="Gordon, B. A. et al. Tau PET in autosomal dominant Alzheimer’s disease: relationship with cognition, dementia and other biomarkers. Brain 142, 1063–1076 (2019)." href="/articles/s41591-026-04206-y#ref-CR4" id="ref-link-section-d37439729e1473">4</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Ossenkoppele, R. et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat. Med. 28, 2381–2387 (2022)." href="/articles/s41591-026-04206-y#ref-CR5" id="ref-link-section-d37439729e1476">5</a></sup>. Although treatments for early symptomatic AD are now clinically available in some countries<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. 388, 9–21 (2023)." href="/articles/s41591-026-04206-y#ref-CR6" id="ref-link-section-d37439729e1480">6</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512–527 (2023)." href="/articles/s41591-026-04206-y#ref-CR7" id="ref-link-section-d37439729e1483">7</a></sup>, treating patients earlier during the preclinical phase of disease before major neurodegeneration has occurred may be more efficacious<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 8" title="Sperling, R. A., Jack Jr, C. R. &amp; Aisen, P. S. Testing the right target and right drug at the right stage. Sci. Transl. Med. 3, 111cm133 (2011)." href="/articles/s41591-026-04206-y#ref-CR8" id="ref-link-section-d37439729e1487">8</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="McDade, E. &amp; Bateman, R. J. Stop Alzheimer’s before it starts. Nature 547, 153–155 (2017)." href="/articles/s41591-026-04206-y#ref-CR9" id="ref-link-section-d37439729e1490">9</a></sup>. Although biomarkers can accurately identify individuals with AD brain pathology, predicting which individuals are likely to develop symptoms is more challenging, and novel predictive modeling approaches are needed.</p><p>Interestingly, once amyloid plaques and neurofibrillary tangles start to accumulate, the burden of pathology follows a remarkably consistent trajectory across individuals<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 2" title="Jack Jr, C. R. et al. Brain β-amyloid load approaches a plateau. Neurology 80, 890–896 (2013)." href="/articles/s41591-026-04206-y#ref-CR2" id="ref-link-section-d37439729e1497">2</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Schindler, S. E. et al. Predicting symptom onset in sporadic Alzheimer disease with amyloid PET. Neurology 97, e1823–e1834 (2021)." href="#ref-CR10" id="ref-link-section-d37439729e1500">10</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Villemagne, V. L. et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann. Neurol. 69, 181–192 (2011)." href="#ref-CR11" id="ref-link-section-d37439729e1500_1">11</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Heston, M. B. et al. Factors associated with age at tau pathology onset and time from tau onset to dementia in Alzheimer's disease. Alzheimers Dement. 21, e70551 (2025)." href="#ref-CR12" id="ref-link-section-d37439729e1500_2">12</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Mila-Aloma, M. et al. Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocks. Ann. Neurol. 98, 508–523 (2025)." href="/articles/s41591-026-04206-y#ref-CR13" id="ref-link-section-d37439729e1503">13</a></sup>. These consistent trajectories enable the creation of clock models that relate levels of amyloid or tau PET signal to time and allow for estimation of when individuals developed amyloid or tau PET abnormality<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 2" title="Jack Jr, C. R. et al. Brain β-amyloid load approaches a plateau. Neurology 80, 890–896 (2013)." href="/articles/s41591-026-04206-y#ref-CR2" id="ref-link-section-d37439729e1507">2</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Villemagne, V. L. et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann. Neurol. 69, 181–192 (2011)." href="#ref-CR11" id="ref-link-section-d37439729e1510">11</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Heston, M. B. et al. Factors associated with age at tau pathology onset and time from tau onset to dementia in Alzheimer's disease. Alzheimers Dement. 21, e70551 (2025)." href="#ref-CR12" id="ref-link-section-d37439729e1510_1">12</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Mila-Aloma, M. et al. Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocks. Ann. Neurol. 98, 508–523 (2025)." href="#ref-CR13" id="ref-link-section-d37439729e1510_2">13</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Budgeon, C. A. et al. Constructing longitudinal disease progression curves using sparse, short-term individual data with an application to Alzheimer’s disease. Stat. Med. 36, 2720–2734 (2017)." href="#ref-CR14" id="ref-link-section-d37439729e1510_3">14</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Koscik, R. L. et al. Amyloid duration is associated with preclinical cognitive decline and tau PET. Alzheimers Dement. 12, e12007 (2020)." href="/articles/s41591-026-04206-y#ref-CR15" id="ref-link-section-d37439729e1513">15</a></sup>. Unlike general biological aging clocks or categorical staging based on multiple biomarkers, clock models track disease progression with a specific biomarker, thereby providing granular and intuitive time-based staging<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Jack Jr, C. R. et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimers Dement. 20, 5143–5169 (2024)." href="/articles/s41591-026-04206-y#ref-CR1" id="ref-link-section-d37439729e1517">1</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Schindler, S. E. et al. Predicting symptom onset in sporadic Alzheimer disease with amyloid PET. Neurology 97, e1823–e1834 (2021)." href="/articles/s41591-026-04206-y#ref-CR10" id="ref-link-section-d37439729e1520">10</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Mila-Aloma, M. et al. Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocks. Ann. Neurol. 98, 508–523 (2025)." href="/articles/s41591-026-04206-y#ref-CR13" id="ref-link-section-d37439729e1523">13</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Li, Y. et al. Timing of biomarker changes in sporadic Alzheimer’s disease in estimated years from symptom onset. Ann. Neurol. 95, 951–965 (2024)." href="/articles/s41591-026-04206-y#ref-CR16" id="ref-link-section-d37439729e1526">16</a></sup>. Clock models allow alignment of trajectories to a reference point (for example, amyloid or tau PET positivity) that reduces heterogeneity compared to models using chronological age alone<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Mila-Aloma, M. et al. Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocks. Ann. Neurol. 98, 508–523 (2025)." href="/articles/s41591-026-04206-y#ref-CR13" id="ref-link-section-d37439729e1530">13</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Li, Y. et al. Timing of biomarker changes in sporadic Alzheimer’s disease in estimated years from symptom onset. Ann. Neurol. 95, 951–965 (2024)." href="/articles/s41591-026-04206-y#ref-CR16" id="ref-link-section-d37439729e1533">16</a></sup>. Furthermore, the age at amyloid or tau abnormality or positivity estimated by clock models can be used to estimate the age at AD symptom onset<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Schindler, S. E. et al. Predicting symptom onset in sporadic Alzheimer disease with amyloid PET. Neurology 97, e1823–e1834 (2021)." href="/articles/s41591-026-04206-y#ref-CR10" id="ref-link-section-d37439729e1537">10</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Heston, M. B. et al. Factors associated with age at tau pathology onset and time from tau onset to dementia in Alzheimer's disease. Alzheimers Dement. 21, e70551 (2025)." href="/articles/s41591-026-04206-y#ref-CR12" id="ref-link-section-d37439729e1540">12</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Mila-Aloma, M. et al. Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocks. Ann. Neurol. 98, 508–523 (2025)." href="/articles/s41591-026-04206-y#ref-CR13" id="ref-link-section-d37439729e1543">13</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Koscik, R. L. et al. Amyloid duration is associated with preclinical cognitive decline and tau PET. Alzheimers Dement. 12, e12007 (2020)." href="/articles/s41591-026-04206-y#ref-CR15" id="ref-link-section-d37439729e1546">15</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Betthauser, T. J. et al. Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts. Brain 145, 4065–4079 (2022)." href="/articles/s41591-026-04206-y#ref-CR17" id="ref-link-section-d37439729e1549">17</a></sup>. Knowing not just if, but also when, AD symptoms are likely to manifest would be very useful to clinical trials that aim to prevent or slow progression to symptomatic AD<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Rafii, M. S. et al. The AHEAD 3-45 study: design of a prevention trial for Alzheimer’s disease. Alzheimers Dement. 19, 1227–1233 (2023)." href="/articles/s41591-026-04206-y#ref-CR18" id="ref-link-section-d37439729e1554">18</a></sup>.</p><p>Amyloid and tau PET are extremely useful tools in research and clinical trials but are expensive and burdensome methods with limited availability<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Rabinovici, G. D. et al. Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimers Dement. 21, e14338 (2025)." href="/articles/s41591-026-04206-y#ref-CR19" id="ref-link-section-d37439729e1561">19</a></sup>. Recently developed blood-based biomarkers are much more accessible and less expensive<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Hampel, H. et al. Blood-based biomarkers for Alzheimer’s disease: current state and future use in a transformed global healthcare landscape. Neuron 111, 2781–2799 (2023)." href="/articles/s41591-026-04206-y#ref-CR20" id="ref-link-section-d37439729e1565">20</a></sup>. The plasma ratio of amyloid-β peptide 42 to 40 (Aβ42/40) decreases very early during the preclinical phase of AD and then plateaus at moderate levels of amyloid plaque burden, resulting in poor correlations with AD symptoms<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Mila-Aloma, M. et al. Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocks. Ann. Neurol. 98, 508–523 (2025)." href="/articles/s41591-026-04206-y#ref-CR13" id="ref-link-section-d37439729e1569">13</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Li, Y. et al. Timing of biomarker changes in sporadic Alzheimer’s disease in estimated years from symptom onset. Ann. Neurol. 95, 951–965 (2024)." href="/articles/s41591-026-04206-y#ref-CR16" id="ref-link-section-d37439729e1572">16</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Wisch, J. K. et al. Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40. Alzheimers Dement. 15, e12405 (2023)." href="#ref-CR21" id="ref-link-section-d37439729e1575">21</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Devanarayan, V. et al. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease. Alzheimers Dement. 20, 5617–5628 (2024)." href="#ref-CR22" id="ref-link-section-d37439729e1575_1">22</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Schindler, S. E. et al. Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology. Alzheimers Dement. 20, 8074–8096 (2024)." href="/articles/s41591-026-04206-y#ref-CR23" id="ref-link-section-d37439729e1578">23</a></sup>. However, plasma levels of tau phosphorylated at position 217 (p-tau217) and the ratio of phosphorylated to non-phosphorylated tau at position 217 (referred to as %p-tau217) increase throughout the preclinical and early symptomatic phases of AD<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Mila-Aloma, M. et al. Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocks. Ann. Neurol. 98, 508–523 (2025)." href="/articles/s41591-026-04206-y#ref-CR13" id="ref-link-section-d37439729e1582">13</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Li, Y. et al. Timing of biomarker changes in sporadic Alzheimer’s disease in estimated years from symptom onset. Ann. Neurol. 95, 951–965 (2024)." href="/articles/s41591-026-04206-y#ref-CR16" id="ref-link-section-d37439729e1585">16</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Devanarayan, V. et al. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease. Alzheimers Dement. 20, 5617–5628 (2024)." href="/articles/s41591-026-04206-y#ref-CR22" id="ref-link-section-d37439729e1588">22</a></sup>. Importantly, plasma measures of p-tau217 and %p-tau217 have high associations not only with amyloid PET<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Devanarayan, V. et al. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease. Alzheimers Dement. 20, 5617–5628 (2024)." href="/articles/s41591-026-04206-y#ref-CR22" id="ref-link-section-d37439729e1592">22</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Barthelemy, N. R. et al. Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests. Nat. Med. 30, 1085–1095 (2024)." href="#ref-CR24" id="ref-link-section-d37439729e1595">24</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Warmenhoven, N. et al. A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. Brain 148, 416–431 (2025)." href="#ref-CR25" id="ref-link-section-d37439729e1595_1">25</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Palmqvist, S. et al. Blood biomarkers to detect Alzheimer disease in primary care and secondary care. JAMA 332, 1245–1257 (2024)." href="#ref-CR26" id="ref-link-section-d37439729e1595_2">26</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Meyer, M. R. et al. Clinical validation of the PrecivityAD2 blood test: a mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid. Alzheimers Dement. 20, 3179–3192 (2024)." href="#ref-CR27" id="ref-link-section-d37439729e1595_3">27</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Janelidze, S. et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease. Brain 146, 1592–1601 (2023)." href="/articles/s41591-026-04206-y#ref-CR28" id="ref-link-section-d37439729e1598">28</a></sup> but also with tau PET<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24" title="Barthelemy, N. R. et al. Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests. Nat. Med. 30, 1085–1095 (2024)." href="/articles/s41591-026-04206-y#ref-CR24" id="ref-link-section-d37439729e1603">24</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Warmenhoven, N. et al. A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. Brain 148, 416–431 (2025)." href="/articles/s41591-026-04206-y#ref-CR25" id="ref-link-section-d37439729e1606">25</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Devanarayan, V. et al. Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid-positive early Alzheimer’s disease. Alzheimers Dement. 21, e14411 (2025)." href="/articles/s41591-026-04206-y#ref-CR29" id="ref-link-section-d37439729e1609">29</a></sup>, brain volumes<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Schindler, S. E. et al. Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology. Alzheimers Dement. 20, 8074–8096 (2024)." href="/articles/s41591-026-04206-y#ref-CR23" id="ref-link-section-d37439729e1613">23</a></sup> and cognition<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Schindler, S. E. et al. Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology. Alzheimers Dement. 20, 8074–8096 (2024)." href="/articles/s41591-026-04206-y#ref-CR23" id="ref-link-section-d37439729e1617">23</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Janelidze, S. et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease. Brain 146, 1592–1601 (2023)." href="/articles/s41591-026-04206-y#ref-CR28" id="ref-link-section-d37439729e1620">28</a></sup>. Although the concentration of plasma p-tau217 was previously demonstrated to predict risk for cognitive decline and progression to AD dementia<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Palmqvist, S. et al. Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures. Nat. Med. 27, 1034–1042 (2021)." href="/articles/s41591-026-04206-y#ref-CR30" id="ref-link-section-d37439729e1624">30</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 31" title="Ossenkoppele, R. et al. Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials. Nat. Aging 5, 883–896 (2025)." href="/articles/s41591-026-04206-y#ref-CR31" id="ref-link-section-d37439729e1627">31</a></sup>, no published studies have used plasma p-tau217 or %p-tau217 to estimate when individuals will develop onset of AD symptoms.</p><p>In the present study, we aimed to use measurements from a single plasma sample to estimate not only the probability of a cognitively unimpaired individual with positive AD biomarkers developing AD symptoms but also when they would be likely to develop symptoms. Primary analyses were performed with the C2N Diagnostics plasma %p-tau217 measure because large longitudinal datasets were available from two cohorts: the Knight Alzheimer’s Disease Research Center (Knight ADRC) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Plasma %p-tau217 has high accuracy in classifying amyloid PET, tau PET and cognitive status; this assay is a component of C2N Diagnostics’ clinically available PrecivityAD2 test and is used by some clinical trials<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Schindler, S. E. et al. Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology. Alzheimers Dement. 20, 8074–8096 (2024)." href="/articles/s41591-026-04206-y#ref-CR23" id="ref-link-section-d37439729e1634">23</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Warmenhoven, N. et al. A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. Brain 148, 416–431 (2025)." href="#ref-CR25" id="ref-link-section-d37439729e1637">25</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Palmqvist, S. et al. Blood biomarkers to detect Alzheimer disease in primary care and secondary care. JAMA 332, 1245–1257 (2024)." href="#ref-CR26" id="ref-link-section-d37439729e1637_1">26</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Meyer, M. R. et al. Clinical validation of the PrecivityAD2 blood test: a mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid. Alzheimers Dement. 20, 3179–3192 (2024)." href="/articles/s41591-026-04206-y#ref-CR27" id="ref-link-section-d37439729e1640">27</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="Rissman, R. A. et al. Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer’s disease. Alzheimers Dement. 20, 1214–1224 (2024)." href="/articles/s41591-026-04206-y#ref-CR32" id="ref-link-section-d37439729e1643">32</a></sup>. Using longitudinal plasma %p-tau217 data, we created clock models that related %p-tau217 values to time and enabled estimation of the age at %p-tau217 positivity for each individual. Two approaches were used to create %p-tau217 clock models: Temporal Integration of Rate Accumulation (TIRA)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Schindler, S. E. et al. Predicting symptom onset in sporadic Alzheimer disease with amyloid PET. Neurology 97, e1823–e1834 (2021)." href="/articles/s41591-026-04206-y#ref-CR10" id="ref-link-section-d37439729e1647">10</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Mila-Aloma, M. et al. Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocks. Ann. Neurol. 98, 508–523 (2025)." href="/articles/s41591-026-04206-y#ref-CR13" id="ref-link-section-d37439729e1650">13</a></sup>, which integrates the inverse of the modeled rate of change, and Sampled Iterative Local Approximation (SILA)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Heston, M. B. et al. Factors associated with age at tau pathology onset and time from tau onset to dementia in Alzheimer's disease. Alzheimers Dement. 21, e70551 (2025)." href="/articles/s41591-026-04206-y#ref-CR12" id="ref-link-section-d37439729e1654">12</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Betthauser, T. J. et al. Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts. Brain 145, 4065–4079 (2022)." href="/articles/s41591-026-04206-y#ref-CR17" id="ref-link-section-d37439729e1657">17</a></sup>, which uses discrete rate sampling and Euler’s method for numerical integration. Multiple statistical models were used to examine the relationships between the estimated age at %p-tau217 positivity and the onset of AD symptoms. Secondary analyses to assess the generalizability of this approach across plasma biomarkers were performed in the ADNI cohort with the Fujirebio Lumipulse p-tau217/Aβ42 measure that was recently cleared by the US Food and Drug Administration and with four commercially available p-tau217 assays: C2N Diagnostics, Janssen LucentAD Quanterix, ALZpath Quanterix and Fujirebio Lumipulse<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Schindler, S. E. et al. Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology. Alzheimers Dement. 20, 8074–8096 (2024)." href="/articles/s41591-026-04206-y#ref-CR23" id="ref-link-section-d37439729e1661">23</a></sup>.</p></div></div></section><section data-title="Results"><div class="c-article-section" id="Sec2-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec2">Results</h2><div class="c-article-section__content" id="Sec2-content"><h3 class="c-article__sub-heading" id="Sec3">Development and validation of plasma %p-tau217 clock models</h3><p>Data from participants with longitudinal plasma %p-tau217 measurements collected at least 1 year apart were considered for potential inclusion in developing the clock models (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">1</a>). When the baseline plasma %p-tau217 sample was collected, 506 individuals from the Knight ADRC cohort had a median age of 67.7 years (interquartile range (IQR) 61.7–72.4 years); 54.2% were female, 35.8% were <i>APOE</i> ε4 carriers and 8.5% were cognitively impaired (defined by Clinical Dementia Rating (CDR) &gt; 0). Knight ADRC participants had a median age of 7.1 years (IQR 5.0−11.0 years) from the first to last plasma collection. Of these participants, 310 of 506 (61.3%) provided three or more plasma samples. The ADNI cohort consisted of 406 individuals with a median age of 72.7 years (IQR 67.9–78.0 years); 49.3% were female, 34.2% were <i>APOE</i> ε4 carriers and 48.3% were cognitively impaired. ADNI participants had a median age of 5.0 years (IQR 4.0-6.5 years) from the first to last plasma collection. Of these participants, 404 of 406 (99.5%) provided three or more plasma samples.</p><p>The rate of change in plasma %p-tau217 as a function of the estimated %p-tau217 value at the midpoint of collected samples for each participant was modeled with generalized additive models (GAMs) separately in the two cohorts (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig1">1a,b</a>). As was described for similar models using amyloid and tau PET<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Mila-Aloma, M. et al. Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocks. Ann. Neurol. 98, 508–523 (2025)." href="/articles/s41591-026-04206-y#ref-CR13" id="ref-link-section-d37439729e1692">13</a></sup>, intervals with relatively low variance in the rate of change (that is, below the 90th percentile) were identified. These intervals were between plasma %p-tau217 values of 0.29% and 10.45% for the Knight ADRC cohort and between 1.06% and 10.59% for the ADNI cohort (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig7">1a</a>). The intersection yielded an interval of consistent change for plasma %p-tau217 of 1.06% to 10.45%.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-1" data-title="Creation of plasma %p-tau217 clock models."><figure><figcaption><b id="Fig1" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 1: Creation of plasma %p-tau217 clock models.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-026-04206-y/figures/1" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig1_HTML.png?as=webp"><img aria-describedby="Fig1" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig1_HTML.png" alt="figure 1" loading="lazy" width="685" height="590"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-1-desc"><p>For the Knight ADRC (<b>a</b>) and ADNI (<b>b</b>) cohorts, each gray point represents the rate of change in plasma %p-tau217 for an individual as a function of the estimated %p-tau217 value at the midpoint of follow-up. Black solid lines represent GAMs fitting the individual data points, showing the predicted mean rate of change. Gray shading indicates 95% confidence intervals around the fitted GAM curves. Red dashed vertical lines represent the estimated %p-tau217 value at which variance in the rate of change was greater than the 90th percentile of variance in rates of change for the cohort, which identified a range of 1.06−10.45% over which %p-tau217 had relatively consistent change. Clock models relating time to %p-tau217 are shown for the Knight ADRC (<b>c</b>) and ADNI (<b>d</b>) cohorts and were created using two approaches: TIRA (green) and SILA (orange). The vertical black dashed line represents the plasma %p-tau217 threshold of 4.06%, which aligns with an amyloid PET Centiloid value of 20. The horizontal black dashed line represents the estimated time that an individual has a %p-tau217 value of 4.06%.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-026-04206-y/figures/1" data-track-dest="link:Figure1 Full size image" aria-label="Full size image figure 1" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>For the development of clock models, the cohort was restricted to individuals with longitudinal data within the interval of consistent change (Extended Data Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-026-04206-y#Tab1">1</a>). The Knight ADRC clock cohort included 258 individuals with a median interval between first and last plasma %p-tau217 values of 6.5 years (IQR 3.9−9.8 years). The ADNI clock cohort included 345 individuals with a median interval between first and last plasma %p-tau217 values of 4.5 years (IQR 4.0−6.3 years). Plasma %p-tau217 positivity was defined as more than 4.06% to align with an amyloid PET Centiloid value of 20 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Schindler, S. E. et al. Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology. Alzheimers Dement. 20, 8074–8096 (2024)." href="/articles/s41591-026-04206-y#ref-CR23" id="ref-link-section-d37439729e1737">23</a></sup>). Two methods that have previously been used to create clock models with longitudinal amyloid and tau PET data were used to estimate the years from plasma %p-tau217 positivity: TIRA<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Schindler, S. E. et al. Predicting symptom onset in sporadic Alzheimer disease with amyloid PET. Neurology 97, e1823–e1834 (2021)." href="/articles/s41591-026-04206-y#ref-CR10" id="ref-link-section-d37439729e1741">10</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Mila-Aloma, M. et al. Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocks. Ann. Neurol. 98, 508–523 (2025)." href="/articles/s41591-026-04206-y#ref-CR13" id="ref-link-section-d37439729e1744">13</a></sup> and SILA<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Heston, M. B. et al. Factors associated with age at tau pathology onset and time from tau onset to dementia in Alzheimer's disease. Alzheimers Dement. 21, e70551 (2025)." href="/articles/s41591-026-04206-y#ref-CR12" id="ref-link-section-d37439729e1748">12</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Betthauser, T. J. et al. Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts. Brain 145, 4065–4079 (2022)." href="/articles/s41591-026-04206-y#ref-CR17" id="ref-link-section-d37439729e1751">17</a></sup>. The clock models relating time to plasma %p-tau217 levels are shown for the Knight ADRC (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig1">1c</a>) and ADNI (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig1">1d</a>) cohorts; numerical values are provided in Extended Data Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-026-04206-y#Tab2">2</a> and can also be accessed via a web-based application: <a href="https://amyloid.shinyapps.io/plasma_ptau217_time/">https://amyloid.shinyapps.io/plasma_ptau217_time/#</a>.</p><p>Similar clock models were constructed using all longitudinal data (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">1</a>). At very low %p-tau217 values (&lt;1.06%), there were highly unstable TIRA time estimates in the ADNI cohort. Longitudinal data from individuals with high %p-tau217 values were sparse (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig1">1a,b</a>), providing less certain clock estimates for higher values. Furthermore, there were rapid increases in %p-tau217 at high values (&gt;10.45%) that could make time estimates unstable. These features provided further rationale to use clocks constructed with the restricted range of %p-tau217 values (1.06−10.45%).</p><p>Plasma %p-tau217 trajectories as a function of age are shown for individuals included in the clock models (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig2">2a,d</a>) and demonstrate considerable heterogeneity, reflecting that AD pathology begins at widely varying ages. The plasma %p-tau217 trajectories were then re-plotted by years from estimated %p-tau217 positivity (age at plasma collection minus the individual’s estimated age at %p-tau217 positivity) for each cohort and clock model (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig2">2b,c,e,f</a>). The trajectories then demonstrated increased alignment, suggesting relatively consistent patterns of change in plasma %p-tau217 across individuals (Supplementary Video <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM4">1</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-2" data-title="Plasma %p-tau217 trajectories as a function of age and estimated years from %p-tau217 positivity."><figure><figcaption><b id="Fig2" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 2: Plasma %p-tau217 trajectories as a function of age and estimated years from %p-tau217 positivity.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-026-04206-y/figures/2" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig2_HTML.png?as=webp"><img aria-describedby="Fig2" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig2_HTML.png" alt="figure 2" loading="lazy" width="685" height="449"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-2-desc"><p>Longitudinal plasma %p-tau217 data from the Knight ADRC (<b>a</b>−<b>c</b>) and ADNI (<b>d</b>−<b>f</b>) cohorts are shown as a function of age (<b>a</b>,<b>d</b>) or estimated years from %p-tau217 positivity by TIRA (<b>b</b>,<b>e</b>) or SILA (<b>c</b>,<b>f</b>) clock models. Thick black lines represent the clock models shown in Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig1">1c,d</a>; red lines represent individuals with at least one plasma %p-tau217 &gt; 4.06%; and gray lines represent individuals with no plasma %p-tau217 &gt; 4.06%. Horizontal black dashed lines represent the plasma %p-tau217 threshold of 4.06%. Vertical black dashed lines represent the estimated time that an individual had a %p-tau217 value of 4.06%.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-026-04206-y/figures/2" data-track-dest="link:Figure2 Full size image" aria-label="Full size image figure 2" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>To assess model performance, the estimated age at plasma %p-tau217 positivity based on the clock models was compared to the age at observed %p-tau217 conversion, which was the average of the age at last negative and first positive %p-tau217 values. For TIRA models, the adjusted <i>R</i><sup>2</sup> was 0.733 in the Knight ADRC cohort and 0.815 in the ADNI cohort; for SILA models, the adjusted <i>R</i><sup>2</sup> was 0.506 in the Knight ADRC cohort and 0.801 in the ADNI cohort (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig8">2</a>). Additionally, we performed cross-cohort comparison of the models and found that the estimated ages at plasma %p-tau217 positivity based on TIRA models implemented on either the Knight ADRC or ADNI cohorts were highly correlated (adjusted <i>R</i><sup>2</sup> of 0.978), and ages based on SILA models from the two cohorts were almost perfectly aligned (adjusted <i>R</i><sup>2</sup> of 0.999) (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">2</a>). The estimated ages at plasma %p-tau217 positivity based on the TIRA or SILA models were also highly correlated in the Knight ADRC cohort (adjusted <i>R</i><sup>2</sup> of 0.942) but were less correlated in the ADNI cohort (adjusted <i>R</i><sup>2</sup> of 0.863) (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">3</a>). Overall, the clock models estimated similar ages at plasma %p-tau217 positivity regardless of the method or cohort and were consistent with observed conversion ages from %p-tau217 negative to positive.</p><h3 class="c-article__sub-heading" id="Sec4">Modeling the probability of developing symptomatic AD</h3><p>Cox proportional hazards models were used in the longitudinally assessed Knight ADRC cohort to estimate the probability of initially cognitively unimpaired individuals developing symptomatic AD as a function of age (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig3">3a</a>). Symptomatic AD was defined to align with the clinical diagnosis of symptomatic AD: cognitive impairment (CDR &gt; 0) with an AD syndrome (clinical features consistent with cognitive impairment caused by AD, including amnestic, logopenic aphasia, posterior cortical dysfunction or dysexecutive presentations<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Jack Jr, C. R. et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimers Dement. 20, 5143–5169 (2024)." href="/articles/s41591-026-04206-y#ref-CR1" id="ref-link-section-d37439729e1897">1</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 263–269 (2011)." href="#ref-CR33" id="ref-link-section-d37439729e1900">33</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 270–279 (2011)." href="#ref-CR34" id="ref-link-section-d37439729e1900_1">34</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Dubois, B. et al. Alzheimer disease as a clinical-biological construct—an international working group recommendation. JAMA Neurol. 81, 1304–1311 (2024)." href="/articles/s41591-026-04206-y#ref-CR35" id="ref-link-section-d37439729e1903">35</a></sup>) in the context of biomarkers, indicating the presence of AD pathology<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Jack Jr, C. R. et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimers Dement. 20, 5143–5169 (2024)." href="/articles/s41591-026-04206-y#ref-CR1" id="ref-link-section-d37439729e1907">1</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Dubois, B. et al. Alzheimer disease as a clinical-biological construct—an international working group recommendation. JAMA Neurol. 81, 1304–1311 (2024)." href="/articles/s41591-026-04206-y#ref-CR35" id="ref-link-section-d37439729e1910">35</a></sup>. The onset of AD symptoms was defined as the first clinical assessment when initially cognitively unimpaired (CDR = 0) individuals with positive AD biomarkers (based on estimated %p-tau217) were found to be cognitively impaired (CDR &gt; 0) with an AD syndrome. Furthermore, AD symptom onset was applied only to individuals who were cognitively impaired (CDR &gt; 0) with an AD syndrome at their last assessment—that is, if an individual had transient cognitive impairment but returned to cognitively unimpaired or had a non-AD diagnosis at their last assessment, the earlier impairment was not considered to be the onset of AD symptoms. To account for variable time between clinical assessments, the time of AD symptom onset was interval-censored between the last cognitively unimpaired assessment and the first symptomatic AD assessment.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-3" data-title="Probability of remaining cognitively unimpaired from AD is related to age at plasma %p-tau217 positivity."><figure><figcaption><b id="Fig3" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 3: Probability of remaining cognitively unimpaired from AD is related to age at plasma %p-tau217 positivity.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-026-04206-y/figures/3" rel="nofollow"><picture><img aria-describedby="Fig3" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig3_HTML.png" alt="figure 3" loading="lazy" width="685" height="356"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-3-desc"><p>For individuals in the Knight ADRC cohort who were cognitively unimpaired at baseline, a Cox model evaluated the probability of remaining cognitively unimpaired from AD as a function of age, stratified by the age at %p-tau217 positivity based on TIRA (<b>a</b>). The estimated time from %p-tau217 positivity until 50% of individuals would be expected to have symptomatic AD is shown as a function of estimated age at %p-tau217 positivity (<b>b</b>).</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-026-04206-y/figures/3" data-track-dest="link:Figure3 Full size image" aria-label="Full size image figure 3" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>Notably, the age at plasma %p-tau217 positivity dramatically affected the time until AD symptom onset. For example, with TIRA-based estimates, participants who became plasma %p-tau217 positive at age 60 had a median time until symptom onset of 20.5 years, whereas participants who became positive at age 80 had a median time until symptom onset of only 11.4 years (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig3">3b</a>). Cox models for both the Knight ADRC and ADNI cohorts are shown in Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">4</a>. The probability of symptomatic AD associated with a specific plasma %p-tau217 value and age can be accessed via a web-based application: <a href="https://amyloid.shinyapps.io/plasma_ptau217_time/">https://amyloid.shinyapps.io/plasma_ptau217_time/</a>.</p><p>The discriminative ability of Cox models to rank individuals by their risk of developing symptoms was assessed with a concordance index (C-index), where 0.5 is random prediction, &gt;0.7 is very good prediction, &gt;0.8 is excellent prediction and 1.0 is perfect prediction. For the Knight ADRC cohort, the TIRA-based model yielded a bootstrapped C-index of 0.784 (95% confidence interval: 0.720−0.843), and the SILA-based model had a C-index of 0.790 (95% confidence interval: 0.728−0.847). For the ADNI cohort, the TIRA-based model yielded a C-index of 0.730 (95% confidence interval: 0.622−0.834), and the SILA-based model had a C-index of 0.750 (95% confidence interval: 0.636−0.853). Additional analyses incorporating left-censored participants for those with cognitive impairment at study enrollment confirmed these associations with better discrimination and addressed potential survivor bias (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">5</a>). Knight ADRC models achieved bootstrapped C-indexes of 0.821 (95% confidence interval: 0.783−0.857) for TIRA-based models and 0.828 (95% confidence interval: 0.791−0.862) for SILA-based models, whereas ADNI models yielded C-indexes of 0.672 (95% confidence interval: 0.614−0.727) for TIRA-based models and 0.707 (95% confidence interval: 0.651−0.759) for SILA-based models.</p><h3 class="c-article__sub-heading" id="Sec5">Predicting the age of AD symptom onset</h3><p>Next, the estimated age of plasma %p-tau217 positivity was used to model the age at onset of AD symptoms.</p><p>For the Knight ADRC cohort, models included 59 individuals using TIRA and 61 individuals using SILA clock models; for the ADNI cohort, models included 20 individuals using TIRA and 22 individuals using SILA (see Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">2</a> for cohort characteristics). The age at onset of AD symptoms was moderately associated with the estimated age at plasma %p-tau217 positivity for both TIRA-based (Knight ADRC adjusted <i>R</i><sup>2</sup> of 0.599; ADNI adjusted <i>R</i><sup>2</sup> of 0.337) and SILA-based (Knight ADRC adjusted <i>R</i><sup>2</sup> of 0.612; ADNI adjusted <i>R</i><sup>2</sup> of 0.470) estimates (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig4">4</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">3</a>). Comprehensive model diagnostics confirmed the appropriateness of linear modeling across all cohort−method combinations (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">4</a>). Sensitivity analyses removing outliers demonstrated continued significance of the linear models. The estimated age at AD symptom onset associated with a specific plasma %p-tau217 value and age can be accessed via a web-based application: <a href="https://amyloid.shinyapps.io/plasma_ptau217_time/">https://amyloid.shinyapps.io/plasma_ptau217_time/#</a>. Consistent with findings from the Cox models, these models demonstrated that older individuals had a much shorter interval from plasma %p-tau217 positivity to symptom onset (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">6</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-4" data-title="Models for age at symptom onset based on estimated age at plasma %p-tau217 positivity."><figure><figcaption><b id="Fig4" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 4: Models for age at symptom onset based on estimated age at plasma %p-tau217 positivity.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-026-04206-y/figures/4" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig4_HTML.png?as=webp"><img aria-describedby="Fig4" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig4_HTML.png" alt="figure 4" loading="lazy" width="685" height="340"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-4-desc"><p>Individuals were included who were initially cognitively unimpaired but had a typical AD syndrome at their last assessment and developed symptoms after estimated plasma %p-tau217 positivity. Age at %p-tau217 positivity was estimated using TIRA (<b>a</b>) or SILA (<b>b</b>) models in the Knight ADRC (green points) or ADNI (black points) cohorts. Each point represents an individual participant. Linear regression lines represent the predicted mean age at symptom onset for each dataset, with shaded bands indicating 95% confidence intervals around the regression lines (green shading for Knight ADRC data and gray shading for ADNI data). Linear regression equations, adjusted <i>R</i><sup>2</sup> values, Spearmanʼs correlation coefficients (<i>ρ</i>) and sample sizes (<i>N</i>) are shown for each cohort.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-026-04206-y/figures/4" data-track-dest="link:Figure4 Full size image" aria-label="Full size image figure 4" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>The effects of <i>APOE</i> ε4 carrier status, sex and years of education were also examined, but these variables were either not significant or had minimal effects and, thus, were not included in the models (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">5</a>). Associations between estimated age at plasma %p-tau217 positivity and age at symptom onset were lower when individuals who developed cognitive impairment before %p-tau217 positivity were included, likely because these individuals had non-AD causes of cognitive impairment (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">7</a>).</p><p>The error in models predicting the age at AD symptom onset based on the estimated age at plasma %p-tau217 positivity was examined (Extended Data Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-026-04206-y#Tab3">3</a>). Within the same cohort, models predicting the age at AD symptom onset had a median absolute error (MdAE) that ranged from 3.0 years to 3.5 years and non-parametric concordance correlation coefficients (CCCs) ranging from 0.771 to 0.839 (CCC &gt; 0.6 is considered good and CCC &gt; 0.8 is considered excellent). For models created in the Knight ADRC cohort and applied to plasma %p-tau217 values in the ADNI cohort, there were moderate associations (adjusted <i>R</i><sup>2</sup> of 0.467 for TIRA and 0.463 for SILA) with an MdAE of 3.0−3.2 years and a CCC of 0.801−0.805. Conversely, for models created in the ADNI cohort and applied to plasma %p-tau217 values in the Knight ADRC cohort, there were also moderate associations (adjusted <i>R</i><sup>2</sup> of 0.509 for TIRA and 0.577 for SILA) with an MdAE of 3.6−3.7 years and a CCC of 0.808−0.820.</p><h3 class="c-article__sub-heading" id="Sec6">Examining predicted AD symptom onset across longitudinal cognitive assessments</h3><p>The relationship between predicted AD symptom onset and longitudinal clinical diagnoses was examined. For initially cognitively unimpaired individuals in the Knight ADRC cohort with an estimated age at plasma %p-tau217 positivity by the TIRA-based model (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">6</a>), individuals who became %p-tau217 positive at age 60 were estimated to develop symptomatic AD after 14.0 years, whereas individuals who became %p-tau217 positive at age 80 were estimated to develop symptomatic AD after only 6.2 years (Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig4">4</a> and <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig5">5</a> Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">7</a>). Similar analyses were performed for individuals with an estimated age at plasma %p-tau217 positivity by TIRA or SILA in both the Knight ADRC and ADNI cohorts, including only those who were initially cognitively unimpaired (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">8</a>) and all individuals regardless of initial cognitive status (Supplementary Tables <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">7</a>–<a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">9</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig9">3</a>). Regardless of the clock model used to estimate the age at plasma %p-tau217 positivity, there was a markedly shorter time until symptom onset for individuals who developed %p-tau217 positivity at older ages in both the Knight ADRC and ADNI cohorts.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-5" data-title="Clinical diagnosis as a function of estimated age at plasma %p-tau217 positivity and years from %p-tau217 positivity."><figure><figcaption><b id="Fig5" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 5: Clinical diagnosis as a function of estimated age at plasma %p-tau217 positivity and years from %p-tau217 positivity.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-026-04206-y/figures/5" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig5_HTML.png?as=webp"><img aria-describedby="Fig5" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig5_HTML.png" alt="figure 5" loading="lazy" width="685" height="1578"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-5-desc"><p>For initially cognitively unimpaired individuals in the Knight ADRC cohort, the age at plasma %p-tau217 positivity was estimated using the TIRA clock model. Each row represents the longitudinal clinical diagnoses for one individual by estimated years from %p-tau217 positivity (<i>x</i> axis). Individuals are sorted vertically by estimated age at %p-tau217 positivity (<i>y</i> axis). The point color denotes the clinical diagnosis: blue represents cognitively unimpaired at the assessment; red (AD syndrome/biomarker positive) represents cognitively impaired at the assessment and a diagnosis of symptomatic AD at their last assessment with symptoms starting after %p-tau217 positivity; purple (AD syndrome/biomarker negative) represents cognitively impaired at the assessment and a diagnosis of symptomatic AD at their last assessment with symptoms starting before %p-tau217 positivity; and orange (non-AD syndrome) represents cognitively impaired and a non-AD diagnosis at their last assessment. The vertical dashed line at 0 represents the estimated time of %p-tau217 positivity. The brown line represents the estimated relationship between %p-tau217 positivity age and estimated symptom onset based on the Knight ADRC model in Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig4">4a</a>.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-026-04206-y/figures/5" data-track-dest="link:Figure5 Full size image" aria-label="Full size image figure 5" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>Progression of initially cognitively unimpaired Knight ADRC participants with a positive plasma %p-tau217 value to cognitive impairment, with either an AD or a non-AD syndrome, demonstrated wide variation in the time until symptom onset (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig6">6a</a>). Progression of individuals to cognitive impairment as a function of years from estimated plasma %p-tau217 positivity (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig6">6b</a>) or estimated years from symptom onset (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig6">6c</a>) is shown for TIRA-based models. Consistent with the other models, binning individuals by estimated age at plasma %p-tau217 positivity demonstrates that older individuals develop symptoms sooner after %p-tau217 positivity (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig6">6d,e</a>). However, models estimating symptom onset based on age at plasma %p-tau217 adjust for this age effect (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig6">6f</a>). Similar analyses are shown for SILA-based models in the Knight ADRC dataset (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">9</a>) and for TIRA-based and SILA-based models in the ADNI dataset (Supplementary Figs. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">10</a> and <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">11</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-6" data-title="Relationships between cognitive impairment and %p-tau217 positivity."><figure><figcaption><b id="Fig6" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 6: Relationships between cognitive impairment and %p-tau217 positivity.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-026-04206-y/figures/6" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig6_HTML.png?as=webp"><img aria-describedby="Fig6" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig6_HTML.png" alt="figure 6" loading="lazy" width="685" height="392"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-6-desc"><p>For initially cognitively unimpaired individuals in the Knight ADRC cohort, the age at plasma %p-tau217 positivity was estimated using the TIRA clock model. Three groups were examined: red (AD syndrome/biomarker positive) had a diagnosis of symptomatic AD at their last assessment with symptoms starting after %p-tau217 positivity; purple (AD syndrome/biomarker negative) had a diagnosis of symptomatic AD at their last assessment with symptoms starting before %p-tau217 positivity; and orange (non-AD syndrome) had a non-AD diagnosis at their last assessment. Kaplan−Meier curves show the probability for each group of remaining cognitively unimpaired individuals as a function of time from first positive %p-tau217 collection (<b>a</b>,<b>d</b>), estimated years from %p-tau217 positivity (<b>b</b>,<b>e</b>) or estimated years from symptom onset (<b>c</b>,<b>f</b>). Density plots and points beneath Kaplan−Meier curves (<b>a</b>−<b>c</b>) represent the onset of symptoms for individuals in each group. For the red group (AD syndrome/biomarker positive), Kaplan−Meier curves are shown for individuals binned by estimated age of %p-tau217 positivity (blue, &lt;70 years; cyan, 70−80 years; green, ≥80 years) (<b>d</b>−<b>f</b>).</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-026-04206-y/figures/6" data-track-dest="link:Figure6 Full size image" aria-label="Full size image figure 6" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec7">Alignment of biological AD stages and plasma %p-tau217-derived measures</h3><p>The alignment of the 2024 Alzheimer’s Association biological stages with plasma %p-tau217, years since estimated plasma %p-tau217 positivity and estimated years from symptom onset based on plasma %p-tau217 were examined. Individuals with amyloid PET, tau PET and an estimated age at plasma %p-tau217 were classified according to the biological staging framework: stage A (normal biomarkers), stage B (AD pathologic change), stage C (AD) and stage D (advanced AD). As expected, all three plasma %p-tau217-derived measures increased with advancing biological stage (stage A, stage B, stage C and stage D), demonstrating that %p-tau217 captures the co-evolution of amyloid and tau pathologies across the AD continuum. Estimated years since symptom onset did not as clearly separate the biological stages (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig10">4</a>); it is possible that biological stages may have different relationships with symptoms across age groups.</p><h3 class="c-article__sub-heading" id="Sec8">Development of additional plasma clocks</h3><p>To assess whether clock models could be generated using other measures of plasma p-tau217, the same approach was implemented in the ADNI cohort with the Fujirebio Lumipulse p-tau217/Aβ42 measure and with four commercially available p-tau217 assays. First, variance analysis was used to find a range of values where the measure had a relatively consistent rate of change: Fujirebio Lumipulse p-tau217/Aβ42, 0.00−0.02; Janssen LucentAD Quanterix p-tau217, 0.01−0.16 pg ml<sup>−1</sup>; ALZpath Quanterix p-tau217, 0.10−1.11 pg ml<sup>−1</sup>; C2N Diagnostics PrecivityAD2 p-tau217, 0.72−7.99 pg ml<sup>−1</sup>; and Fujirebio Lumipulse p-tau217, 0.02−0.51 pg ml<sup>−1</sup> (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig7">1b−e</a>). Previously published positivity thresholds that align with amyloid PET Centiloid 20 were used for the p-tau217 measures<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Schindler, S. E. et al. Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology. Alzheimers Dement. 20, 8074–8096 (2024)." href="/articles/s41591-026-04206-y#ref-CR23" id="ref-link-section-d37439729e2248">23</a></sup>; using the same methodology, the threshold for Fujirebio Lumipulse p-tau217/Aβ42 was 0.00631. Next, TIRA and SILA were implemented to create clock models that related time from plasma positivity. Plasma trajectories by age or estimated years from positivity are shown for each plasma measure (Extended Data Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig11">5</a>−<a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig13">7</a> and Supplementary Figs. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">12</a> and <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">13</a>). Dynamic visualizations of trajectory alignment for each assay are provided in Supplementary Videos <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM5">2</a>−<a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM9">6</a>.</p><p>The associations between age at symptom onset and age at plasma positivity were examined: Fujirebio Lumipulse p-tau217/Aβ42, TIRA adjusted <i>R</i><sup>2</sup> of 0.276 and SILA adjusted <i>R</i><sup>2</sup> of 0.584 (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig11">5</a>); Janssen LucentAD Quanterix p-tau217, TIRA adjusted <i>R</i><sup>2</sup> of 0.041 and SILA adjusted <i>R</i><sup>2</sup> of 0.211 (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig12">6</a>); ALZpath Quanterix p-tau217, TIRA adjusted <i>R</i><sup>2</sup> of 0.082 and SILA adjusted <i>R</i><sup>2</sup> of 0.258 (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig13">7</a>); C2N Diagnostics p-tau217, TIRA adjusted <i>R</i><sup>2</sup> of 0.084 and SILA adjusted <i>R</i><sup>2</sup> of 0.301 (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">12</a>); and Fujirebio Lumipulse p-tau217, TIRA adjusted <i>R</i><sup>2</sup> of 0.239 and SILA adjusted <i>R</i><sup>2</sup> of 0.450 (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM1">13</a>).</p></div></div></section><section data-title="Discussion"><div class="c-article-section" id="Sec9-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec9">Discussion</h2><div class="c-article-section__content" id="Sec9-content"><p>In this study, we demonstrated that clock modeling methods can be used to estimate the age at plasma %p-tau217 positivity and align %p-tau217 trajectories, revealing a relatively consistent change across individuals in %p-tau217 during the preclinical and early symptomatic phase of AD. Furthermore, the estimated age at plasma %p-tau217 positivity was associated with the age at AD symptom onset, enabling prediction of the age at AD symptom onset with a single %p-tau217 value. We found similar results with plasma p-tau217/Aβ42 and p-tau217 measured by immunoassays, demonstrating the generalizability of our approach across different blood biomarker tests.</p><p>The estimated years until AD symptom onset based on plasma %p-tau217 had an MdAE of 3−4 years, which would limit its utility for individual decision-making, but it could still be useful for group-level studies. Clock models could improve selection of participants for clinical trials who are more likely to develop symptoms within the trial period, increasing statistical power and reducing the time needed to demonstrate treatment efficacy. The variance in age at AD symptom onset explained by estimated age at %p-tau217 positivity ranges from 0.337 to 0.599, which is similar to that explained by parental age at onset for autosomal dominant Alzheimerʼs disease (ADAD) (<i>R</i><sup>2</sup> = 0.384 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 36" title="Ryman, D. C. et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 83, 253–260 (2014)." href="/articles/s41591-026-04206-y#ref-CR36" id="ref-link-section-d37439729e2348">36</a></sup>)). The relatively predictable age at symptom onset has been a major advantage of performing clinical trials in ADAD cohorts<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N. Engl. J. Med. 367, 795–804 (2012)." href="/articles/s41591-026-04206-y#ref-CR3" id="ref-link-section-d37439729e2352">3</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 37" title="Bateman, R. J. et al. The DIAN-TU Next Generation Alzheimer’s prevention trial: adaptive design and disease progression model. Alzheimers Dement. 13, 8–19 (2017)." href="/articles/s41591-026-04206-y#ref-CR37" id="ref-link-section-d37439729e2355">37</a></sup>.</p><p>It is possible that clock models incorporating plasma %p-tau217 or p-tau217 with other biomarkers, such as eMTBR-tau243 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 38" title="Horie, K. et al. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease. Nat. Med. 31, 2044–2053 (2025)." href="/articles/s41591-026-04206-y#ref-CR38" id="ref-link-section-d37439729e2362">38</a></sup>) or biomarkers of cerebrovascular disease<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 39" title="Du, L. et al. Onset ages of cerebrovascular disease and amyloid and effects on cognition in risk-enriched cohorts. Brain Commun. 7, fcaf158 (2025)." href="/articles/s41591-026-04206-y#ref-CR39" id="ref-link-section-d37439729e2366">39</a></sup>, may enable greater precision in estimating time until AD symptom onset. Future investigations could also explore continuous cognitive measures that identify subtle cognitive changes that occur before the threshold for clinical diagnosis. More precise models may decrease the error in the estimated years until AD symptom onset to a level that it becomes relevant for individual decision-making, which could have considerable clinical and ethical implications<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 40" title="Schindler, S. E. Predicting symptom onset in sporadic Alzheimer’s disease: ‘How long do I have?’ J. Alzheimers Dis. 90, 975–979 (2022)." href="/articles/s41591-026-04206-y#ref-CR40" id="ref-link-section-d37439729e2370">40</a></sup>. AD biomarker testing of cognitively unimpaired individuals is currently not recommended outside of research studies or clinical trials due to uncertain benefits and potential risks<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Rabinovici, G. D. et al. Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimers Dement. 21, e14338 (2025)." href="/articles/s41591-026-04206-y#ref-CR19" id="ref-link-section-d37439729e2374">19</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Shaw, L. M. et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease. Alzheimers Dement. 14, 1505–1521 (2018)." href="#ref-CR41" id="ref-link-section-d37439729e2377">41</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Hansson, O. et al. The Alzheimer’s Association appropriate use recommendations for blood biomarkers in Alzheimer’s disease. Alzheimers Dement. 18, 2669–2686 (2022)." href="#ref-CR42" id="ref-link-section-d37439729e2377_1">42</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 43" title="Palmqvist, S. et al. Alzheimer’s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease within specialized care settings. Alzheimers Dement. 21, e70535 (2025)." href="/articles/s41591-026-04206-y#ref-CR43" id="ref-link-section-d37439729e2380">43</a></sup>, and we discourage individuals from using these models to determine their personal estimated age at AD symptom onset.</p><p>Notably, we found that older individuals have a markedly shorter time until AD symptom onset after developing plasma %p-tau217 positivity. This is consistent with our previous work predicting symptom onset with amyloid PET<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Schindler, S. E. et al. Predicting symptom onset in sporadic Alzheimer disease with amyloid PET. Neurology 97, e1823–e1834 (2021)." href="/articles/s41591-026-04206-y#ref-CR10" id="ref-link-section-d37439729e2387">10</a></sup>, where we found that older individuals developed symptoms at a lower amyloid PET burden. Age-related brain changes, including age-related increases in the prevalence of co-pathologies that affect the relationships between clinical symptoms and AD pathology<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 44" title="Pichet Binette, A. et al. Evaluation of the revised criteria for biological and clinical staging of Alzheimer disease. JAMA Neurol. 82, 666–675 (2025)." href="/articles/s41591-026-04206-y#ref-CR44" id="ref-link-section-d37439729e2391">44</a></sup>, may underlie this effect. As age increases, co-pathologies become more common and may further complicate the interpretation of %p-tau217 levels in older individuals. This finding has major implications for clinical trials: individuals with the same plasma %p-tau217 values likely have very different risks of developing cognitive impairment over a 3−5-year period depending on their age. Although statistical models typically include age as a covariate, the relationship between plasma %p-tau217 levels and symptom onset is complex and may not be well captured by linear or nonlinear models, although age-stratified analyses may be helpful. Nonlinear mixed-effects models characterize population-level trajectories with individual random effects, but clock models explicitly convert biomarker levels into individualized estimates that are intuitive (for example, years since biomarker positivity) and may reveal important findings such as the marked effect of age at plasma %p-tau217 positivity on the age at AD symptom onset.</p><p>Although our clock models use the single biomarker %p-tau217, its strong associations with amyloid and tau PET effectively integrate the pathological processes of amyloid plaques and neurofibrillary tangles into the models. Notably, %p-tau217 dynamics likely capture the intertwined progression of both amyloid and tau pathology. Furthermore, the shorter interval from %p-tau217 positivity to symptom onset observed in older individuals may, in part, reflect the influence of age-related co-pathologies, such as cerebrovascular disease and other neurodegenerative diseases<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 44" title="Pichet Binette, A. et al. Evaluation of the revised criteria for biological and clinical staging of Alzheimer disease. JAMA Neurol. 82, 666–675 (2025)." href="/articles/s41591-026-04206-y#ref-CR44" id="ref-link-section-d37439729e2399">44</a></sup>. Recognizing the impact of these additional pathologies is crucial, as they may modify clinical trajectories beyond the core AD pathology. Future work incorporating complementary biomarkers of amyloid, tau and other pathologies will be important for improving the accuracy and applicability of these models.</p><p>The %p-tau217 clock models were created by implementing two different mathematical approaches in the single-site Knight ADRC cohort and the multicenter ADNI cohort. Knight ADRC participants were younger, had a much lower rate of cognitive impairment at baseline and were more likely to be <i>APOE</i> ε4 carriers. Despite these differences, the TIRA and SILA models generally were aligned, and neither was clearly superior, indicating the robustness of the clock concept for modeling years until AD symptom onset. Still, there were some differences, such as TIRA estimating longer periods compared to SILA, particularly in the ADNI cohort. These findings suggest that it may be helpful to implement multiple approaches when developing clocks and to rigorously evaluate the model fit. We have shared code for the TIRA method (the code for the SILA method is already publicly available from the Betthauser laboratory at the University of Wisconsin), which will facilitate testing of these modeling approaches in additional cohorts and using other measures. We encourage interested investigators to further refine these and other approaches to improve prediction of AD symptom onset. We also recommend that clinical trialists use this code and data to create models tailored to their specific goals—for example, determining p-tau217 values for specific age groups that identify individuals at high risk of developing AD symptom onset within 3 years.</p><p>Despite these promising findings, our approach has limitations. The clock models can only be used for values over which there is a consistent change in %p-tau217 (values between 1.06% and 10.45%). Values outside this range, such as a %p-tau217 of 12%, cannot be used to estimate years until AD symptom onset, although individuals with very high %p-tau217 values are likely at very high risk for developing symptomatic AD. Similarly, very low %p-tau217 values suggest a low likelihood of developing symptomatic AD for many years, but precise estimates of years until AD symptom onset cannot be made. Our analysis focused on participants with plasma %p-tau217 values within the interval of consistent change, which increases model reliability but may limit generalizability to individuals with values outside this range. Symptomatic AD was defined as cognitive impairment with an AD syndrome in the context of an estimated positive %p-tau217 value. The threshold for %p-tau217 positivity corresponds to an amyloid PET Centiloid value of 20, below which very few individuals have symptoms due to AD<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Schindler, S. E. et al. Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology. Alzheimers Dement. 20, 8074–8096 (2024)." href="/articles/s41591-026-04206-y#ref-CR23" id="ref-link-section-d37439729e2412">23</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 45" title="Farrar, G., Weber, C. J. &amp; Rabinovici, G. D. Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer’s Association Research Roundtable. J. Prev. Alzheimers Dis. 12, 100008 (2025)." href="/articles/s41591-026-04206-y#ref-CR45" id="ref-link-section-d37439729e2415">45</a></sup>, making it unlikely that individuals with an estimated negative %p-tau217 value have cognitive impairment due to AD pathology. However, occasional individuals may have discrepant %p-tau217 values. Notably, results were also shown for individuals with an AD syndrome with an estimated negative %p-tau217 value and those with non-AD dementia syndromes. Interpretation of estimates for smaller subgroups or those with mixed clinical presentations may be affected by limited sample sizes and co-pathologies.</p><p>Additional limitations include that participants in the study had a variety of clinical diagnoses that were grouped together for analyses, and the models do not reflect the full complexity of clinical symptoms. Participants in the study largely identified as non-Hispanic White, which may limit the generalizability of these models to other groups, especially groups with different rates of non-AD co-pathologies. Furthermore, like other longitudinal aging studies, our analysis did not explicitly model participant dropout or death, which could introduce survival bias if individuals who develop more rapid cognitive decline are more likely to discontinue participation. This potential for survival bias is an important consideration when interpreting our results, as it may lead to underestimation of decline among the most vulnerable individuals.</p><p>In conclusion, our study demonstrates that a single plasma %p-tau217 value can be used to estimate years from onset of AD symptoms with an MdAE of 3−4 years. Models with this level of precision may assist in selecting participants for clinical trials targeting certain phases of preclinical AD. Further refinement of these models could potentially improve predictions, enabling shorter clinical trials and possible relevance for individual decision-making.</p></div></div></section><section data-title="Methods"><div class="c-article-section" id="Sec10-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec10">Methods</h2><div class="c-article-section__content" id="Sec10-content"><h3 class="c-article__sub-heading" id="Sec11">Study participants</h3><p>The STROBE requirements for an observational study were followed. Research participants were included who had been enrolled in previously described studies of memory and aging at the Knight ADRC<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Li, Y. et al. Timing of biomarker changes in sporadic Alzheimer’s disease in estimated years from symptom onset. Ann. Neurol. 95, 951–965 (2024)." href="/articles/s41591-026-04206-y#ref-CR16" id="ref-link-section-d37439729e2437">16</a></sup> or the ADNI<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Mila-Aloma, M. et al. Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocks. Ann. Neurol. 98, 508–523 (2025)." href="/articles/s41591-026-04206-y#ref-CR13" id="ref-link-section-d37439729e2441">13</a></sup>. Both cohorts consisted of community-dwelling older adults, including participants with and without cognitive impairment, who were followed longitudinally with standardized clinical and biomarker assessments. Sex was self-reported by participants in both cohorts. The Knight ADRC cohort is focused on longitudinal characterization of preclinical AD and the transition to symptomatic AD. ADNI was initiated in 2003 and represents a collaborative effort between public and private sectors, with Michael W. Weiner serving as the principal investigator (<a href="http://adni.loni.usc.edu/">https://adni.loni.usc.edu/</a>). The primary goal of the ADNI has been to test whether serial imaging scans, other biological markers and clinical and neuropsychological assessment can be combined to measure the progression of early AD.</p><p>All protocols were approved by the Washington University in St. Louis institutional review board (Human Research Protection Office) and by the local institutional review boards at each participating ADNI site. Written informed consent was obtained from every participant or, when appropriate, from a legally authorized representative.</p><h3 class="c-article__sub-heading" id="Sec12">Plasma biomarkers</h3><p>Plasma was collected as previously described in the Knight ADRC<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Li, Y. et al. Timing of biomarker changes in sporadic Alzheimer’s disease in estimated years from symptom onset. Ann. Neurol. 95, 951–965 (2024)." href="/articles/s41591-026-04206-y#ref-CR16" id="ref-link-section-d37439729e2463">16</a></sup> and ADNI<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 46" title="Figurski, M. J. et al. Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer’s Disease Neuroimaging Initiative study patients. Alzheimers Dement. 8, 250–260 (2012)." href="/articles/s41591-026-04206-y#ref-CR46" id="ref-link-section-d37439729e2467">46</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 47" title="Shaw, L. M. et al. ADNI Biomarker Core: a review of progress since 2004 and future challenges. Alzheimers Dement. 21, e14264 (2025)." href="/articles/s41591-026-04206-y#ref-CR47" id="ref-link-section-d37439729e2470">47</a></sup> cohorts. Plasma %p-tau217 was measured by C2N Diagnostics with a liquid chromatography−mass spectrometry (LC−MS)-based assay<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="Rissman, R. A. et al. Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer’s disease. Alzheimers Dement. 20, 1214–1224 (2024)." href="/articles/s41591-026-04206-y#ref-CR32" id="ref-link-section-d37439729e2474">32</a></sup>. The plasma %p-tau217 measure was calculated as p-tau217 concentration divided by non-phosphorylated tau217 concentration times 100 and is also described as the percent phosphorylation occupancy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Meyer, M. R. et al. Clinical validation of the PrecivityAD2 blood test: a mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid. Alzheimers Dement. 20, 3179–3192 (2024)." href="/articles/s41591-026-04206-y#ref-CR27" id="ref-link-section-d37439729e2478">27</a></sup>. The Fujirebio Lumipulse G assay for p-tau217 and Aβ42 was run in singlicate with research-use-only commercially available kits on a Fujirebio Lumipulse G1200 analyzer at the Indiana University National Centralized Repository for Alzheimer’s Disease and Related Dementias Biomarker Assay Laboratory (NCRAD-BAL)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Schindler, S. E. et al. Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology. Alzheimers Dement. 20, 8074–8096 (2024)." href="/articles/s41591-026-04206-y#ref-CR23" id="ref-link-section-d37439729e2482">23</a></sup>. The Janssen LucentAD Quanterix and ALZpath Quanterix p-tau217 assays were run in duplicate on a Quanterix Simoa-HD-X analyzer at the Quanterix Accelerator Laboratory. Additional details are included in the study methodology report, available in the ADNI database (<a href="http://adni.loni.usc.edu/">https://adni.loni.usc.edu/</a>).</p><h3 class="c-article__sub-heading" id="Sec13">Clinical and cognitive assessments</h3><p>Participants underwent clinical assessments that included a detailed interview with a collateral source, a neurological examination of the participant and the CDR<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 48" title="Morris, J. C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412–2414 (1993)." href="/articles/s41591-026-04206-y#ref-CR48" id="ref-link-section-d37439729e2502">48</a></sup>. Individuals with CDR = 0 were categorized as ‘cognitively unimpaired’. Individuals with CDR &gt; 0 were categorized as ‘cognitively impaired’; this group includes individuals with mild cognitive impairment and dementia. Individuals with clinical features consistent with cognitive impairment caused by AD (for example, most commonly, insidious onset, slowly progressive decline and early amnestic impairment but also including logopenic aphasia, posterior cortical dysfunction or dysexecutive presentations) were considered to have an AD syndrome<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Jack Jr, C. R. et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimers Dement. 20, 5143–5169 (2024)." href="/articles/s41591-026-04206-y#ref-CR1" id="ref-link-section-d37439729e2506">1</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 263–269 (2011)." href="#ref-CR33" id="ref-link-section-d37439729e2509">33</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 270–279 (2011)." href="#ref-CR34" id="ref-link-section-d37439729e2509_1">34</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Dubois, B. et al. Alzheimer disease as a clinical-biological construct—an international working group recommendation. JAMA Neurol. 81, 1304–1311 (2024)." href="/articles/s41591-026-04206-y#ref-CR35" id="ref-link-section-d37439729e2512">35</a></sup>. Individuals with a primary clinical diagnosis that did not include AD (such as Parkinson disease dementia and vascular dementia) were considered to have a non-AD syndrome. The assessment of clinical syndrome was made by experienced clinicians who were blinded to biomarker results, and determinations were based solely on clinical presentation and established diagnostic criteria and were recorded as the primary clinical diagnosis<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Jack Jr, C. R. et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimers Dement. 20, 5143–5169 (2024)." href="/articles/s41591-026-04206-y#ref-CR1" id="ref-link-section-d37439729e2516">1</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 263–269 (2011)." href="#ref-CR33" id="ref-link-section-d37439729e2519">33</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 270–279 (2011)." href="#ref-CR34" id="ref-link-section-d37439729e2519_1">34</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Dubois, B. et al. Alzheimer disease as a clinical-biological construct—an international working group recommendation. JAMA Neurol. 81, 1304–1311 (2024)." href="/articles/s41591-026-04206-y#ref-CR35" id="ref-link-section-d37439729e2522">35</a></sup>.</p><p>Symptomatic AD was defined to align with the established guidelines for clinical diagnosis of symptomatic AD: cognitive impairment with an AD syndrome in the context of biomarkers, indicating the presence of AD pathology<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Jack Jr, C. R. et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimers Dement. 20, 5143–5169 (2024)." href="/articles/s41591-026-04206-y#ref-CR1" id="ref-link-section-d37439729e2529">1</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Dubois, B. et al. Alzheimer disease as a clinical-biological construct—an international working group recommendation. JAMA Neurol. 81, 1304–1311 (2024)." href="/articles/s41591-026-04206-y#ref-CR35" id="ref-link-section-d37439729e2532">35</a></sup>. The onset of AD symptoms was defined as the first clinical assessment when initially cognitively unimpaired individuals with positive AD biomarkers (based on estimated %p-tau217) were found to be cognitively impaired with an AD syndrome. Furthermore, AD symptom onset was applied only to individuals who were cognitively impaired with an AD syndrome at their last assessment—that is, if an individual had transient cognitive impairment but returned to cognitively unimpaired or had a non-AD diagnosis at their last assessment, the earlier impairment was not considered to be the onset of AD symptoms.</p><p>For longitudinal visualization and analysis, participants were categorized based on their cognitive status at each assessment and final diagnostic outcome relative to estimated %p-tau217 positivity timing: (1) cognitively unimpaired at the assessment; (2) AD syndrome/biomarker positive: cognitively impaired at the assessment with a diagnosis of symptomatic AD at their last assessment and symptoms starting after %p-tau217 positivity; (3) AD syndrome/biomarker negative: cognitively impaired at the assessment with a diagnosis of symptomatic AD at their last assessment but symptoms starting before %p-tau217 positivity; and (4) non-AD syndrome: cognitively impaired with a non-AD diagnosis at their last assessment.</p><h3 class="c-article__sub-heading" id="Sec14">Amyloid and tau PET imaging</h3><p>Amyloid and tau PET imaging was conducted as previously described<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Schindler, S. E. et al. Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology. Alzheimers Dement. 20, 8074–8096 (2024)." href="/articles/s41591-026-04206-y#ref-CR23" id="ref-link-section-d37439729e2547">23</a></sup>. A mesial-temporal meta-region of interest (ROI) that included the entorhinal, parahippocampal and amygdala regions was used to assess early tau pathology (<i>T</i><sub>early</sub>) with a corresponding positivity threshold of 1.328 standardized uptake value ratio (SUVR) derived from Gaussian mixture modeling using the mean plus 2 s.d. of the first component<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Schindler, S. E. et al. Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology. Alzheimers Dement. 20, 8074–8096 (2024)." href="/articles/s41591-026-04206-y#ref-CR23" id="ref-link-section-d37439729e2555">23</a></sup>. A temporo-parietal meta-ROI that included the superior temporal, cuneus, inferior-superior parietal, inferior-middle-superior temporal, isthmus cingulate, lateral occipital, lingual, posterior cingulate, precuneus and superior marginal was used to assess late tau pathology (<i>T</i><sub>late</sub>) with a corresponding positivity threshold of 1.224 SUVR, using a similar approach for identifying the threshold.</p><h3 class="c-article__sub-heading" id="Sec15">Cohorts</h3><p>For analysis of variance in the rate of change in plasma %p-tau217, participants were included who had two or more %p-tau217 values at least 1 year apart. For development of clock models, the cohort was restricted to individuals who had two or more plasma %p-tau217 values between 1.06% and 10.45% at least 1 year apart. For models of age at AD symptom onset, individuals were included who were (1) initially cognitively unimpaired (CDR = 0), (2) subsequently developed cognitive impairment (CDR &gt; 0) with an AD syndrome after estimated plasma %p-tau217 positivity and (3) were cognitively impaired (CDR &gt; 0) with an AD syndrome at their last assessment. For visualization of predicted AD symptom onset as a function of estimated age at plasma %p-tau217 positivity, all individuals or individuals who were cognitively unimpaired at baseline were included.</p><h3 class="c-article__sub-heading" id="Sec16">Statistical analysis</h3><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec17">Development and validation of plasma %p-tau217 clock models</h4><p>Clock models refer to mathematical transformations that convert biomarker levels (for example, plasma %p-tau217) into disease time (estimated years since biomarker positivity), enabling temporal staging of AD pathology progression. This approach first identifies periods of consistent biomarker change and then aligns data relative to time since estimated biomarker positivity rather than chronological age, which complements traditional longitudinal modeling methods. This terminology should be distinguished from general biological aging clocks. Our clock models are developed using the single biomarker %p-tau217, which reflects pathological processes of both amyloid plaques and neurofibrillary tangles<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Schindler, S. E. et al. Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology. Alzheimers Dement. 20, 8074–8096 (2024)." href="/articles/s41591-026-04206-y#ref-CR23" id="ref-link-section-d37439729e2584">23</a></sup>. Although these pathologies typically evolve jointly during the progression of AD, our approach does not explicitly model their joint evolution. Instead, by leveraging the strong associations of %p-tau217 with both amyloid and tau PET, our models may capture an integrated measure of disease progression.</p><p>The rate of change in plasma %p-tau217 as a function of the estimated %p-tau217 value at the midpoint was modeled with GAMs as previously described<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Mila-Aloma, M. et al. Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocks. Ann. Neurol. 98, 508–523 (2025)." href="/articles/s41591-026-04206-y#ref-CR13" id="ref-link-section-d37439729e2591">13</a></sup>. To determine the range of plasma %p-tau217 values over which rates of change were consistent, we quantified prediction uncertainty using squared standard errors from GAMs, which represent the variance of model-estimated rates. As was previously described for models using amyloid and tau PET<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Mila-Aloma, M. et al. Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocks. Ann. Neurol. 98, 508–523 (2025)." href="/articles/s41591-026-04206-y#ref-CR13" id="ref-link-section-d37439729e2595">13</a></sup>, intervals with variance in rates of change below the 90th percentile were identified. Plasma %p-tau217 values within the interval of consistent change were used for developing clock models.</p><p>The TIRA approach estimates individual plasma %p-tau217 rates of change using linear mixed-effects modeling with random slopes and intercepts<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Schindler, S. E. et al. Predicting symptom onset in sporadic Alzheimer disease with amyloid PET. Neurology 97, e1823–e1834 (2021)." href="/articles/s41591-026-04206-y#ref-CR10" id="ref-link-section-d37439729e2602">10</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Li, Y. et al. Timing of biomarker changes in sporadic Alzheimer’s disease in estimated years from symptom onset. Ann. Neurol. 95, 951–965 (2024)." href="/articles/s41591-026-04206-y#ref-CR16" id="ref-link-section-d37439729e2605">16</a></sup>. The rates of change are used in GAMs with cubic splines to characterize nonlinear relationships between the rates of change and plasma %p-tau217 levels at the estimated midpoint of follow-up. The inverse of the modeled rate of change is integrated to derive the time between plasma %p-tau217 values.</p><p>The SILA algorithm models longitudinal biomarker trajectories through discrete rate sampling and numerical integration<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Betthauser, T. J. et al. Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts. Brain 145, 4065–4079 (2022)." href="/articles/s41591-026-04206-y#ref-CR17" id="ref-link-section-d37439729e2612">17</a></sup>. The method estimates the first-order relationship between biomarker accumulation rate and biomarker levels by sampling rates across evenly distributed values and then applies Euler’s method to numerically integrate this relationship into a non-parametric biomarker versus time curve.</p><p>Both clocks were centered so that time zero was a plasma %p-tau217 value of 4.06%, which aligns with an amyloid PET Centiloid value of 20 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Schindler, S. E. et al. Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology. Alzheimers Dement. 20, 8074–8096 (2024)." href="/articles/s41591-026-04206-y#ref-CR23" id="ref-link-section-d37439729e2620">23</a></sup>). To obtain an estimated age of plasma %p-tau217 positivity, participants with at least one %p-tau217 value between 1.06% and 10.45% were included. The plasma %p-tau217 clocks were used to calculate an individual’s estimated age of %p-tau217 positivity by subtracting the %p-tau217 time from the age at the plasma collection. For example, if an 80-year-old person had a plasma %p-tau217 value of 7.06%, which corresponds to 8.8 years from %p-tau217 positivity (based on the Knight ADRC TIRA clock), their estimated age at %p-tau217 positivity would be 71.2 years (80 years minus 8.8 years). For individuals with more than one plasma %p-tau217 value, their estimated age at %p-tau217 positivity was an average of estimates from all plasma samples.</p><p>Scatter plots were generated with data points being color coded by cohort for visualization, to assess the concordance of estimated ages of plasma %p-tau217 positivity between different clock models (TIRA and SILA) and across cohorts (Knight ADRC and ADNI). Associations were evaluated using metrics of adjusted <i>R</i><sup>2</sup>, Spearmanʼs <i>r</i> and CCC.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec18">Modeling the probability of developing symptomatic AD</h4><p>The onset of AD symptoms was defined as the first clinical assessment when initially cognitively unimpaired (CDR = 0) individuals with positive AD biomarkers (based on %p-tau217) were found to be cognitively impaired (CDR &gt; 0) with an AD clinical syndrome. For participants who were cognitively normal at baseline, we used interval-censored and right-censored Cox proportional hazards regression models to examine the association between estimated age at plasma %p-tau217 positivity and time to cognitive impairment, accounting for the uncertainty in exact onset timing inherent in longitudinal studies. For participants who remained cognitively unimpaired throughout follow-up, survival times were right-censored at their last assessment age. To account for variable time between assessments, the time of AD symptom onset was interval-censored between the last cognitively unimpaired assessment and the first symptomatic AD assessment. In a sensitivity analysis, participants with cognitive impairment at baseline were included in the models and were left-censored. The models were fitted using the icenReg package in R with semi-parametric baseline hazard estimation. Bootstrap resampling (<i>n</i> = 5,000 samples) was performed to obtain robust standard errors and confidence intervals. Model discrimination was assessed using C-indexes calculated specifically for interval-censored data. Survival curves were generated to visualize the probability of remaining cognitively unimpaired across different estimated plasma %p-tau217 positivity age groups. Survival models treated estimated age at %p-tau217 positivity as a fixed covariate from the clock model estimation.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec19">Estimating the age of AD symptom onset</h4><p>For individuals with AD symptom onset after plasma %p-tau217 positivity, linear models estimated AD symptom onset as a function of the estimated age of %p-tau217 positivity. Sensitivity analyses included individuals with AD symptom onset prior to plasma %p-tau217 positivity. Sex, years of education and <i>APOE</i> ε4 carrier status were considered as covariates in the models but not included in the final models due to not being significant predictors. Model diagnostics were conducted to ensure the appropriateness of linear modeling. Normality of residuals was assessed using Shapiro−Wilk tests; homoscedasticity was evaluated using Breusch−Pagan tests; and linearity was confirmed through Akaike information criterion (AIC)-based model comparison and <i>F</i>-tests comparing linear, quadratic and cubic polynomial specifications. Sensitivity analyses were performed by refitting models after excluding observations with Cook’s distance &gt; 4/<i>n</i> to assess model robustness to influential points.</p><p>Participant data were visualized as raster plots with estimated age at plasma %p-tau217 positivity on the <i>y</i> axis and estimated years from %p-tau217 positivity on the <i>x</i> axis, with participants ordered by their estimated positivity age and color coded by clinical diagnosis category to illustrate the temporal relationship between estimated %p-tau217 positivity and symptom onset. The estimated age at symptom onset from the linear models was overlaid on the plots to aid visualization of how the timing of symptom onset varies as a function of estimated years since plasma %p-tau217 positivity.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec20">Examining predicted AD symptom onset across longitudinal cognitive assessments</h4><p>To examine cognitive impairment risk across different temporal frameworks, we used Kaplan−Meier curves with different timelines. The primary analysis used time from baseline plasma %p-tau217 collection to onset of cognitive impairment. We also used estimated years from plasma %p-tau217 positivity and estimated years from predicted symptom onset, where predicted symptom onset age was calculated using the linear models described above. Kaplan−Meier curves were combined with density plots showing the distribution of observed events to visualize both survival probabilities and the timing of actual cognitive impairment for each outcome. For each timescale, we binned participants by age at estimated %p-tau217 positivity (&lt;70 years, 70−80 years and ≥80 years) to assess age-dependent risk patterns.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec21">Alignment of biological AD stages and plasma %p-tau217-derived measures</h4><p>Statistical comparisons were performed to evaluate differences in plasma %p-tau217 levels and estimated years from %p-tau217 positivity across the four 2024 Alzheimer’s Association biological stages: stage A (normal biomarkers; equivalent to <i>A</i><i>−T</i><sub>early</sub><i>−T</i><sub>lat</sub><sub>e</sub>−), stage B (AD pathologic change; equivalent to <i>A</i><i>+T</i><sub>early</sub><i>−T</i><sub>late</sub>−), stage C (AD; equivalent to <i>A</i><i>+T</i><sub>early</sub><i>+T</i><sub>late</sub>−) and stage D (advanced AD; equivalent to <i>A</i><i>+T</i><sub>early</sub><i>+T</i><sub>lat</sub><sub>e</sub>+). Pairwise comparisons between all groups were conducted using non-parametric Conover−Iman tests with Benjamini−Hochberg adjustment for multiple comparisons.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec22">Development of additional plasma clocks</h4><p>The same methodology for developing clocks was implemented using Fujirebio Lumipulse p-tau217/Aβ42 and p-tau217, C2N Diagnostics p-tau217, Janssen LucentAD Quanterix p-tau217 and ALZpath Quanterix p-tau217. Thresholds for each were obtained from previously work<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Schindler, S. E. et al. Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology. Alzheimers Dement. 20, 8074–8096 (2024)." href="/articles/s41591-026-04206-y#ref-CR23" id="ref-link-section-d37439729e2736">23</a></sup>. Thresholds were 2.34 pg ml<sup>−1</sup> for C2N Diagnostics p-tau217, 0.158 pg ml<sup>−1</sup> for Fujirebio Lumipulse p-tau217, 0.0615 pg ml<sup>−1</sup> for Janssen LucentAD Quanterix p-tau217 and 0.444 pg ml<sup>−1</sup> for ALZpath Quanterix p-tau217.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec23">Software used</h4><p>R version 4.4.1 was used for all analyses except SILA models, which used MATLAB 2024b. Data manipulation and visualization were performed using the ‘tidyverse’ package for core data handling. Statistical annotations and advanced plot arrangements used the ‘ggpubr’ package. Publication-ready plot themes were achieved using the ‘cowplot’ package. Multiple plots were combined and arranged using the ‘patchwork’ package. Specialized distribution visualization was implemented using the ‘ggdist’ package. Project management utilities included the ‘here’ package for project-relative file path management and the ‘conflicted’ package for function conflict resolution. Parallel computing support was enabled by the ‘doParallel’ package to enhance computational efficiency.</p><p>Statistical modeling employed several specialized packages. Linear mixed-effects modeling was conducted using the ‘nlme’ package. Generalized additive modeling was implemented using the ‘mgcv’ package. Interval-censored regression modeling was implemented using the ‘icenReg’ package. CCC analysis was conducted using the ‘DescTools’ package. Survival analysis used the ‘survival’ package with advanced survival plotting provided by the ‘survminer’ package. Statistical tests and post hoc comparisons were performed with the ‘rstatix’ package.</p><h3 class="c-article__sub-heading" id="Sec24">Reporting summary</h3><p>Further information on research design is available in the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM2">Nature Portfolio Reporting Summary</a> linked to this article.</p></div></div></section>
                    
                </div>
            

            <div class="u-mt-32">
                <section data-title="Data availability"><div class="c-article-section" id="data-availability-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="data-availability">Data availability</h2><div class="c-article-section__content" id="data-availability-content">
            
            <p>The data that support the findings of this study are not publicly available due to privacy restrictions and participant consent agreements that require controlled access to protect research participant confidentiality. Data from the Knight ADRC can be requested by qualified investigators (<a href="https://knightadrc.wustl.edu/professionals-clinicians/request-center-resources/">https://knightadrc.wustl.edu/professionals-clinicians/request-center-resources/</a>). Data from the ADNI can be requested via the LONI website (<a href="http://adni.loni.usc.edu/">https://adni.loni.usc.edu/</a>).</p>
          </div></div></section><section data-title="Code availability"><div class="c-article-section" id="code-availability-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="code-availability">Code availability</h2><div class="c-article-section__content" id="code-availability-content">
            
            <p>Code developed by the authors for this study is available for download from GitHub: <a href="https://github.com/WashUFluidBiomarkers/plasma_ptau217_time">https://github.com/WashUFluidBiomarkers/plasma_ptau217_time</a>. Code for implementing the SILA algorithm is available at <a href="https://github.com/Betthauser-Neuro-Lab/SILA-AD-Biomarker">https://github.com/Betthauser-Neuro-Lab/SILA-AD-Biomarker</a>.</p>
          </div></div></section><div id="MagazineFulltextArticleBodySuffix"><section aria-labelledby="Bib1" data-title="References"><div class="c-article-section" id="Bib1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Bib1">References</h2><div class="c-article-section__content" id="Bib1-content"><div data-container-section="references"><ol class="c-article-references" data-track-component="outbound reference" data-track-context="references section"><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="1."><p class="c-article-references__text" id="ref-CR1">Jack Jr, C. R. et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. <i>Alzheimers Dement.</i> <b>20</b>, 5143–5169 (2024).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/alz.13859" data-track-item_id="10.1002/alz.13859" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Falz.13859" aria-label="Article reference 1" data-doi="10.1002/alz.13859">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=38934362" aria-label="PubMed reference 1">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11350039" aria-label="PubMed Central reference 1">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 1" href="http://scholar.google.com/scholar_lookup?&amp;title=Revised%20criteria%20for%20diagnosis%20and%20staging%20of%20Alzheimer%E2%80%99s%20disease%3A%20Alzheimer%E2%80%99s%20Association%20Workgroup&amp;journal=Alzheimers%20Dement.&amp;doi=10.1002%2Falz.13859&amp;volume=20&amp;pages=5143-5169&amp;publication_year=2024&amp;author=Jack%20Jr%2CCR">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="2."><p class="c-article-references__text" id="ref-CR2">Jack Jr, C. R. et al. Brain β-amyloid load approaches a plateau. <i>Neurology</i> <b>80</b>, 890–896 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1212/WNL.0b013e3182840bbe" data-track-item_id="10.1212/WNL.0b013e3182840bbe" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1212%2FWNL.0b013e3182840bbe" aria-label="Article reference 2" data-doi="10.1212/WNL.0b013e3182840bbe">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23446680" aria-label="PubMed reference 2">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653215" aria-label="PubMed Central reference 2">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 2" href="http://scholar.google.com/scholar_lookup?&amp;title=Brain%20%CE%B2-amyloid%20load%20approaches%20a%20plateau&amp;journal=Neurology&amp;doi=10.1212%2FWNL.0b013e3182840bbe&amp;volume=80&amp;pages=890-896&amp;publication_year=2013&amp;author=Jack%20Jr%2CCR">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="3."><p class="c-article-references__text" id="ref-CR3">Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. <i>N. Engl. J. Med.</i> <b>367</b>, 795–804 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1202753" data-track-item_id="10.1056/NEJMoa1202753" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1202753" aria-label="Article reference 3" data-doi="10.1056/NEJMoa1202753">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38XhtlGktL7J" aria-label="CAS reference 3">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22784036" aria-label="PubMed reference 3">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474597" aria-label="PubMed Central reference 3">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 3" href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20and%20biomarker%20changes%20in%20dominantly%20inherited%20Alzheimer%E2%80%99s%20disease&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1202753&amp;volume=367&amp;pages=795-804&amp;publication_year=2012&amp;author=Bateman%2CRJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="4."><p class="c-article-references__text" id="ref-CR4">Gordon, B. A. et al. Tau PET in autosomal dominant Alzheimer’s disease: relationship with cognition, dementia and other biomarkers. <i>Brain</i> <b>142</b>, 1063–1076 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/brain/awz019" data-track-item_id="10.1093/brain/awz019" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fbrain%2Fawz019" aria-label="Article reference 4" data-doi="10.1093/brain/awz019">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30753379" aria-label="PubMed reference 4">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439328" aria-label="PubMed Central reference 4">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 4" href="http://scholar.google.com/scholar_lookup?&amp;title=Tau%20PET%20in%20autosomal%20dominant%20Alzheimer%E2%80%99s%20disease%3A%20relationship%20with%20cognition%2C%20dementia%20and%20other%20biomarkers&amp;journal=Brain&amp;doi=10.1093%2Fbrain%2Fawz019&amp;volume=142&amp;pages=1063-1076&amp;publication_year=2019&amp;author=Gordon%2CBA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="5."><p class="c-article-references__text" id="ref-CR5">Ossenkoppele, R. et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. <i>Nat. Med.</i> <b>28</b>, 2381–2387 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41591-022-02049-x" data-track-item_id="10.1038/s41591-022-02049-x" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-022-02049-x" aria-label="Article reference 5" data-doi="10.1038/s41591-022-02049-x">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XivVGltL%2FN" aria-label="CAS reference 5">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=36357681" aria-label="PubMed reference 5">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671808" aria-label="PubMed Central reference 5">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 5" href="http://scholar.google.com/scholar_lookup?&amp;title=Amyloid%20and%20tau%20PET-positive%20cognitively%20unimpaired%20individuals%20are%20at%20high%20risk%20for%20future%20cognitive%20decline&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-022-02049-x&amp;volume=28&amp;pages=2381-2387&amp;publication_year=2022&amp;author=Ossenkoppele%2CR">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="6."><p class="c-article-references__text" id="ref-CR6">van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease. <i>N. Engl. J. Med.</i> <b>388</b>, 9–21 (2023).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2212948" data-track-item_id="10.1056/NEJMoa2212948" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2212948" aria-label="Article reference 6" data-doi="10.1056/NEJMoa2212948">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=36449413" aria-label="PubMed reference 6">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 6" href="http://scholar.google.com/scholar_lookup?&amp;title=Lecanemab%20in%20early%20Alzheimer%E2%80%99s%20disease&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2212948&amp;volume=388&amp;pages=9-21&amp;publication_year=2023&amp;author=Dyck%2CCH">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="7."><p class="c-article-references__text" id="ref-CR7">Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. <i>JAMA</i> <b>330</b>, 512–527 (2023).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1001/jama.2023.13239" data-track-item_id="10.1001/jama.2023.13239" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1001%2Fjama.2023.13239" aria-label="Article reference 7" data-doi="10.1001/jama.2023.13239">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3sXhs1KhurvM" aria-label="CAS reference 7">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=37459141" aria-label="PubMed reference 7">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352931" aria-label="PubMed Central reference 7">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 7" href="http://scholar.google.com/scholar_lookup?&amp;title=Donanemab%20in%20early%20symptomatic%20Alzheimer%20disease%3A%20the%20TRAILBLAZER-ALZ%202%20randomized%20clinical%20trial&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2023.13239&amp;volume=330&amp;pages=512-527&amp;publication_year=2023&amp;author=Sims%2CJR">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="8."><p class="c-article-references__text" id="ref-CR8">Sperling, R. A., Jack Jr, C. R. &amp; Aisen, P. S. Testing the right target and right drug at the right stage. <i>Sci. Transl. Med.</i> <b>3</b>, 111cm133 (2011).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1126/scitranslmed.3002609" data-track-item_id="10.1126/scitranslmed.3002609" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1126%2Fscitranslmed.3002609" aria-label="Article reference 8" data-doi="10.1126/scitranslmed.3002609">Article</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 8" href="http://scholar.google.com/scholar_lookup?&amp;title=Testing%20the%20right%20target%20and%20right%20drug%20at%20the%20right%20stage&amp;journal=Sci.%20Transl.%20Med.&amp;doi=10.1126%2Fscitranslmed.3002609&amp;volume=3&amp;publication_year=2011&amp;author=Sperling%2CRA&amp;author=Jack%20Jr%2CCR&amp;author=Aisen%2CPS">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="9."><p class="c-article-references__text" id="ref-CR9">McDade, E. &amp; Bateman, R. J. Stop Alzheimer’s before it starts. <i>Nature</i> <b>547</b>, 153–155 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/547153a" data-track-item_id="10.1038/547153a" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2F547153a" aria-label="Article reference 9" data-doi="10.1038/547153a">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtFOjt7rE" aria-label="CAS reference 9">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28703214" aria-label="PubMed reference 9">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 9" href="http://scholar.google.com/scholar_lookup?&amp;title=Stop%20Alzheimer%E2%80%99s%20before%20it%20starts&amp;journal=Nature&amp;doi=10.1038%2F547153a&amp;volume=547&amp;pages=153-155&amp;publication_year=2017&amp;author=McDade%2CE&amp;author=Bateman%2CRJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="10."><p class="c-article-references__text" id="ref-CR10">Schindler, S. E. et al. Predicting symptom onset in sporadic Alzheimer disease with amyloid PET. <i>Neurology</i> <b>97</b>, e1823–e1834 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1212/WNL.0000000000012775" data-track-item_id="10.1212/WNL.0000000000012775" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1212%2FWNL.0000000000012775" aria-label="Article reference 10" data-doi="10.1212/WNL.0000000000012775">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34504028" aria-label="PubMed reference 10">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610624" aria-label="PubMed Central reference 10">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 10" href="http://scholar.google.com/scholar_lookup?&amp;title=Predicting%20symptom%20onset%20in%20sporadic%20Alzheimer%20disease%20with%20amyloid%20PET&amp;journal=Neurology&amp;doi=10.1212%2FWNL.0000000000012775&amp;volume=97&amp;pages=e1823-e1834&amp;publication_year=2021&amp;author=Schindler%2CSE">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="11."><p class="c-article-references__text" id="ref-CR11">Villemagne, V. L. et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. <i>Ann. Neurol.</i> <b>69</b>, 181–192 (2011).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/ana.22248" data-track-item_id="10.1002/ana.22248" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Fana.22248" aria-label="Article reference 11" data-doi="10.1002/ana.22248">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3MXisVCisLs%3D" aria-label="CAS reference 11">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21280088" aria-label="PubMed reference 11">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3045039" aria-label="PubMed Central reference 11">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 11" href="http://scholar.google.com/scholar_lookup?&amp;title=Longitudinal%20assessment%20of%20A%CE%B2%20and%20cognition%20in%20aging%20and%20Alzheimer%20disease&amp;journal=Ann.%20Neurol.&amp;doi=10.1002%2Fana.22248&amp;volume=69&amp;pages=181-192&amp;publication_year=2011&amp;author=Villemagne%2CVL">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="12."><p class="c-article-references__text" id="ref-CR12">Heston, M. B. et al. Factors associated with age at tau pathology onset and time from tau onset to dementia in Alzheimer's disease. <i>Alzheimers Dement.</i> <b>21</b>, e70551 (2025).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/alz.70551" data-track-item_id="10.1002/alz.70551" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Falz.70551" aria-label="Article reference 12" data-doi="10.1002/alz.70551">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB2MXitlagsbvO" aria-label="CAS reference 12">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=40859634" aria-label="PubMed reference 12">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12381359" aria-label="PubMed Central reference 12">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 12" href="http://scholar.google.com/scholar_lookup?&amp;title=Factors%20associated%20with%20age%20at%20tau%20pathology%20onset%20and%20time%20from%20tau%20onset%20to%20dementia%20in%20Alzheimer%27s%20disease&amp;journal=Alzheimers%20Dement.&amp;doi=10.1002%2Falz.70551&amp;volume=21&amp;publication_year=2025&amp;author=Heston%2CMB">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="13."><p class="c-article-references__text" id="ref-CR13">Mila-Aloma, M. et al. Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocks. <i>Ann. Neurol.</i> <b>98</b>, 508–523 (2025).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/ana.27285" data-track-item_id="10.1002/ana.27285" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Fana.27285" aria-label="Article reference 13" data-doi="10.1002/ana.27285">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB2MXisVaktL%2FL" aria-label="CAS reference 13">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=40539416" aria-label="PubMed reference 13">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335434" aria-label="PubMed Central reference 13">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 13" href="http://scholar.google.com/scholar_lookup?&amp;title=Timing%20of%20changes%20in%20Alzheimer%27s%20disease%20plasma%20biomarkers%20as%20assessed%20by%20amyloid%20and%20tau%20PET%20clocks&amp;journal=Ann.%20Neurol.&amp;doi=10.1002%2Fana.27285&amp;volume=98&amp;pages=508-523&amp;publication_year=2025&amp;author=Mila-Aloma%2CM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="14."><p class="c-article-references__text" id="ref-CR14">Budgeon, C. A. et al. Constructing longitudinal disease progression curves using sparse, short-term individual data with an application to Alzheimer’s disease. <i>Stat. Med.</i> <b>36</b>, 2720–2734 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/sim.7300" data-track-item_id="10.1002/sim.7300" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Fsim.7300" aria-label="Article reference 14" data-doi="10.1002/sim.7300">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DC%2BC1crhtlCnsA%3D%3D" aria-label="CAS reference 14">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28444781" aria-label="PubMed reference 14">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 14" href="http://scholar.google.com/scholar_lookup?&amp;title=Constructing%20longitudinal%20disease%20progression%20curves%20using%20sparse%2C%20short-term%20individual%20data%20with%20an%20application%20to%20Alzheimer%E2%80%99s%20disease&amp;journal=Stat.%20Med.&amp;doi=10.1002%2Fsim.7300&amp;volume=36&amp;pages=2720-2734&amp;publication_year=2017&amp;author=Budgeon%2CCA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="15."><p class="c-article-references__text" id="ref-CR15">Koscik, R. L. et al. Amyloid duration is associated with preclinical cognitive decline and tau PET. <i>Alzheimers Dement.</i> <b>12</b>, e12007 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 15" href="http://scholar.google.com/scholar_lookup?&amp;title=Amyloid%20duration%20is%20associated%20with%20preclinical%20cognitive%20decline%20and%20tau%20PET&amp;journal=Alzheimers%20Dement.&amp;volume=12&amp;publication_year=2020&amp;author=Koscik%2CRL">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="16."><p class="c-article-references__text" id="ref-CR16">Li, Y. et al. Timing of biomarker changes in sporadic Alzheimer’s disease in estimated years from symptom onset. <i>Ann. Neurol.</i> <b>95</b>, 951–965 (2024).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/ana.26891" data-track-item_id="10.1002/ana.26891" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Fana.26891" aria-label="Article reference 16" data-doi="10.1002/ana.26891">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB2cXlsFyltLw%3D" aria-label="CAS reference 16">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=38400792" aria-label="PubMed reference 16">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11060905" aria-label="PubMed Central reference 16">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 16" href="http://scholar.google.com/scholar_lookup?&amp;title=Timing%20of%20biomarker%20changes%20in%20sporadic%20Alzheimer%E2%80%99s%20disease%20in%20estimated%20years%20from%20symptom%20onset&amp;journal=Ann.%20Neurol.&amp;doi=10.1002%2Fana.26891&amp;volume=95&amp;pages=951-965&amp;publication_year=2024&amp;author=Li%2CY">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="17."><p class="c-article-references__text" id="ref-CR17">Betthauser, T. J. et al. Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts. <i>Brain</i> <b>145</b>, 4065–4079 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/brain/awac213" data-track-item_id="10.1093/brain/awac213" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fbrain%2Fawac213" aria-label="Article reference 17" data-doi="10.1093/brain/awac213">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35856240" aria-label="PubMed reference 17">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679170" aria-label="PubMed Central reference 17">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 17" href="http://scholar.google.com/scholar_lookup?&amp;title=Multi-method%20investigation%20of%20factors%20influencing%20amyloid%20onset%20and%20impairment%20in%20three%20cohorts&amp;journal=Brain&amp;doi=10.1093%2Fbrain%2Fawac213&amp;volume=145&amp;pages=4065-4079&amp;publication_year=2022&amp;author=Betthauser%2CTJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="18."><p class="c-article-references__text" id="ref-CR18">Rafii, M. S. et al. The AHEAD 3-45 study: design of a prevention trial for Alzheimer’s disease. <i>Alzheimers Dement.</i> <b>19</b>, 1227–1233 (2023).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/alz.12748" data-track-item_id="10.1002/alz.12748" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Falz.12748" aria-label="Article reference 18" data-doi="10.1002/alz.12748">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XisVegu7jL" aria-label="CAS reference 18">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35971310" aria-label="PubMed reference 18">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 18" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20AHEAD%203-45%20study%3A%20design%20of%20a%20prevention%20trial%20for%20Alzheimer%E2%80%99s%20disease&amp;journal=Alzheimers%20Dement.&amp;doi=10.1002%2Falz.12748&amp;volume=19&amp;pages=1227-1233&amp;publication_year=2023&amp;author=Rafii%2CMS">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="19."><p class="c-article-references__text" id="ref-CR19">Rabinovici, G. D. et al. Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. <i>Alzheimers Dement.</i> <b>21</b>, e14338 (2025).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/alz.14338" data-track-item_id="10.1002/alz.14338" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Falz.14338" aria-label="Article reference 19" data-doi="10.1002/alz.14338">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB2MXhtVakurk%3D" aria-label="CAS reference 19">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=39776249" aria-label="PubMed reference 19">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11772739" aria-label="PubMed Central reference 19">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 19" href="http://scholar.google.com/scholar_lookup?&amp;title=Updated%20appropriate%20use%20criteria%20for%20amyloid%20and%20tau%20PET%3A%20a%20report%20from%20the%20Alzheimer%E2%80%99s%20Association%20and%20Society%20for%20Nuclear%20Medicine%20and%20Molecular%20Imaging%20Workgroup&amp;journal=Alzheimers%20Dement.&amp;doi=10.1002%2Falz.14338&amp;volume=21&amp;publication_year=2025&amp;author=Rabinovici%2CGD">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="20."><p class="c-article-references__text" id="ref-CR20">Hampel, H. et al. Blood-based biomarkers for Alzheimer’s disease: current state and future use in a transformed global healthcare landscape. <i>Neuron</i> <b>111</b>, 2781–2799 (2023).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.neuron.2023.05.017" data-track-item_id="10.1016/j.neuron.2023.05.017" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.neuron.2023.05.017" aria-label="Article reference 20" data-doi="10.1016/j.neuron.2023.05.017">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3sXht1WnsbnN" aria-label="CAS reference 20">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=37295421" aria-label="PubMed reference 20">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10720399" aria-label="PubMed Central reference 20">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 20" href="http://scholar.google.com/scholar_lookup?&amp;title=Blood-based%20biomarkers%20for%20Alzheimer%E2%80%99s%20disease%3A%20current%20state%20and%20future%20use%20in%20a%20transformed%20global%20healthcare%20landscape&amp;journal=Neuron&amp;doi=10.1016%2Fj.neuron.2023.05.017&amp;volume=111&amp;pages=2781-2799&amp;publication_year=2023&amp;author=Hampel%2CH">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="21."><p class="c-article-references__text" id="ref-CR21">Wisch, J. K. et al. Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40. <i>Alzheimers Dement.</i> <b>15</b>, e12405 (2023).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 21" href="http://scholar.google.com/scholar_lookup?&amp;title=Predicting%20continuous%20amyloid%20PET%20values%20with%20CSF%20and%20plasma%20A%CE%B242%2FA%CE%B240&amp;journal=Alzheimers%20Dement.&amp;volume=15&amp;publication_year=2023&amp;author=Wisch%2CJK">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="22."><p class="c-article-references__text" id="ref-CR22">Devanarayan, V. et al. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease. <i>Alzheimers Dement.</i> <b>20</b>, 5617–5628 (2024).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/alz.14073" data-track-item_id="10.1002/alz.14073" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Falz.14073" aria-label="Article reference 22" data-doi="10.1002/alz.14073">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB2cXhsFSmsr%2FN" aria-label="CAS reference 22">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=38940656" aria-label="PubMed reference 22">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11350129" aria-label="PubMed Central reference 22">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 22" href="http://scholar.google.com/scholar_lookup?&amp;title=Plasma%20pTau217%20predicts%20continuous%20brain%20amyloid%20levels%20in%20preclinical%20and%20early%20Alzheimer%27s%20disease&amp;journal=Alzheimers%20Dement.&amp;doi=10.1002%2Falz.14073&amp;volume=20&amp;pages=5617-5628&amp;publication_year=2024&amp;author=Devanarayan%2CV">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="23."><p class="c-article-references__text" id="ref-CR23">Schindler, S. E. et al. Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology. <i>Alzheimers Dement.</i> <b>20</b>, 8074–8096 (2024).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/alz.14315" data-track-item_id="10.1002/alz.14315" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Falz.14315" aria-label="Article reference 23" data-doi="10.1002/alz.14315">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB2cXit1OjsrrK" aria-label="CAS reference 23">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=39394841" aria-label="PubMed reference 23">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11567821" aria-label="PubMed Central reference 23">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 23" href="http://scholar.google.com/scholar_lookup?&amp;title=Head-to-head%20comparison%20of%20leading%20blood%20tests%20for%20Alzheimer%E2%80%99s%20disease%20pathology&amp;journal=Alzheimers%20Dement.&amp;doi=10.1002%2Falz.14315&amp;volume=20&amp;pages=8074-8096&amp;publication_year=2024&amp;author=Schindler%2CSE">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="24."><p class="c-article-references__text" id="ref-CR24">Barthelemy, N. R. et al. Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests. <i>Nat. Med.</i> <b>30</b>, 1085–1095 (2024).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="25."><p class="c-article-references__text" id="ref-CR25">Warmenhoven, N. et al. A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. <i>Brain</i> <b>148</b>, 416–431 (2025).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/brain/awae346" data-track-item_id="10.1093/brain/awae346" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fbrain%2Fawae346" aria-label="Article reference 25" data-doi="10.1093/brain/awae346">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=39468767" aria-label="PubMed reference 25">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788211" aria-label="PubMed Central reference 25">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 25" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20comprehensive%20head-to-head%20comparison%20of%20key%20plasma%20phosphorylated%20tau%20217%20biomarker%20tests&amp;journal=Brain&amp;doi=10.1093%2Fbrain%2Fawae346&amp;volume=148&amp;pages=416-431&amp;publication_year=2025&amp;author=Warmenhoven%2CN">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="26."><p class="c-article-references__text" id="ref-CR26">Palmqvist, S. et al. Blood biomarkers to detect Alzheimer disease in primary care and secondary care. <i>JAMA</i> <b>332</b>, 1245–1257 (2024).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1001/jama.2024.13855" data-track-item_id="10.1001/jama.2024.13855" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1001%2Fjama.2024.13855" aria-label="Article reference 26" data-doi="10.1001/jama.2024.13855">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB2cXit1GlsLbP" aria-label="CAS reference 26">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=39068545" aria-label="PubMed reference 26">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11284636" aria-label="PubMed Central reference 26">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 26" href="http://scholar.google.com/scholar_lookup?&amp;title=Blood%20biomarkers%20to%20detect%20Alzheimer%20disease%20in%20primary%20care%20and%20secondary%20care&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2024.13855&amp;volume=332&amp;pages=1245-1257&amp;publication_year=2024&amp;author=Palmqvist%2CS">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="27."><p class="c-article-references__text" id="ref-CR27">Meyer, M. R. et al. Clinical validation of the PrecivityAD2 blood test: a mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid. <i>Alzheimers Dement.</i> <b>20</b>, 3179–3192 (2024).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="28."><p class="c-article-references__text" id="ref-CR28">Janelidze, S. et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease. <i>Brain</i> <b>146</b>, 1592–1601 (2023).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="29."><p class="c-article-references__text" id="ref-CR29">Devanarayan, V. et al. Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid-positive early Alzheimer’s disease. <i>Alzheimers Dement.</i> <b>21</b>, e14411 (2025).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/alz.14411" data-track-item_id="10.1002/alz.14411" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Falz.14411" aria-label="Article reference 29" data-doi="10.1002/alz.14411">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB2cXisF2ntbzL" aria-label="CAS reference 29">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=39575854" aria-label="PubMed reference 29">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 29" href="http://scholar.google.com/scholar_lookup?&amp;title=Plasma%20pTau217%20ratio%20predicts%20continuous%20regional%20brain%20tau%20accumulation%20in%20amyloid-positive%20early%20Alzheimer%E2%80%99s%20disease&amp;journal=Alzheimers%20Dement.&amp;doi=10.1002%2Falz.14411&amp;volume=21&amp;publication_year=2025&amp;author=Devanarayan%2CV">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="30."><p class="c-article-references__text" id="ref-CR30">Palmqvist, S. et al. Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures. <i>Nat. Med.</i> <b>27</b>, 1034–1042 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41591-021-01348-z" data-track-item_id="10.1038/s41591-021-01348-z" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-021-01348-z" aria-label="Article reference 30" data-doi="10.1038/s41591-021-01348-z">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtFGltbrI" aria-label="CAS reference 30">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34031605" aria-label="PubMed reference 30">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 30" href="http://scholar.google.com/scholar_lookup?&amp;title=Prediction%20of%20future%20Alzheimer%E2%80%99s%20disease%20dementia%20using%20plasma%20phospho-tau%20combined%20with%20other%20accessible%20measures&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-021-01348-z&amp;volume=27&amp;pages=1034-1042&amp;publication_year=2021&amp;author=Palmqvist%2CS">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="31."><p class="c-article-references__text" id="ref-CR31">Ossenkoppele, R. et al. Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials. <i>Nat. Aging</i> <b>5</b>, 883–896 (2025).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s43587-025-00835-z" data-track-item_id="10.1038/s43587-025-00835-z" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs43587-025-00835-z" aria-label="Article reference 31" data-doi="10.1038/s43587-025-00835-z">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB2MXhsVWlsr3L" aria-label="CAS reference 31">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=40155777" aria-label="PubMed reference 31">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12092243" aria-label="PubMed Central reference 31">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 31" href="http://scholar.google.com/scholar_lookup?&amp;title=Plasma%20p-tau217%20and%20tau-PET%20predict%20future%20cognitive%20decline%20among%20cognitively%20unimpaired%20individuals%3A%20implications%20for%20clinical%20trials&amp;journal=Nat.%20Aging&amp;doi=10.1038%2Fs43587-025-00835-z&amp;volume=5&amp;pages=883-896&amp;publication_year=2025&amp;author=Ossenkoppele%2CR">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="32."><p class="c-article-references__text" id="ref-CR32">Rissman, R. A. et al. Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer’s disease. <i>Alzheimers Dement.</i> <b>20</b>, 1214–1224 (2024).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="33."><p class="c-article-references__text" id="ref-CR33">McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. <i>Alzheimers Dement.</i> <b>7</b>, 263–269 (2011).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jalz.2011.03.005" data-track-item_id="10.1016/j.jalz.2011.03.005" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jalz.2011.03.005" aria-label="Article reference 33" data-doi="10.1016/j.jalz.2011.03.005">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21514250" aria-label="PubMed reference 33">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312024" aria-label="PubMed Central reference 33">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 33" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20diagnosis%20of%20dementia%20due%20to%20Alzheimer%E2%80%99s%20disease%3A%20recommendations%20from%20the%20National%20Institute%20on%20Aging-Alzheimer%E2%80%99s%20Association%20workgroups%20on%20diagnostic%20guidelines%20for%20Alzheimer%E2%80%99s%20disease&amp;journal=Alzheimers%20Dement.&amp;doi=10.1016%2Fj.jalz.2011.03.005&amp;volume=7&amp;pages=263-269&amp;publication_year=2011&amp;author=McKhann%2CGM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="34."><p class="c-article-references__text" id="ref-CR34">Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. <i>Alzheimers Dement.</i> <b>7</b>, 270–279 (2011).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jalz.2011.03.008" data-track-item_id="10.1016/j.jalz.2011.03.008" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jalz.2011.03.008" aria-label="Article reference 34" data-doi="10.1016/j.jalz.2011.03.008">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21514249" aria-label="PubMed reference 34">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312027" aria-label="PubMed Central reference 34">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 34" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20diagnosis%20of%20mild%20cognitive%20impairment%20due%20to%20Alzheimer%E2%80%99s%20disease%3A%20recommendations%20from%20the%20National%20Institute%20on%20Aging-Alzheimer%E2%80%99s%20Association%20workgroups%20on%20diagnostic%20guidelines%20for%20Alzheimer%E2%80%99s%20disease&amp;journal=Alzheimers%20Dement.&amp;doi=10.1016%2Fj.jalz.2011.03.008&amp;volume=7&amp;pages=270-279&amp;publication_year=2011&amp;author=Albert%2CMS">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="35."><p class="c-article-references__text" id="ref-CR35">Dubois, B. et al. Alzheimer disease as a clinical-biological construct—an international working group recommendation. <i>JAMA Neurol.</i> <b>81</b>, 1304–1311 (2024).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1001/jamaneurol.2024.3770" data-track-item_id="10.1001/jamaneurol.2024.3770" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1001%2Fjamaneurol.2024.3770" aria-label="Article reference 35" data-doi="10.1001/jamaneurol.2024.3770">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=39483064" aria-label="PubMed reference 35">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010406" aria-label="PubMed Central reference 35">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 35" href="http://scholar.google.com/scholar_lookup?&amp;title=Alzheimer%20disease%20as%20a%20clinical-biological%20construct%E2%80%94an%20international%20working%20group%20recommendation&amp;journal=JAMA%20Neurol.&amp;doi=10.1001%2Fjamaneurol.2024.3770&amp;volume=81&amp;pages=1304-1311&amp;publication_year=2024&amp;author=Dubois%2CB">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="36."><p class="c-article-references__text" id="ref-CR36">Ryman, D. C. et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. <i>Neurology</i> <b>83</b>, 253–260 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1212/WNL.0000000000000596" data-track-item_id="10.1212/WNL.0000000000000596" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1212%2FWNL.0000000000000596" aria-label="Article reference 36" data-doi="10.1212/WNL.0000000000000596">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXhtFyntr3P" aria-label="CAS reference 36">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24928124" aria-label="PubMed reference 36">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117367" aria-label="PubMed Central reference 36">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 36" href="http://scholar.google.com/scholar_lookup?&amp;title=Symptom%20onset%20in%20autosomal%20dominant%20Alzheimer%20disease%3A%20a%20systematic%20review%20and%20meta-analysis&amp;journal=Neurology&amp;doi=10.1212%2FWNL.0000000000000596&amp;volume=83&amp;pages=253-260&amp;publication_year=2014&amp;author=Ryman%2CDC">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="37."><p class="c-article-references__text" id="ref-CR37">Bateman, R. J. et al. The DIAN-TU Next Generation Alzheimer’s prevention trial: adaptive design and disease progression model. <i>Alzheimers Dement.</i> <b>13</b>, 8–19 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jalz.2016.07.005" data-track-item_id="10.1016/j.jalz.2016.07.005" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jalz.2016.07.005" aria-label="Article reference 37" data-doi="10.1016/j.jalz.2016.07.005">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27583651" aria-label="PubMed reference 37">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 37" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20DIAN-TU%20Next%20Generation%20Alzheimer%E2%80%99s%20prevention%20trial%3A%20adaptive%20design%20and%20disease%20progression%20model&amp;journal=Alzheimers%20Dement.&amp;doi=10.1016%2Fj.jalz.2016.07.005&amp;volume=13&amp;pages=8-19&amp;publication_year=2017&amp;author=Bateman%2CRJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="38."><p class="c-article-references__text" id="ref-CR38">Horie, K. et al. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease. <i>Nat. Med.</i> <b>31</b>, 2044–2053 (2025).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41591-025-03617-7" data-track-item_id="10.1038/s41591-025-03617-7" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-025-03617-7" aria-label="Article reference 38" data-doi="10.1038/s41591-025-03617-7">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB2MXhsVSqsrfO" aria-label="CAS reference 38">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=40164726" aria-label="PubMed reference 38">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12176612" aria-label="PubMed Central reference 38">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 38" href="http://scholar.google.com/scholar_lookup?&amp;title=Plasma%20MTBR-tau243%20biomarker%20identifies%20tau%20tangle%20pathology%20in%20Alzheimer%E2%80%99s%20disease&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-025-03617-7&amp;volume=31&amp;pages=2044-2053&amp;publication_year=2025&amp;author=Horie%2CK">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="39."><p class="c-article-references__text" id="ref-CR39">Du, L. et al. Onset ages of cerebrovascular disease and amyloid and effects on cognition in risk-enriched cohorts. <i>Brain Commun.</i> <b>7</b>, fcaf158 (2025).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/braincomms/fcaf158" data-track-item_id="10.1093/braincomms/fcaf158" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fbraincomms%2Ffcaf158" aria-label="Article reference 39" data-doi="10.1093/braincomms/fcaf158">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB2MXit1ahtbjJ" aria-label="CAS reference 39">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=40337464" aria-label="PubMed reference 39">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12056727" aria-label="PubMed Central reference 39">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 39" href="http://scholar.google.com/scholar_lookup?&amp;title=Onset%20ages%20of%20cerebrovascular%20disease%20and%20amyloid%20and%20effects%20on%20cognition%20in%20risk-enriched%20cohorts&amp;journal=Brain%20Commun.&amp;doi=10.1093%2Fbraincomms%2Ffcaf158&amp;volume=7&amp;publication_year=2025&amp;author=Du%2CL">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="40."><p class="c-article-references__text" id="ref-CR40">Schindler, S. E. Predicting symptom onset in sporadic Alzheimer’s disease: ‘How long do I have?’ <i>J. Alzheimers Dis.</i> <b>90</b>, 975–979 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.3233/JAD-215722" data-track-item_id="10.3233/JAD-215722" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.3233%2FJAD-215722" aria-label="Article reference 40" data-doi="10.3233/JAD-215722">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XivFGhu7nM" aria-label="CAS reference 40">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35213383" aria-label="PubMed reference 40">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 40" href="http://scholar.google.com/scholar_lookup?&amp;title=Predicting%20symptom%20onset%20in%20sporadic%20Alzheimer%E2%80%99s%20disease%3A%20%E2%80%98How%20long%20do%20I%20have%3F%E2%80%99&amp;journal=J.%20Alzheimers%20Dis.&amp;doi=10.3233%2FJAD-215722&amp;volume=90&amp;pages=975-979&amp;publication_year=2022&amp;author=Schindler%2CSE">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="41."><p class="c-article-references__text" id="ref-CR41">Shaw, L. M. et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease. <i>Alzheimers Dement.</i> <b>14</b>, 1505–1521 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jalz.2018.07.220" data-track-item_id="10.1016/j.jalz.2018.07.220" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jalz.2018.07.220" aria-label="Article reference 41" data-doi="10.1016/j.jalz.2018.07.220">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30316776" aria-label="PubMed reference 41">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013957" aria-label="PubMed Central reference 41">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 41" href="http://scholar.google.com/scholar_lookup?&amp;title=Appropriate%20use%20criteria%20for%20lumbar%20puncture%20and%20cerebrospinal%20fluid%20testing%20in%20the%20diagnosis%20of%20Alzheimer%E2%80%99s%20disease&amp;journal=Alzheimers%20Dement.&amp;doi=10.1016%2Fj.jalz.2018.07.220&amp;volume=14&amp;pages=1505-1521&amp;publication_year=2018&amp;author=Shaw%2CLM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="42."><p class="c-article-references__text" id="ref-CR42">Hansson, O. et al. The Alzheimer’s Association appropriate use recommendations for blood biomarkers in Alzheimer’s disease. <i>Alzheimers Dement.</i> <b>18</b>, 2669–2686 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/alz.12756" data-track-item_id="10.1002/alz.12756" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Falz.12756" aria-label="Article reference 42" data-doi="10.1002/alz.12756">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XitVOlsL3P" aria-label="CAS reference 42">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35908251" aria-label="PubMed reference 42">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087669" aria-label="PubMed Central reference 42">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 42" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20Alzheimer%E2%80%99s%20Association%20appropriate%20use%20recommendations%20for%20blood%20biomarkers%20in%20Alzheimer%E2%80%99s%20disease&amp;journal=Alzheimers%20Dement.&amp;doi=10.1002%2Falz.12756&amp;volume=18&amp;pages=2669-2686&amp;publication_year=2022&amp;author=Hansson%2CO">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="43."><p class="c-article-references__text" id="ref-CR43">Palmqvist, S. et al. Alzheimer’s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease within specialized care settings. <i>Alzheimers Dement.</i> <b>21</b>, e70535 (2025).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/alz.70535" data-track-item_id="10.1002/alz.70535" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Falz.70535" aria-label="Article reference 43" data-doi="10.1002/alz.70535">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=40729527" aria-label="PubMed reference 43">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306682" aria-label="PubMed Central reference 43">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 43" href="http://scholar.google.com/scholar_lookup?&amp;title=Alzheimer%E2%80%99s%20Association%20Clinical%20Practice%20Guideline%20on%20the%20use%20of%20blood-based%20biomarkers%20in%20the%20diagnostic%20workup%20of%20suspected%20Alzheimer%E2%80%99s%20disease%20within%20specialized%20care%20settings&amp;journal=Alzheimers%20Dement.&amp;doi=10.1002%2Falz.70535&amp;volume=21&amp;publication_year=2025&amp;author=Palmqvist%2CS">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="44."><p class="c-article-references__text" id="ref-CR44">Pichet Binette, A. et al. Evaluation of the revised criteria for biological and clinical staging of Alzheimer disease. <i>JAMA Neurol.</i> <b>82</b>, 666–675 (2025).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1001/jamaneurol.2025.1100" data-track-item_id="10.1001/jamaneurol.2025.1100" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1001%2Fjamaneurol.2025.1100" aria-label="Article reference 44" data-doi="10.1001/jamaneurol.2025.1100">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=40388185" aria-label="PubMed reference 44">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090069" aria-label="PubMed Central reference 44">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 44" href="http://scholar.google.com/scholar_lookup?&amp;title=Evaluation%20of%20the%20revised%20criteria%20for%20biological%20and%20clinical%20staging%20of%20Alzheimer%20disease&amp;journal=JAMA%20Neurol.&amp;doi=10.1001%2Fjamaneurol.2025.1100&amp;volume=82&amp;pages=666-675&amp;publication_year=2025&amp;author=Pichet%20Binette%2CA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="45."><p class="c-article-references__text" id="ref-CR45">Farrar, G., Weber, C. J. &amp; Rabinovici, G. D. Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer’s Association Research Roundtable. <i>J. Prev. Alzheimers Dis.</i> <b>12</b>, 100008 (2025).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.tjpad.2024.100008" data-track-item_id="10.1016/j.tjpad.2024.100008" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.tjpad.2024.100008" aria-label="Article reference 45" data-doi="10.1016/j.tjpad.2024.100008">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=39800462" aria-label="PubMed reference 45">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12183938" aria-label="PubMed Central reference 45">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 45" href="http://scholar.google.com/scholar_lookup?&amp;title=Expert%20opinion%20on%20Centiloid%20thresholds%20suitable%20for%20initiating%20anti-amyloid%20therapy.%20Summary%20of%20discussion%20at%20the%202024%20spring%20Alzheimer%E2%80%99s%20Association%20Research%20Roundtable&amp;journal=J.%20Prev.%20Alzheimers%20Dis.&amp;doi=10.1016%2Fj.tjpad.2024.100008&amp;volume=12&amp;publication_year=2025&amp;author=Farrar%2CG&amp;author=Weber%2CCJ&amp;author=Rabinovici%2CGD">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="46."><p class="c-article-references__text" id="ref-CR46">Figurski, M. J. et al. Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer’s Disease Neuroimaging Initiative study patients. <i>Alzheimers Dement.</i> <b>8</b>, 250–260 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jalz.2012.01.001" data-track-item_id="10.1016/j.jalz.2012.01.001" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jalz.2012.01.001" aria-label="Article reference 46" data-doi="10.1016/j.jalz.2012.01.001">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38XpvFGntb0%3D" aria-label="CAS reference 46">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22748936" aria-label="PubMed reference 46">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732031" aria-label="PubMed Central reference 46">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 46" href="http://scholar.google.com/scholar_lookup?&amp;title=Improved%20protocol%20for%20measurement%20of%20plasma%20%CE%B2-amyloid%20in%20longitudinal%20evaluation%20of%20Alzheimer%E2%80%99s%20Disease%20Neuroimaging%20Initiative%20study%20patients&amp;journal=Alzheimers%20Dement.&amp;doi=10.1016%2Fj.jalz.2012.01.001&amp;volume=8&amp;pages=250-260&amp;publication_year=2012&amp;author=Figurski%2CMJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="47."><p class="c-article-references__text" id="ref-CR47">Shaw, L. M. et al. ADNI Biomarker Core: a review of progress since 2004 and future challenges. <i>Alzheimers Dement.</i> <b>21</b>, e14264 (2025).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/alz.14264" data-track-item_id="10.1002/alz.14264" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Falz.14264" aria-label="Article reference 47" data-doi="10.1002/alz.14264">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=39614747" aria-label="PubMed reference 47">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 47" href="http://scholar.google.com/scholar_lookup?&amp;title=ADNI%20Biomarker%20Core%3A%20a%20review%20of%20progress%20since%202004%20and%20future%20challenges&amp;journal=Alzheimers%20Dement.&amp;doi=10.1002%2Falz.14264&amp;volume=21&amp;publication_year=2025&amp;author=Shaw%2CLM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="48."><p class="c-article-references__text" id="ref-CR48">Morris, J. C. The Clinical Dementia Rating (CDR): current version and scoring rules. <i>Neurology</i> <b>43</b>, 2412–2414 (1993).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1212/WNL.43.11.2412-a" data-track-item_id="10.1212/WNL.43.11.2412-a" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1212%2FWNL.43.11.2412-a" aria-label="Article reference 48" data-doi="10.1212/WNL.43.11.2412-a">Article</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DyaK2c%2FltVKnuw%3D%3D" aria-label="CAS reference 48">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=8232972" aria-label="PubMed reference 48">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 48" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20Clinical%20Dementia%20Rating%20%28CDR%29%3A%20current%20version%20and%20scoring%20rules&amp;journal=Neurology&amp;doi=10.1212%2FWNL.43.11.2412-a&amp;volume=43&amp;pages=2412-2414&amp;publication_year=1993&amp;author=Morris%2CJC">
                    Google Scholar</a> 
                </p></li></ol><p class="c-article-references__download u-hide-print"><a data-track="click" data-track-action="download citation references" data-track-label="link" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-026-04206-y?format=refman&amp;flavour=references">Download references<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p></div></div></div></section></div><section data-title="Acknowledgements"><div class="c-article-section" id="Ack1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Ack1">Acknowledgements</h2><div class="c-article-section__content" id="Ack1-content"><p>This study represents results of the Foundation for the National Institutes of Health (FNIH; <a href="http://fnih.org/">https://fnih.org/</a>) Biomarkers Consortium ‘Biomarkers Consortium, Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer’s Disease’ project, which was made possible through a public−private partnership managed by the FNIH and funded by AbbVie Inc., the Alzheimer’s Association, the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation, Biogen, Janssen Research &amp; Development LLC and Takeda. We are grateful for the contributions of the following project team members: A. Bannon (AbbVie), M. Baratta (Takeda), J. Coomaraswamy (Takeda), J. Dage (Indiana University), I. Dobler (Takeda), L. Du-Cuny (AbbVie), K. Ferber (Biogen), J. Hsiao (National Institute on Aging (NIA)), H. Kolb (formerly with Johnson &amp; Johnson Innovative Medicine), E. Meyers (Alzheimer’s Association), Y. Mordashova (AbbVie), W. Potter, M. Quinton (AbbVie), D. Raunig (Takeda), E. Rosenbaugh (FNIH), C. Rubel (Biogen), Z. Saad (Johnson &amp; Johnson Innovative Medicine), M. Sabandal (FNIH), P. Saletti (Alzheimer’s Drug Discovery Foundation), S. Schindler (Washington University in St. Louis), L. Shaw (University of Pennsylvania), G. Triana-Baltzer (Johnson &amp; Johnson Innovative Medicine), C. Weber (Alzheimer’s Association) and H. Zetterberg (University of Gothenburg). Funding partners of the project include AbbVie, the Alzheimer’s Association, the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation, Biogen, Janssen Research &amp; Development and Takeda Pharmaceutical Company. Private sector funding for the study was managed by the FNIH. This study was also supported by NIA grants R01AG070941 (S.E.S.), P30AG066444 (D.M.H.), P01AG003991 (J.C.M.), P01AG026276 (J.C.M.), R01AG067505 (C.X.) and RF1R01AG053550 (C.X.).</p><p>Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (NIH grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). The ADNI is funded by the NIA and the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: AbbVie, the Alzheimer’s Association; the Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica Inc.; Biogen; Bristol Myers Squibb Company; CereSpir Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company, Genentech Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research &amp; Development LLC; Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC; Lumosity; Lundbeck; Merck &amp; Co. Inc.; Meso Scale Diagnostics LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the FNIH. The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. A complete listing of ADNI investigators can be found at <a href="http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.0">https://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.0</a>.</p></div></div></section><section aria-labelledby="author-information" data-title="Author information"><div class="c-article-section" id="author-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="author-information">Author information</h2><div class="c-article-section__content" id="author-information-content"><span class="c-article-author-information__subtitle u-visually-hidden" id="author-notes">Author notes</span><ol class="c-article-author-information__list"><li class="c-article-author-information__item" id="na2"><p>A full list of members and their affiliations appears in the supplementary information.</p></li></ol><h3 class="c-article__sub-heading" id="affiliations">Authors and Affiliations</h3><ol class="c-article-author-affiliation__list"><li id="Aff1"><p class="c-article-author-affiliation__address">Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA</p><p class="c-article-author-affiliation__authors-list">Kellen K. Petersen, Yan Li, Benjamin Saef, Eric McDade, David M. Holtzman, John C. Morris, Randall J. Bateman &amp; Suzanne E. Schindler</p></li><li id="Aff2"><p class="c-article-author-affiliation__address">Northern California Institute for Research and Education, San Francisco, CA, USA</p><p class="c-article-author-affiliation__authors-list">Marta Milà-Alomà &amp; Duygu Tosun</p></li><li id="Aff3"><p class="c-article-author-affiliation__address">Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA</p><p class="c-article-author-affiliation__authors-list">Marta Milà-Alomà &amp; Duygu Tosun</p></li><li id="Aff4"><p class="c-article-author-affiliation__address">Wisconsin Alzheimer’s Institute, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA</p><p class="c-article-author-affiliation__authors-list">Lianlian Du</p></li><li id="Aff5"><p class="c-article-author-affiliation__address">Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA</p><p class="c-article-author-affiliation__authors-list">Lianlian Du</p></li><li id="Aff6"><p class="c-article-author-affiliation__address">Rush Alzheimer’s Disease Center, Chicago, IL, USA</p><p class="c-article-author-affiliation__authors-list">Lianlian Du</p></li><li id="Aff7"><p class="c-article-author-affiliation__address">Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA</p><p class="c-article-author-affiliation__authors-list">Lianlian Du</p></li><li id="Aff8"><p class="c-article-author-affiliation__address">Knight Alzheimer Disease Research Center, St. Louis, MO, USA</p><p class="c-article-author-affiliation__authors-list">Chengjie Xiong, Carlos Cruchaga, Eric McDade, David M. Holtzman, John C. Morris, Randall J. Bateman &amp; Suzanne E. Schindler</p></li><li id="Aff9"><p class="c-article-author-affiliation__address">Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA</p><p class="c-article-author-affiliation__authors-list">Chengjie Xiong</p></li><li id="Aff10"><p class="c-article-author-affiliation__address">Precision Measures, Johnson &amp; Johnson, San Diego, CA, USA</p><p class="c-article-author-affiliation__authors-list">Ziad S. Saad &amp; Gallen Triana-Baltzer</p></li><li id="Aff11"><p class="c-article-author-affiliation__address">AbbVie Deutschland GmbH &amp; Co. KG, Ludwigshafen am Rhein, Germany</p><p class="c-article-author-affiliation__authors-list">Lei Du-Cuny &amp; Yulia Mordashova</p></li><li id="Aff12"><p class="c-article-author-affiliation__address">Takeda Pharmaceutical Company Ltd., Cambridge, MA, USA</p><p class="c-article-author-affiliation__authors-list">Janaky Coomaraswamy &amp; Michael Baratta</p></li><li id="Aff13"><p class="c-article-author-affiliation__address">Biogen, Cambridge, MA, USA</p><p class="c-article-author-affiliation__authors-list">Carrie E. Rubel &amp; Kyle Ferber</p></li><li id="Aff14"><p class="c-article-author-affiliation__address">Alzheimer’s Association, Chicago, IL, USA</p><p class="c-article-author-affiliation__authors-list">Emily A. Meyers</p></li><li id="Aff15"><p class="c-article-author-affiliation__address">Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA</p><p class="c-article-author-affiliation__authors-list">Leslie M. Shaw</p></li><li id="Aff16"><p class="c-article-author-affiliation__address">Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA</p><p class="c-article-author-affiliation__authors-list">Jeffrey L. Dage</p></li><li id="Aff17"><p class="c-article-author-affiliation__address">Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA</p><p class="c-article-author-affiliation__authors-list">Jeffrey L. Dage</p></li><li id="Aff18"><p class="c-article-author-affiliation__address">Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden</p><p class="c-article-author-affiliation__authors-list">Nicholas J. Ashton &amp; Henrik Zetterberg</p></li><li id="Aff19"><p class="c-article-author-affiliation__address">Banner Alzheimer’s Institute, Phoenix, AZ, USA</p><p class="c-article-author-affiliation__authors-list">Nicholas J. Ashton</p></li><li id="Aff20"><p class="c-article-author-affiliation__address">Banner Sun Health Research Institute, Sun City, AZ, USA</p><p class="c-article-author-affiliation__authors-list">Nicholas J. Ashton</p></li><li id="Aff21"><p class="c-article-author-affiliation__address">Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden</p><p class="c-article-author-affiliation__authors-list">Henrik Zetterberg</p></li><li id="Aff22"><p class="c-article-author-affiliation__address">UK Dementia Research Institute Fluid Biomarkers Laboratory, UK DRI at UCL, London, UK</p><p class="c-article-author-affiliation__authors-list">Henrik Zetterberg</p></li><li id="Aff23"><p class="c-article-author-affiliation__address">Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK</p><p class="c-article-author-affiliation__authors-list">Henrik Zetterberg</p></li><li id="Aff24"><p class="c-article-author-affiliation__address">Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China</p><p class="c-article-author-affiliation__authors-list">Henrik Zetterberg</p></li><li id="Aff25"><p class="c-article-author-affiliation__address">Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA</p><p class="c-article-author-affiliation__authors-list">Henrik Zetterberg</p></li><li id="Aff26"><p class="c-article-author-affiliation__address">Foundation for the National Institutes of Health, North Bethesda, MD, USA</p><p class="c-article-author-affiliation__authors-list">Erin G. Rosenbaugh &amp; J. Martin Sabandal</p></li><li id="Aff27"><p class="c-article-author-affiliation__address">Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA</p><p class="c-article-author-affiliation__authors-list">Carlos Cruchaga</p></li><li id="Aff28"><p class="c-article-author-affiliation__address">NeuroGenomics and Informatics Center, Washington University, St. Louis, MO, USA</p><p class="c-article-author-affiliation__authors-list">Carlos Cruchaga</p></li><li id="Aff29"><p class="c-article-author-affiliation__address">Hope Center for Neurologic Diseases, St. Louis, MO, USA</p><p class="c-article-author-affiliation__authors-list">Carlos Cruchaga, David M. Holtzman, Randall J. Bateman &amp; Suzanne E. Schindler</p></li><li id="Aff30"><p class="c-article-author-affiliation__address">Tracy Family SILQ Center for Neurodegenerative Biology, St. Louis, MO, USA</p><p class="c-article-author-affiliation__authors-list">Randall J. Bateman</p></li><li id="Aff31"><p class="c-article-author-affiliation__address">AbbVie, North Chicago, IL, USA</p><p class="c-article-author-affiliation__authors-list">Anthony W. Bannon</p></li></ol><div class="u-js-hide u-hide-print" data-test="author-info"><span class="c-article__sub-heading">Authors</span><ol class="c-article-authors-search u-list-reset"><li id="auth-Kellen_K_-Petersen-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Kellen K. Petersen</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Kellen%20K.%20Petersen" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Kellen%20K.%20Petersen" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Kellen%20K.%20Petersen%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Marta-Mil__Alom_-Aff2-Aff3"><span class="c-article-authors-search__title u-h3 js-search-name">Marta Milà-Alomà</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Marta%20Mil%C3%A0-Alom%C3%A0" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Marta%20Mil%C3%A0-Alom%C3%A0" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Marta%20Mil%C3%A0-Alom%C3%A0%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Yan-Li-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Yan Li</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Yan%20Li" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Yan%20Li" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Yan%20Li%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Lianlian-Du-Aff4-Aff5-Aff6-Aff7"><span class="c-article-authors-search__title u-h3 js-search-name">Lianlian Du</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Lianlian%20Du" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Lianlian%20Du" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Lianlian%20Du%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Chengjie-Xiong-Aff8-Aff9"><span class="c-article-authors-search__title u-h3 js-search-name">Chengjie Xiong</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Chengjie%20Xiong" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Chengjie%20Xiong" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Chengjie%20Xiong%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Duygu-Tosun-Aff2-Aff3"><span class="c-article-authors-search__title u-h3 js-search-name">Duygu Tosun</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Duygu%20Tosun" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Duygu%20Tosun" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Duygu%20Tosun%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Benjamin-Saef-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Benjamin Saef</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Benjamin%20Saef" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Benjamin%20Saef" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Benjamin%20Saef%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Ziad_S_-Saad-Aff10"><span class="c-article-authors-search__title u-h3 js-search-name">Ziad S. Saad</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Ziad%20S.%20Saad" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Ziad%20S.%20Saad" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Ziad%20S.%20Saad%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Lei-Du_Cuny-Aff11"><span class="c-article-authors-search__title u-h3 js-search-name">Lei Du-Cuny</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Lei%20Du-Cuny" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Lei%20Du-Cuny" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Lei%20Du-Cuny%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Janaky-Coomaraswamy-Aff12"><span class="c-article-authors-search__title u-h3 js-search-name">Janaky Coomaraswamy</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Janaky%20Coomaraswamy" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Janaky%20Coomaraswamy" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Janaky%20Coomaraswamy%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Yulia-Mordashova-Aff11"><span class="c-article-authors-search__title u-h3 js-search-name">Yulia Mordashova</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Yulia%20Mordashova" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Yulia%20Mordashova" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Yulia%20Mordashova%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Carrie_E_-Rubel-Aff13"><span class="c-article-authors-search__title u-h3 js-search-name">Carrie E. Rubel</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Carrie%20E.%20Rubel" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Carrie%20E.%20Rubel" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Carrie%20E.%20Rubel%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Emily_A_-Meyers-Aff14"><span class="c-article-authors-search__title u-h3 js-search-name">Emily A. Meyers</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Emily%20A.%20Meyers" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Emily%20A.%20Meyers" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Emily%20A.%20Meyers%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Leslie_M_-Shaw-Aff15"><span class="c-article-authors-search__title u-h3 js-search-name">Leslie M. Shaw</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Leslie%20M.%20Shaw" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Leslie%20M.%20Shaw" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Leslie%20M.%20Shaw%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Jeffrey_L_-Dage-Aff16-Aff17"><span class="c-article-authors-search__title u-h3 js-search-name">Jeffrey L. Dage</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Jeffrey%20L.%20Dage" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Jeffrey%20L.%20Dage" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Jeffrey%20L.%20Dage%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Nicholas_J_-Ashton-Aff18-Aff19-Aff20"><span class="c-article-authors-search__title u-h3 js-search-name">Nicholas J. Ashton</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Nicholas%20J.%20Ashton" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Nicholas%20J.%20Ashton" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Nicholas%20J.%20Ashton%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Henrik-Zetterberg-Aff18-Aff21-Aff22-Aff23-Aff24-Aff25"><span class="c-article-authors-search__title u-h3 js-search-name">Henrik Zetterberg</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Henrik%20Zetterberg" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Henrik%20Zetterberg" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Henrik%20Zetterberg%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Kyle-Ferber-Aff13"><span class="c-article-authors-search__title u-h3 js-search-name">Kyle Ferber</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Kyle%20Ferber" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Kyle%20Ferber" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Kyle%20Ferber%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Gallen-Triana_Baltzer-Aff10"><span class="c-article-authors-search__title u-h3 js-search-name">Gallen Triana-Baltzer</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Gallen%20Triana-Baltzer" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Gallen%20Triana-Baltzer" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Gallen%20Triana-Baltzer%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Michael-Baratta-Aff12"><span class="c-article-authors-search__title u-h3 js-search-name">Michael Baratta</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Michael%20Baratta" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Michael%20Baratta" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Michael%20Baratta%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Erin_G_-Rosenbaugh-Aff26"><span class="c-article-authors-search__title u-h3 js-search-name">Erin G. Rosenbaugh</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Erin%20G.%20Rosenbaugh" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Erin%20G.%20Rosenbaugh" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Erin%20G.%20Rosenbaugh%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Carlos-Cruchaga-Aff8-Aff27-Aff28-Aff29"><span class="c-article-authors-search__title u-h3 js-search-name">Carlos Cruchaga</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Carlos%20Cruchaga" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Carlos%20Cruchaga" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Carlos%20Cruchaga%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Eric-McDade-Aff1-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Eric McDade</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Eric%20McDade" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Eric%20McDade" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Eric%20McDade%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-David_M_-Holtzman-Aff1-Aff8-Aff29"><span class="c-article-authors-search__title u-h3 js-search-name">David M. Holtzman</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=David%20M.%20Holtzman" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=David%20M.%20Holtzman" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22David%20M.%20Holtzman%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-John_C_-Morris-Aff1-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">John C. Morris</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=John%20C.%20Morris" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=John%20C.%20Morris" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22John%20C.%20Morris%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-J__Martin-Sabandal-Aff26"><span class="c-article-authors-search__title u-h3 js-search-name">J. Martin Sabandal</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=J.%20Martin%20Sabandal" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=J.%20Martin%20Sabandal" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22J.%20Martin%20Sabandal%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Randall_J_-Bateman-Aff1-Aff8-Aff29-Aff30"><span class="c-article-authors-search__title u-h3 js-search-name">Randall J. Bateman</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Randall%20J.%20Bateman" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Randall%20J.%20Bateman" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Randall%20J.%20Bateman%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Anthony_W_-Bannon-Aff31"><span class="c-article-authors-search__title u-h3 js-search-name">Anthony W. Bannon</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Anthony%20W.%20Bannon" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Anthony%20W.%20Bannon" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Anthony%20W.%20Bannon%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-William_Z_-Potter"><span class="c-article-authors-search__title u-h3 js-search-name">William Z. Potter</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=William%20Z.%20Potter" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=William%20Z.%20Potter" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22William%20Z.%20Potter%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Suzanne_E_-Schindler-Aff1-Aff8-Aff29"><span class="c-article-authors-search__title u-h3 js-search-name">Suzanne E. Schindler</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Suzanne%20E.%20Schindler" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Suzanne%20E.%20Schindler" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Suzanne%20E.%20Schindler%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li></ol></div><h3 class="c-article__sub-heading" id="groups">Consortia</h3><div class="c-article-author-institutional-author" id="group-1"><h3 class="c-article-author-institutional-author__name u-h3">Alzheimer’s Disease Neuroimaging Initiative (ADNI)</h3><ul class="c-article-author-institutional-author__author-list"><li class="c-article-author-institutional-author__author-name">Leslie M. Shaw</li></ul></div><div class="c-article-author-institutional-author" id="group-2"><h3 class="c-article-author-institutional-author__name u-h3">On behalf of the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer’s Disease Project Team</h3><ul class="c-article-author-institutional-author__author-list"><li class="c-article-author-institutional-author__author-name">Ziad S. Saad</li><li class="c-article-author-institutional-author__author-name">, Lei Du-Cuny</li><li class="c-article-author-institutional-author__author-name">, Janaky Coomaraswamy</li><li class="c-article-author-institutional-author__author-name">, Yulia Mordashova</li><li class="c-article-author-institutional-author__author-name">, Carrie E. Rubel</li><li class="c-article-author-institutional-author__author-name">, Emily A. Meyers</li><li class="c-article-author-institutional-author__author-name">, Leslie M. Shaw</li><li class="c-article-author-institutional-author__author-name">, Jeffrey L. Dage</li><li class="c-article-author-institutional-author__author-name">, Henrik Zetterberg</li><li class="c-article-author-institutional-author__author-name">, Kyle Ferber</li><li class="c-article-author-institutional-author__author-name">, Gallen Triana-Baltzer</li><li class="c-article-author-institutional-author__author-name">, Michael Baratta</li><li class="c-article-author-institutional-author__author-name">, Erin G. Rosenbaugh</li><li class="c-article-author-institutional-author__author-name">, J. Martin Sabandal</li><li class="c-article-author-institutional-author__author-name">, Anthony W. Bannon</li><li class="c-article-author-institutional-author__author-name">, William Z. Potter</li><li class="c-article-author-institutional-author__author-name"> &amp; Suzanne E. Schindler</li></ul></div><h3 class="c-article__sub-heading" id="contributions">Contributions</h3><p>W.Z.P. is a highly qualified expert. K.K.P., M.M.-A., Y.L., L.D.-C., C.X., D.T., B.S., Z.S.S., D.C., J.C., C.E.R., E.A.M., C.M., R.J.B., A.W.B., W.Z.P. and S.E.S. contributed to the conceptualization and study design. K.K.P., M.M.-A., Y.L., L.D.-C., C.X., B.S., L.M.S., J.L.A., N.J.A., H.Z., C.C., E.M., D.M.H., J.C.M. and R.J.B. contributed to data acquisition and curation. K.K.P., M.M.-A. and Y.L. contributed to methodology and software development. K.K.P., M.M.-A., Y.L., L.D.-C., C.X., D.T. and B.S. performed formal analysis. K.K.P., M.M.-A., C.X., D.M.H., R.J.B. and S.E.S. provided resources and supervision. K.K.P. wrote the original draft. All authors edited and approved the final version for publication and agree to be accountable for all aspects of the work.</p><h3 class="c-article__sub-heading" id="corresponding-author">Corresponding author</h3><p id="corresponding-author-list">Correspondence to
                <a id="corresp-c1" aria-label="email Suzanne E. Schindler" href="mailto:schindlers@neuro.wustl.edu">Suzanne E. Schindler</a>.</p></div></div></section><section data-title="Ethics declarations"><div class="c-article-section" id="ethics-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="ethics">Ethics declarations</h2><div class="c-article-section__content" id="ethics-content">
            
              <h3 class="c-article__sub-heading" id="FPar4">Competing interests</h3>
              <p>K.K.P. has served as a consultant for Eli Lilly and Company. Y.L. is the co-inventor of the technology ‘Novel Tau isoforms to predict onset of symptoms and dementia in Alzheimer’s disease’, which is in the process of licensing by C2N Diagnostics. Z.S.S. and G.T.-B. are employed by Johnson &amp; Johnson Innovative Medicine and may receive salary and stock for their employment. L.D.-C. and Y.M. are employed by AbbVie Deutschland GmbH &amp; Co. KG. J.C. and M.B. receive salary and company stock as compensation for their employment with Takeda Pharmaceutical Company. C.E.R. and K.F. are employees of and may own stock in Biogen. E.A.M. is employed by the Alzheimer’s Association. L.M.S. receives funding from the NIA for ADNI4 and from the NIA for the University of Pennsylvania ADRC P30 for the Biomarker Core. J.L.D. is an inventor on patents or patent applications of Eli Lilly and Company relating to the assays, methods, reagents and/or compositions of matter for P-tau assays and Aβ-targeting therapeutics. J.L.D. has served or is serving as a consultant or on advisory boards for Eisai, AbbVie, Genotix Biotechnologies Inc., Gates Ventures, Gate Neurosciences, Dolby Family Ventures, Karuna Therapeutics, AlzPath Inc., Cognito Therapeutics, Inc., Prevail Therapeutics, Neurogen Biomarking, Spear Bio, the University of Kentucky, Rush University, Tymora and Quanterix. J.L.D. has received research support from ADx Neurosciences, Fujirebio, Roche Diagnostics and Eli Lilly and Company in the past 2 years. J.L.D. has received speaker fees from Eli Lilly and Company and LabCorp. J.L.D. is a founder of and advisor to Monument Biosciences. J.L.D. has stock or stock options in Eli Lilly and Company, Genotix Biotechnologies, AlzPath Inc., Neurogen Biomarking and Monument Biosciences. N.J.A. has received speaking fees from Eli Lilly, Biogen, Quanterix and Alamar Biosciences. H.Z. has served on scientific advisory boards and/or as a consultant for AbbVie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave; has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Eli Lilly, Novo Nordisk, Roche and WebMD; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). C.C. has received research support from GlaxoSmithKline and Eisai. C.C. is a member of the scientific advisory board of Circular Genomics and owns stocks. C.C. is also a member of the scientific advisory board of Admit and has served on the scientific advisory boards of GlaxoSmithKline and Novo Nordisk. E.M.M. has participated in speaker engagements for Eisai, Neurology Live and Projects in Knowledge-Kaplan. E.M.M. has had advisory board roles, consulting and data safety monitoring board (DSMB) relationships with Eli Lilly, Alnylam, Alector, Alzamend, Sanofi, AstraZeneca, F. Hoffmann-La Roche, Grifols and Merck. D.M.H. and R.J.B. have equity ownership interest in C2N Diagnostics. D.M.H. and R.J.B. receive income from C2N Diagnostics for serving on the scientific advisory board. D.M.H. is on the scientific advisory board of Genentech, Denali, Cajal Neurosciences, Acta Pharmaceuticals and Switch and consults for Alnylam, Pfizer and Roche. R.J.B. is a co-inventor on the following US patent applications: ‘Methods to detect novel tau species in CSF and use thereof to track tau neuropathology in Alzheimer’s disease and other tauopathies’ and ‘CSF phosphorylated tau and amyloid beta profiles as biomarkers of Tauopathies’. R.J.B. is a co-inventor on a non-provisional patent application: ‘Methods of diagnosing and treating based on site-specific tau phosphorylation’. R.J.B. is an unpaid scientific advisory board member of Roche and Biogen and receives research funding from Avid Radiopharmaceuticals, Janssen, Roche/Genentech, Eli Lilly, Eisai, Biogen, AbbVie, Bristol Myers Squibb and Novartis. A.W.B. receives salary and company stock as compensation for his employment with AbbVie. W.Z.P. was previously employed by the National Institute of Mental Health and is a stockholder in Merck &amp; Co. W.Z.P. is a Co-Chair Emeritus for the FNIH Biomarkers Consortium Neuroscience Steering Committee. W.Z.P. serves as a consultant for Karuna, Neurocrine, Neumarker and Vaaji and receives grant support from the NIA along with stock options from Praxis Bioresearch. S.E.S. has served on scientific advisory boards on biomarker testing and education for Eisai and Novo Nordisk and has received speaking fees for presentations on biomarker testing from Eisai, Eli Lilly, Novo Nordisk, Medscape and PeerView. She has provided unpaid scientific advising to Eisai, Johnson &amp; Johnson Innovative Medicine, Eli Lilly, Biogen, Acumen, Cognito Therapeutics and Danaher. M.M.-A., L.D.-C., C.X., D.T., B.S., E.G.R., J.C.M. and J.M.S. have nothing to disclose.</p>
            
          </div></div></section><section data-title="Peer review"><div class="c-article-section" id="peer-review-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="peer-review">Peer review</h2><div class="c-article-section__content" id="peer-review-content">
            
            
              <h3 class="c-article__sub-heading" id="FPar3">Peer review information</h3>
              <p><i>Nature Medicine</i> thanks Junhao Wen and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-026-04206-y#MOESM3">Peer reviewer reports</a> are available. Primary Handling Editor: Jerome Staal, in collaboration with the <i>Nature Medicine</i> team.</p>
            
          </div></div></section><section data-title="Additional information"><div class="c-article-section" id="additional-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="additional-information">Additional information</h2><div class="c-article-section__content" id="additional-information-content"><p><b>Publisher’s note</b> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div></div></section><section data-title="Extended data"><div class="c-article-section" id="Sec26-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec26">Extended data</h2><div class="c-article-section__content" id="Sec26-content"><div data-test="supplementary-info"><div id="figshareContainer" class="c-article-figshare-container" data-test="figshare-container"></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig7"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 1 variance analysis for plasma " href="/articles/s41591-026-04206-y/figures/7" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig7_ESM.jpg">Extended Data Fig. 1 Variance analysis for plasma p-tau217 biomarkers identifies intervals of consistent change.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Variance analysis was performed to identify biomarker ranges with relatively consistent rates of change (below the 90th percentile) for five plasma p-tau217 assays: C2N PrecivityAD2 %p-tau217 (<b>A</b>), Fujirebio Lumipulse p-tau217/Aβ42 (<b>B</b>), Fujirebio Lumipulse p-tau217 (<b>C</b>), ALZpath Quanterix p-tau217 (<b>D</b>), and Janssen LucentAD Quanterix p-tau217 (<b>E</b>). The rate of change in each biomarker was modeled using Generalized Additive Models (GAMs), and variance in the rate of change was calculated across biomarker values. Red dashed vertical lines mark the boundaries of intervals where variance in rates of change was below the 90th percentile, defining the biomarker ranges suitable for clock model development. Blue points indicate intervals with variance below the 90th percentile; red points indicate intervals with variance above the 90th percentile.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig8"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 2 relationship between estimate" href="/articles/s41591-026-04206-y/figures/8" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig8_ESM.jpg">Extended Data Fig. 2 Relationship between estimated age at plasma %p-tau217 positivity and age of observed conversion to %p-tau217 positive.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>The estimated age at plasma %p-tau217 positivity based on clock models is shown as a function of the observed conversion age, which is the average of the age at last negative and first positive %p-tau217. Clock models in the Knight ADRC (<b>A, B</b>) and ADNI cohorts (<b>C, D</b>) were created with the TIRA (<b>A, C</b>) and SILA (<b>B, D</b>) approaches. Each point represents an individual participant. Blue lines represent linear regression fits, and gray shaded bands represent 95% confidence intervals for the regression line. Adjusted R² and Spearman correlation coefficients (ρ) are shown for each model.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig9"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 3 clinical diagnosis as a funct" href="/articles/s41591-026-04206-y/figures/9" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig9_ESM.jpg">Extended Data Fig. 3 Clinical diagnosis as a function of estimated age at plasma %p-tau217 positivity and years from %p-tau217 positivity.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>For individuals in the Knight ADRC (<b>A, B</b>) and ADNI (<b>C, D</b>) cohorts, age at plasma %p-tau217 positivity was estimated using either the TIRA (<b>A, C</b>) or SILA (<b>B, D</b>) models. Each row represents the longitudinal clinical diagnoses for one individual by estimated years from %p-tau217 positivity (x-axis). Individuals are sorted vertically by estimated age at %p-tau217 positivity (y-axis). The point color denotes the clinical diagnosis: blue was cognitively unimpaired at the assessment; red (AD syndrome/biomarker positive) was cognitively impaired at the assessment and had a diagnosis of symptomatic AD at their last assessment with symptoms starting after %p-tau217 positivity; purple (AD syndrome/biomarker negative) was cognitively impaired at the assessment and had a diagnosis of symptomatic AD at their last assessment with symptoms starting before %p-tau217 positivity; orange (non-AD syndrome) was cognitively impaired and had a non-AD diagnosis at their last assessment. Vertical dashed lines at 0 represent the estimated time of %p-tau217 positivity. Brown lines indicate the relationship between %p-tau217 positivity age and estimated symptom onset based on the Knight ADRC models in Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-026-04206-y#Fig4">4</a>.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig10"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 4 plasma %p-tau217 level, estim" href="/articles/s41591-026-04206-y/figures/10" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig10_ESM.jpg">Extended Data Fig. 4 Plasma %p-tau217 level, estimated years since %p-tau217 positivity, and years since estimated symptom onset across Alzheimer’s Association biological stages.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Using data from ADNI, raincloud plots show plasma %p-tau217 levels (<b>A</b>), estimated years since %p-tau217 positivity by TIRA (<b>B</b>) and SILA (<b>C</b>), and years since estimated symptom onset by TIRA (<b>D</b>) and SILA (<b>E</b>) stratified by the 2024 Alzheimer’s Association biological staging framework: Stage A (normal biomarkers), Stage B (Alzheimer’s disease pathologic change), Stage C (Alzheimer’s disease), and Stage D (advanced Alzheimer’s disease). The n values provided for each group indicate the number of individual human participants included in that biological stage; each participant contributes one data point to the analysis. Raincloud plots display individual data points, probability distributions (violin plots), and box plots where the box represents the interquartile range (25th to 75th percentile), the center line represents the median, and whiskers extend to the minimum and maximum values within 1.5× the interquartile range; points beyond whiskers represent outliers. Group means with 95% confidence intervals are shown. Statistical comparisons between all biological stages were conducted using two-sided non-parametric Conover-Iman tests with Benjamini-Hochberg adjustment for multiple comparisons. Significant group differences are indicated by asterisks (*p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001).</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig11"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 5 fujirebio diagnostics’ lumipu" href="/articles/s41591-026-04206-y/figures/11" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig11_ESM.jpg">Extended Data Fig. 5 Fujirebio Diagnostics’ Lumipulse plasma p-tau217/Aβ42 clock and symptom onset models based on estimated years from p-tau217/Aβ42 positivity.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Longitudinal plasma p-tau217/Aβ42 data from ADNI is shown as a function of age (<b>A</b>) or estimated years from p-tau217/Aβ42 positivity by TIRA (<b>B</b>) or SILA clock models (<b>C</b>). Thick black lines represent the clock models, red lines represent individuals with at least one plasma p-tau217/Aβ42 &gt; 0.006312, and grey lines represent individuals with no plasma p-tau217/Aβ42 &gt; 0.006312. The horizontal black dashed lines represent the plasma p-tau217/Aβ42 threshold of 0.006312. Models for age at symptom onset included individuals who were initially cognitively unimpaired but had a typical AD syndrome at their last assessment and developed symptoms after estimated plasma p-tau217/Aβ42 positivity. Age at p-tau217/Aβ42 positivity was estimated using TIRA (<b>D</b>) or SILA (<b>E</b>) models. Each point represents an individual participant. In D and E, black lines represent linear regression fits showing the predicted mean age at symptom onset, and gray shaded bands indicate 95% confidence intervals around the regression lines. Linear regression equations, adjusted R² values, Spearman correlation coefficients (ρ), and sample sizes (N) are shown.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig12"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 6 janssen’s lucentad quanterix " href="/articles/s41591-026-04206-y/figures/12" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig12_ESM.jpg">Extended Data Fig. 6 Janssen’s LucentAD Quanterix plasma p-tau217 and symptom onset models based on estimated years from p-tau217 positivity.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Longitudinal plasma p-tau217 data from ADNI is shown as a function of age (<b>A</b>) or estimated years from p-tau217 positivity by TIRA (<b>B</b>) or SILA clock models (<b>C</b>). Thick black lines represent the clock models; red lines represent individuals with at least one plasma p-tau217 &gt; 0.0615 pg ml<sup>−</sup><sup>1</sup> and grey lines represent individuals with no plasma p-tau217 &gt; 0.0615 pg ml<sup>−1</sup>. The horizontal black dashed lines represent the plasma p-tau217 threshold of 0.0615 pg ml<sup>−1</sup>. Models for age at symptom onset included individuals who were initially cognitively unimpaired but had a typical AD syndrome at their last assessment and developed symptoms after estimated plasma p-tau217 positivity. Age at p-tau217 positivity was estimated using TIRA (<b>D</b>) or SILA (<b>E</b>) models. Each point represents an individual participant. In D and E, black lines represent linear regression fits showing the predicted mean age at symptom onset, and gray shaded bands indicate 95% confidence intervals around the regression lines. Linear regression equations, adjusted R² values, Spearman correlation coefficients (ρ), and sample sizes (N) are shown.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig13"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 7 alzpath quanterix plasma p-ta" href="/articles/s41591-026-04206-y/figures/13" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_Fig13_ESM.jpg">Extended Data Fig. 7 ALZpath Quanterix plasma p-tau217 and symptom onset models based on estimated years from p-tau217 positivity.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Longitudinal plasma p-tau217 data from ADNI is shown as a function of age (<b>A</b>) or estimated years from p-tau217 positivity by TIRA (<b>B</b>) or SILA clock models (<b>C</b>). Thick black lines represent the clock models; red lines represent individuals with at least one plasma p-tau217 &gt; 0.444 pg ml<sup>−1</sup> and grey lines represent individuals with no plasma p-tau217 &gt; 0.444 pg ml<sup>−1</sup>. The horizontal black dashed lines represent the plasma p-tau217 threshold of 0.444 pg ml<sup>−1</sup>. Models for age at symptom onset included individuals who were initially cognitively unimpaired but had a typical AD syndrome at their last assessment and developed symptoms after estimated plasma p-tau217 positivity. Age at p-tau217 positivity was estimated using TIRA (<b>D</b>) or SILA (<b>E</b>) models. Each point represents an individual participant. In D and E, black lines represent linear regression fits showing the predicted mean age at symptom onset, and gray shaded bands indicate 95% confidence intervals around the regression lines. Linear regression equations, adjusted R² values, Spearman correlation coefficients (ρ), and sample sizes (N) are shown.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item"><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-1"><figure><figcaption class="c-article-table__figcaption"><b id="Tab1" data-test="table-caption">Extended Data Table 1 Characteristics of clock model development cohorts</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/s41591-026-04206-y/tables/1" aria-label="Full size table 1"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div></div><div class="c-article-supplementary__item" data-test="supp-item"><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-2"><figure><figcaption class="c-article-table__figcaption"><b id="Tab2" data-test="table-caption">Extended Data Table 2 Clock models estimating time between plasma %p-tau217 levels</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/s41591-026-04206-y/tables/2" aria-label="Full size table 2"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div></div><div class="c-article-supplementary__item" data-test="supp-item"><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-3"><figure><figcaption class="c-article-table__figcaption"><b id="Tab3" data-test="table-caption">Extended Data Table 3 Validation of estimated age at symptom onset</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/s41591-026-04206-y/tables/3" aria-label="Full size table 3"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div></div></div></div></div></section><section data-title="Supplementary information"><div class="c-article-section" id="Sec27-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec27">Supplementary information</h2><div class="c-article-section__content" id="Sec27-content"><div data-test="supplementary-info"><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM1"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supplementary information" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_MOESM1_ESM.pdf" data-supp-info-image="">Supplementary Information</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Nine supplementary tables, 13 supplementary figures and captions for six supplementary videos.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM2"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="reporting summary" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_MOESM2_ESM.pdf" data-supp-info-image="">Reporting Summary</a></h3></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM3"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="peer review file" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_MOESM3_ESM.pdf" data-supp-info-image="">Peer Review file</a></h3></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM4"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supplementary video 1" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_MOESM4_ESM.gif" data-supp-info-image="">Supplementary Video 1</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Animation of C2N Diagnostics’ PrecivityAD2 plasma %p-tau217 trajectories transitioning between plots versus age and years since plasma %p-tau217 positivity. The animation shows longitudinal plasma %p-tau217 data plotted as a function of age and years since plasma positivity. Red lines represent individuals with at least one plasma %p-tau217 &gt; 4.06%; gray lines represent individuals with no plasma %p-tau217 &gt; 4.06%; and thick black lines represent the clock models.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM5"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supplementary video 2" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_MOESM5_ESM.gif" data-supp-info-image="">Supplementary Video 2</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Animation of C2N Diagnostics’ PrecivityAD2 plasma p-tau217 trajectories transitioning between plots versus age and years since plasma p-tau217 positivity. The animation shows longitudinal plasma p-tau217 data plotted as a function of age and years since plasma positivity. Red lines represent individuals with at least one plasma p-tau217 &gt; 2.34 pg ml<sup>−1</sup>; gray lines represent individuals with no plasma p-tau217 &gt; 2.34 pg ml<sup>−1</sup>; and thick black lines represent the clock models.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM6"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supplementary video 3" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_MOESM6_ESM.gif" data-supp-info-image="">Supplementary Video 3</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Animation of Fujirebio Diagnostics’ Lumipulse plasma p-tau217/Aβ42 trajectories transitioning between plots versus age and years since plasma p-tau217/Aβ42 positivity. The animation shows longitudinal plasma p-tau217/Aβ42 data plotted as a function of age and years since plasma positivity. Red lines represent individuals with at least one plasma p-tau217/Aβ42 &gt; 0.006312; gray lines represent individuals with no plasma p-tau217/Aβ42 &gt; 0.006312; and thick black lines represent the clock models.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM7"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supplementary video 4" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_MOESM7_ESM.gif" data-supp-info-image="">Supplementary Video 4</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Animation of Fujirebio Diagnostics’ Lumipulse plasma p-tau217 trajectories transitioning between plots versus age and years since plasma p-tau217 positivity. The animation shows longitudinal plasma p-tau217 data plotted as a function of age and years since plasma positivity. Red lines represent individuals with at least one plasma p-tau217 &gt; 0.158 pg ml<sup>−1</sup>; gray lines represent individuals with no plasma p-tau217 &gt; 0.158 pg ml<sup>−1</sup>; and thick black lines represent the clock models.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM8"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supplementary video 5" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_MOESM8_ESM.gif" data-supp-info-image="">Supplementary Video 5</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Animation of Janssen’s LucentAD Quanterix plasma p-tau217 trajectories transitioning between plots versus age and years since plasma positivity. The animation shows longitudinal plasma p-tau217 data plotted as a function of age and years since plasma positivity. Red lines represent individuals with at least one plasma p-tau217 &gt; 0.0615 pg ml<sup>−1</sup>; gray lines represent individuals with no plasma p-tau217 &gt; 0.0615 pg ml<sup>−1</sup>; and thick black lines represent the clock models.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM9"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supplementary video 6" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-026-04206-y/MediaObjects/41591_2026_4206_MOESM9_ESM.gif" data-supp-info-image="">Supplementary Video 6</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Animation of ALZpath’s Quanterix plasma p-tau217 trajectories transitioning between plots versus age and years since plasma p-tau217 positivity. The animation shows longitudinal plasma p-tau217 data plotted as a function of age and years since plasma positivity. Red lines represent individuals with at least one plasma p-tau217 &gt; 0.444 pg ml<sup>−1</sup>; gray lines represent individuals with no plasma p-tau217 &gt; 0.444 pg ml<sup>−1</sup>; and thick black lines represent the clock models.</p></div></div></div></div></div></section><section data-title="Rights and permissions"><div class="c-article-section" id="rightslink-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="rightslink">Rights and permissions</h2><div class="c-article-section__content" id="rightslink-content">
              <p><b>Open Access</b>  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="http://creativecommons.org/licenses/by/4.0/" rel="license">http://creativecommons.org/licenses/by/4.0/</a>.</p>
            <p class="c-article-rights"><a data-track="click" data-track-action="view rights and permissions" data-track-label="link" href="https://s100.copyright.com/AppDispatchServlet?title=Predicting%20onset%20of%20symptomatic%20Alzheimer%CA%BCs%20disease%20with%20plasma%20p-tau217%20clocks&amp;author=Kellen%20K.%20Petersen%20et%20al&amp;contentID=10.1038%2Fs41591-026-04206-y&amp;copyright=The%20Author%28s%29&amp;publication=1078-8956&amp;publicationDate=2026-02-19&amp;publisherName=SpringerNature&amp;orderBeanReset=true&amp;oa=CC%20BY">Reprints and permissions</a></p></div></div></section><section aria-labelledby="article-info" data-title="About this article"><div class="c-article-section" id="article-info-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="article-info">About this article</h2><div class="c-article-section__content" id="article-info-content"><div class="c-bibliographic-information"><div class="u-hide-print c-bibliographic-information__column c-bibliographic-information__column--border"><a data-crossmark="10.1038/s41591-026-04206-y" target="_blank" rel="noopener" href="https://crossmark.crossref.org/dialog/?doi=10.1038/s41591-026-04206-y" data-track="click" data-track-action="Click Crossmark" data-track-label="link" data-test="crossmark"><img loading="lazy" width="57" height="81" alt="Check for updates. Verify currency and authenticity via CrossMark" src="data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>"></a></div><div class="c-bibliographic-information__column"><h3 class="c-article__sub-heading" id="citeas">Cite this article</h3><p class="c-bibliographic-information__citation">Petersen, K.K., Milà-Alomà, M., Li, Y. <i>et al.</i> Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks.
                    <i>Nat Med</i>  (2026). https://doi.org/10.1038/s41591-026-04206-y</p><p class="c-bibliographic-information__download-citation u-hide-print"><a data-test="citation-link" data-track="click" data-track-action="download article citation" data-track-label="link" data-track-external="" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-026-04206-y?format=refman&amp;flavour=citation">Download citation<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p><ul class="c-bibliographic-information__list" data-test="publication-history"><li class="c-bibliographic-information__list-item"><p>Received<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2025-07-06">06 July 2025</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Accepted<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2025-12-31">31 December 2025</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Published<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2026-02-19">19 February 2026</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Version of record<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2026-02-19">19 February 2026</time></span></p></li><li class="c-bibliographic-information__list-item c-bibliographic-information__list-item--full-width"><p><abbr title="Digital Object Identifier">DOI</abbr><span class="u-hide">: </span><span class="c-bibliographic-information__value">https://doi.org/10.1038/s41591-026-04206-y</span></p></li></ul><div data-component="share-box"><div class="c-article-share-box u-display-none" hidden=""><h3 class="c-article__sub-heading">Share this article</h3><p class="c-article-share-box__description">Anyone you share the following link with will be able to read this content:</p><button class="js-get-share-url c-article-share-box__button" type="button" id="get-share-url" data-track="click" data-track-label="button" data-track-external="" data-track-action="get shareable link">Get shareable link</button><div class="js-no-share-url-container u-display-none" hidden=""><p class="js-c-article-share-box__no-sharelink-info c-article-share-box__no-sharelink-info">Sorry, a shareable link is not currently available for this article.</p></div><div class="js-share-url-container u-display-none" hidden=""><p class="js-share-url c-article-share-box__only-read-input" id="share-url" data-track="click" data-track-label="button" data-track-action="select share url"></p><button class="js-copy-share-url c-article-share-box__button--link-like" type="button" id="copy-share-url" data-track="click" data-track-label="button" data-track-action="copy share url" data-track-external="">Copy shareable link to clipboard</button></div><p class="js-c-article-share-box__additional-info c-article-share-box__additional-info">
                            Provided by the Springer Nature SharedIt content-sharing initiative
                        </p></div></div><div data-component="article-info-list"></div></div></div></div></div></section>
            </div>

            
            

        </div>
</article>
</main>

<aside class="c-article-extras u-hide-print" aria-label="Article navigation" data-component-reading-companion data-container-type="reading-companion" data-track-component="reading companion">
    <div class="u-mb-48 js-context-bar-sticky-point-desktop" data-track-context="reading companion">
        

        
            
                
                    
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-026-04206-y.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external download>
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"/></svg>
            </a>
        </div>
    

                    
                
            
        
    </div>

    
        
    

    
    
        <div class="c-article-associated-content__container">
            <section>
                <h2 class="c-article-associated-content__title u-mb-24">Associated content</h2>
                
                    
                    
                        <div class="u-full-height u-mb-24">
                            
    <article class="u-full-height c-card c-card--flush">
        <div class="c-card__layout u-full-height">
            <div class="c-card__body">
                <h3 class="c-card__title">
                    <a href="https://www.nature.com/articles/d41586-026-00531-x"
                       class="c-card__link u-link-inherit"
                       data-track="click"
                       data-track-action="view article"
                       data-track-category="associated content"
                       
                       data-track-label="news">Blood test holds promise for predicting when Alzheimer’s symptoms will start</a>
                </h3>
                
<ul data-test="author-list" class="app-author-list app-author-list--compact">
    <li>Heidi Ledford</li>
</ul>

                
    <div class="c-card__section c-meta">
        
            <span class="c-meta__item">Nature</span>
        
        <span class="c-meta__item" data-test="article.type"><span class="c-meta__type">News</span></span>
        
        
            <time class="c-meta__item" datetime="2026-02-19">19 Feb 2026</time>
        
    </div>

            </div>
        </div>
    </article>


                        </div>
                    
                
            </section>
        </div>
        <script>
            window.dataLayer = window.dataLayer || [];
            window.dataLayer[0] = window.dataLayer[0] || {};
            window.dataLayer[0].content = window.dataLayer[0].content || {};
            window.dataLayer[0].content.associatedContentTypes = "news";
            
        </script>
    

    

    <div class="c-reading-companion">
        <div class="c-reading-companion__sticky" data-component="reading-companion-sticky" data-test="reading-companion-sticky">
            <div class="c-reading-companion__panel c-reading-companion__sections c-reading-companion__panel--active" id="tabpanel-sections">
                <div class="u-lazy-ad-wrapper u-mt-16 u-hide" data-component-mpu>
                    <div class="c-ad c-ad--300x250">
                        <div class="c-ad__inner">
                            <p class="c-ad__label">Advertisement</p>
                            
    <div id="div-gpt-ad-right-2"
         class="div-gpt-ad advert medium-rectangle js-ad text-center hide-print grade-c-hide"
         data-ad-type="right"
         data-test="right-ad"
         data-pa11y-ignore
         data-gpt
         data-gpt-unitpath="/285/medicine.nature.com/article"
         data-gpt-sizes="300x250"
         data-gpt-targeting="type=article;pos=right;artid=s41591-026-04206-y;doi=10.1038/s41591-026-04206-y;subjmeta=1283,1689,378,631;kwrd=Alzheimer%27s+disease">
        
        <script>
            window.SN = window.SN || {};
            window.SN.libs = window.SN.libs || {};
            window.SN.libs.ads = window.SN.libs.ads || {};
            window.SN.libs.ads.slotConfig = window.SN.libs.ads.slotConfig || {};
            
                window.SN.libs.ads.slotConfig['right'] = {
                    'pos': 'right',
                    'type': 'article',
                    'path': 's41591-026-04206-y'
                };
            
            
            window.SN.libs.ads.slotConfig['kwrd'] = 'Alzheimer%27s+disease';
            
            
            window.SN.libs.ads.slotConfig['subjmeta'] = '1283,1689,378,631';
            
            
        </script>
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=1006426245&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-026-04206-y%26doi%3D10.1038/s41591-026-04206-y%26subjmeta%3D1283,1689,378,631%26kwrd%3DAlzheimer%27s+disease">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=1006426245&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-026-04206-y%26doi%3D10.1038/s41591-026-04206-y%26subjmeta%3D1283,1689,378,631%26kwrd%3DAlzheimer%27s+disease"
                     alt="Advertisement"
                     width="300"
                     height="250"></a>
        </noscript>
    </div>

                        </div>
                    </div>
                </div>
            </div>
            <div class="c-reading-companion__panel c-reading-companion__figures c-reading-companion__panel--full-width" id="tabpanel-figures"></div>
            <div class="c-reading-companion__panel c-reading-companion__references c-reading-companion__panel--full-width" id="tabpanel-references"></div>
        </div>
    </div>
</aside>
</div>


    
        <nav class="c-header__dropdown" aria-labelledby="Explore-content" data-test="Explore-content" id="explore" data-track-component="nature-150-split-header">
            <div class="c-header__container">
                <h2 id="Explore-content" class="c-header__heading c-header__heading--js-hide">Explore content</h2>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nm/research-articles"
                                   data-track="click"
                                   data-track-action="research articles"
                                   data-track-label="link"
                                   data-test="explore-nav-item">
                                    Research articles
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nm/reviews-and-analysis"
                                   data-track="click"
                                   data-track-action="reviews &amp; analysis"
                                   data-track-label="link"
                                   data-test="explore-nav-item">
                                    Reviews &amp; Analysis
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nm/news-and-comment"
                                   data-track="click"
                                   data-track-action="news &amp; comment"
                                   data-track-label="link"
                                   data-test="explore-nav-item">
                                    News &amp; Comment
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nm/podcast"
                                   data-track="click"
                                   data-track-action="podcasts"
                                   data-track-label="link"
                                   data-test="explore-nav-item">
                                    Podcasts
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nm/current-issue"
                                   data-track="click"
                                   data-track-action="current issue"
                                   data-track-label="link"
                                   data-test="explore-nav-item">
                                    Current issue
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nm/collections"
                                   data-track="click"
                                   data-track-action="collections"
                                   data-track-label="link"
                                   data-test="explore-nav-item">
                                    Collections
                                </a>
                            </li>
                        
                    
                </ul>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        <li class="c-header__item">
                            <a class="c-header__link"
                               href="https://www.facebook.com/Nature-Medicine-193691346949/"
                               data-track="click"
                               data-track-action="facebook"
                               data-track-label="link">Follow us on Facebook
                            </a>
                        </li>
                    
                    
                    
                        <li class="c-header__item">
                            <a class="c-header__link"
                               href="https://twitter.com/naturemedicine"
                               data-track="click"
                               data-track-action="twitter"
                               data-track-label="link">Follow us on X
                            </a>
                        </li>
                    
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link"
                               href="https://journal-alerts.springernature.com/subscribe?journal_id&#x3D;41591"
                               rel="nofollow"
                               data-track="nav_sign_up_for_alerts"
                               data-track-action="Sign up for alerts"
                               data-track-external
                               data-track-label="link (mobile dropdown)">Sign up for alerts<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#fff"/></svg>
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link"
                               href="https://www.nature.com/nm.rss"
                               data-track="click"
                               data-track-action="rss feed"
                               data-track-label="link">
                                <span>RSS feed</span>
                            </a>
                        </li>
                    
                </ul>
            </div>
        </nav>
    
    
        
            <nav class="c-header__dropdown" aria-labelledby="About-the-journal" id="about-the-journal" data-test="about-the-journal" data-track-component="nature-150-split-header">
                <div class="c-header__container">
                    <h2 id="About-the-journal" class="c-header__heading c-header__heading--js-hide">About the journal</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nm/aims"
                                   data-track="click"
                                   data-track-action="aims &amp; scope"
                                   data-track-label="link">
                                    Aims &amp; Scope
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nm/journal-information"
                                   data-track="click"
                                   data-track-action="journal information"
                                   data-track-label="link">
                                    Journal Information
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nm/journal-impact"
                                   data-track="click"
                                   data-track-action="journal metrics"
                                   data-track-label="link">
                                    Journal Metrics
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nm/editors"
                                   data-track="click"
                                   data-track-action="about the editors"
                                   data-track-label="link">
                                    About the Editors
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nm/research-cross-journal-editorial-team"
                                   data-track="click"
                                   data-track-action="research cross-journal editorial team"
                                   data-track-label="link">
                                    Research Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nm/reviews-cross-journal-editorial-team"
                                   data-track="click"
                                   data-track-action="reviews cross-journal editorial team"
                                   data-track-label="link">
                                    Reviews Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nm/statistics-advisory-panel"
                                   data-track="click"
                                   data-track-action="statistical advisory panel"
                                   data-track-label="link">
                                    Statistical Advisory Panel
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nm/our-publishing-models"
                                   data-track="click"
                                   data-track-action="our publishing models"
                                   data-track-label="link">
                                    Our publishing models
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nm/editorial-values-statement"
                                   data-track="click"
                                   data-track-action="editorial values statement"
                                   data-track-label="link">
                                    Editorial Values Statement
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nm/editorial-policies"
                                   data-track="click"
                                   data-track-action="editorial policies"
                                   data-track-label="link">
                                    Editorial Policies
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nm/content"
                                   data-track="click"
                                   data-track-action="content types"
                                   data-track-label="link">
                                    Content Types
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nm/web-feeds"
                                   data-track="click"
                                   data-track-action="web feeds"
                                   data-track-label="link">
                                    Web Feeds
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nm/contact"
                                   data-track="click"
                                   data-track-action="contact"
                                   data-track-label="link">
                                    Contact
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
        

        
            <nav class="c-header__dropdown" aria-labelledby="Publish-with-us-label" id="publish-with-us" data-test="publish-with-us" data-track-component="nature-150-split-header">
                <div class="c-header__container">
                    <h2 id="Publish-with-us-label" class="c-header__heading c-header__heading--js-hide">Publish with us</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nm/submission-guidelines"
                                   data-track="click"
                                   data-track-action="submission guidelines"
                                   data-track-label="link">
                                    Submission Guidelines
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nm/for-reviewers"
                                   data-track="click"
                                   data-track-action="for reviewers"
                                   data-track-label="link">
                                    For Reviewers
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" data-test="nature-author-services"
                                   data-track="nav_language_services"
                                   data-track-context="header publish with us dropdown menu"
                                   data-track-action="manuscript author services"
                                   data-track-label="link manuscript author services"
                                   href="https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022">
                                    Language editing services
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/nm/open-access-funding"
                                   data-test="funding-eligibility-link"
                                   data-track="click_explore_funding"
                                   data-track-context="header publish with us"
                                   data-track-action="funding eligibility">Open access funding</a>
                            </li>
                        
                        
                            <li class="c-header__item c-header__item--keyline">
                                <a class="c-header__link"
                                   href="https://mts-nmed.nature.com/cgi-bin/main.plex"
                                   data-track="click_submit_manuscript"
                                   data-track-context="submit link in Nature header dropdown menu"
                                   data-track-action="submit manuscript"
                                   data-track-label="link (publish with us dropdown menu)"
                                   data-track-external
                                   data-gtm-criteo="submit-manuscript">Submit manuscript<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m15 0c1.1045695 0 2 .8954305 2 2v5.5c0 .27614237-.2238576.5-.5.5s-.5-.22385763-.5-.5v-5.5c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-9v3c0 1.1045695-.8954305 2-2 2h-3v10c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h7.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-7.5c-1.1045695 0-2-.8954305-2-2v-10.17157288c0-.53043297.21071368-1.0391408.58578644-1.41421356l3.82842712-3.82842712c.37507276-.37507276.88378059-.58578644 1.41421356-.58578644zm-.5442863 8.18867991 3.3545404 3.35454039c.2508994.2508994.2538696.6596433.0035959.909917-.2429543.2429542-.6561449.2462671-.9065387-.0089489l-2.2609825-2.3045251.0010427 7.2231989c0 .3569916-.2898381.6371378-.6473715.6371378-.3470771 0-.6473715-.2852563-.6473715-.6371378l-.0010428-7.2231995-2.2611222 2.3046654c-.2531661.2580415-.6562868.2592444-.9065605.0089707-.24295423-.2429542-.24865597-.6576651.0036132-.9099343l3.3546673-3.35466731c.2509089-.25090888.6612706-.25227691.9135302-.00001728zm-.9557137-3.18867991c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm-8.5-3.587-3.587 3.587h2.587c.55228475 0 1-.44771525 1-1zm8.5 1.587c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill="#fff"/></svg>
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
        
    
    <script>
        window.dataLayer = window.dataLayer || [];
        window.dataLayer.push({
            page: {
                content: {
                    fundingWidget: "true",
                        }
                    }
                });
    </script>


<div id="search-menu" class="c-header__dropdown c-header__dropdown--full-width" data-track-component="nature-150-split-header">
    <div class="c-header__container">
        <h2 class="c-header__visually-hidden">Search</h2>
        <form class="c-header__search-form" action="/search" method="get" role="search" autocomplete="off" data-test="inline-search">
            <label class="c-header__heading" for="keywords">Search articles by subject, keyword or author</label>
            <div class="c-header__search-layout c-header__search-layout--max-width">
                <div>
                    <input type="text" required="" class="c-header__input" id="keywords" name="q" value="">
                </div>
                <div class="c-header__search-layout">
                    <div>
                        <label for="results-from" class="c-header__visually-hidden">Show results from</label>
                        <select id="results-from" name="journal" class="c-header__select">
                            
                                
                                    <option value="" selected>All journals</option>
                                    <option value="nm">This journal</option>
                                
                            
                        </select>
                    </div>
                    <div>
                        <button type="submit" class="c-header__search-button">Search</button>
                    </div>
                </div>

            </div>
        </form>

        <div class="c-header__flush">
            <a class="c-header__link" href="/search/advanced"
               data-track="click" data-track-action="advanced search" data-track-label="link">
                Advanced search
            </a>
        </div>

        <h3 class="c-header__heading c-header__heading--keyline">Quick links</h3>
        <ul class="c-header__list">
            <li><a class="c-header__link" href="/subjects" data-track="click" data-track-action="explore articles by subject" data-track-label="link">Explore articles by subject</a></li>
            <li><a class="c-header__link" href="/naturecareers" data-track="click" data-track-action="find a job" data-track-label="link">Find a job</a></li>
            <li><a class="c-header__link" href="/authors/index.html" data-track="click" data-track-action="guide to authors" data-track-label="link">Guide to authors</a></li>
            <li><a class="c-header__link" href="/authors/editorial_policies/" data-track="click" data-track-action="editorial policies" data-track-label="link">Editorial policies</a></li>
        </ul>
    </div>
</div>

<footer class="composite-layer" itemscope itemtype="http://schema.org/Periodical">
        <meta itemprop="publisher" content="Springer Nature">
        

        <div class="u-mt-16 u-mb-16">
    <div class="u-container">
        <div class="u-display-flex u-flex-wrap u-justify-content-space-between">
            

            <div class="c-meta u-ma-0 u-flex-shrink">
                <p class="c-meta__item c-meta__type u-mt-0">
                    <span itemprop="name">
                        Nature Medicine
                    </span>
                    (<i itemprop="alternateName">Nat Med</i>)
                </p>
                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1546-170X</span> (online)
        </p>
    

                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1078-8956</span> (print)
        </p>
    

            </div>
        </div>
    </div>
</div>

    <div class="c-footer">
        <div class="u-hide-print" data-track-component="footer">
    <h2 class="u-visually-hidden">nature.com sitemap</h2>
    <div class="c-footer__container">
        <div class="c-footer__grid c-footer__group--separator">
            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">About Nature Portfolio</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.nature.com/npg_/company_info/index.html"
                                                  data-track="click" data-track-action="about us"
                                                  data-track-label="link">About us</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.nature.com/npg_/press_room/press_releases.html"
                                                  data-track="click" data-track-action="press releases"
                                                  data-track-label="link">Press releases</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://press.nature.com/"
                                                  data-track="click" data-track-action="press office"
                                                  data-track-label="link">Press office</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://support.nature.com/support/home"
                                                  data-track="click" data-track-action="contact us"
                                                  data-track-label="link">Contact us</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Discover content</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/siteindex"
                                                  data-track="click" data-track-action="journals a-z"
                                                  data-track-label="link">Journals A-Z</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/subjects"
                                                  data-track="click" data-track-action="article by subject"
                                                  data-track-label="link">Articles by subject</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.protocols.io/"
                                                  data-track="click" data-track-action="protocols.io"
                                                  data-track-label="link">protocols.io</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureindex.com/"
                                                  data-track="click" data-track-action="nature index"
                                                  data-track-label="link">Nature Index</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Publishing policies</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.nature.com/authors/editorial_policies"
                                                  data-track="click" data-track-action="Nature portfolio policies"
                                                  data-track-label="link">Nature portfolio policies</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.nature.com/nature-research/open-access"
                                                  data-track="click" data-track-action="open access"
                                                  data-track-label="link">Open access</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Author &amp; Researcher services</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/reprints"
                                                  data-track="click" data-track-action="reprints and permissions"
                                                  data-track-label="link">Reprints &amp; permissions</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.springernature.com/gp/authors/research-data"
                                                  data-track="click" data-track-action="data research service"
                                                  data-track-label="link">Research data</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://authorservices.springernature.com/language-editing/"
                                                  data-track="click" data-track-action="language editing"
                                                  data-track-label="link">Language editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://authorservices.springernature.com/scientific-editing/"
                                                  data-track="click" data-track-action="scientific editing"
                                                  data-track-label="link">Scientific editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://masterclasses.nature.com/"
                                                  data-track="click" data-track-action="nature masterclasses"
                                                  data-track-label="link">Nature Masterclasses</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://solutions.springernature.com/"
                                                  data-track="click" data-track-action="research solutions"
                                                  data-track-label="link">Research Solutions</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Libraries &amp; institutions</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.springernature.com/gp/librarians/tools-services"
                                                  data-track="click" data-track-action="librarian service and tools"
                                                  data-track-label="link">Librarian service &amp; tools</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.springernature.com/gp/librarians/manage-your-account/librarianportal"
                                                  data-track="click" data-track-action="librarian portal"
                                                  data-track-label="link">Librarian portal</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.nature.com/openresearch/about-open-access/information-for-institutions"
                                                  data-track="click" data-track-action="open research"
                                                  data-track-label="link">Open research</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.springernature.com/gp/librarians/recommend-to-your-library"
                                                  data-track="click" data-track-action="Recommend to library"
                                                  data-track-label="link">Recommend to library</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Advertising &amp; partnerships</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://partnerships.nature.com/product/digital-advertising/"
                                                  data-track="click" data-track-action="advertising"
                                                  data-track-label="link">Advertising</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/"
                                                  data-track="click" data-track-action="partnerships and services"
                                                  data-track-label="link">Partnerships &amp; Services</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://partnerships.nature.com/media-kits/" data-track="click"
                                                  data-track-action="media kits" data-track-label="link">Media kits</a>
                    </li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://partnerships.nature.com/product/branded-content-native-advertising/"
                                                  data-track-action="branded content" data-track-label="link">Branded
                        content</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Professional development</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/immersive/natureawards/index.html"
                                                  data-track="click" data-track-action="nature awards"
                                                  data-track-label="link">Nature Awards</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/naturecareers/"
                                                  data-track="click" data-track-action="nature careers"
                                                  data-track-label="link">Nature Careers</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://conferences.nature.com"
                                                  data-track="click" data-track-action="nature conferences"
                                                  data-track-label="link">Nature<span class="u-visually-hidden"> </span>
                        Conferences</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Regional websites</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natafrica"
                                                  data-track="click" data-track-action="nature africa"
                                                  data-track-label="link">Nature Africa</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="http://www.naturechina.com"
                                                  data-track="click" data-track-action="nature china"
                                                  data-track-label="link">Nature China</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nindia"
                                                  data-track="click" data-track-action="nature india"
                                                  data-track-label="link">Nature India</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureasia.com/ja-jp"
                                                  data-track="click" data-track-action="nature japan"
                                                  data-track-label="link">Nature Japan</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nmiddleeast"
                                                  data-track="click" data-track-action="nature middle east"
                                                  data-track-label="link">Nature Middle East</a></li>
                </ul>
            </div>

        </div>
    </div>
    <div class="c-footer__container">
        <ul class="c-footer__links">
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/privacy"
                                          data-track="click" data-track-action="privacy policy" data-track-label="link">Privacy
                Policy</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/cookies"
                                          data-track="click" data-track-action="use of cookies" data-track-label="link">Use
                of cookies</a></li>
            <li class="c-footer__item">
                <button class="optanon-toggle-display c-footer__link" onclick="javascript:;"
                        data-cc-action="preferences" data-track="click" data-track-action="manage cookies"
                        data-track-label="link">Your privacy choices/Manage cookies
                </button>
            </li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/legal-notice"
                                          data-track="click" data-track-action="legal notice" data-track-label="link">Legal
                notice</a></li>
            <li class="c-footer__item"><a class="c-footer__link"
                                          href="https://www.nature.com/info/accessibility-statement" data-track="click"
                                          data-track-action="accessibility statement" data-track-label="link">Accessibility
                statement</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/terms-and-conditions"
                                          data-track="click" data-track-action="terms and conditions"
                                          data-track-label="link">Terms &amp; Conditions</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/ccpa"
                                          data-track="click" data-track-action="california privacy statement"
                                          data-track-label="link">Your US state privacy rights</a></li>
            
        </ul>
    </div>
</div>


        <div class="c-footer__container">
    <a href="https://www.springernature.com/" class="c-footer__link">
        <img src="/static/images/logos/sn-logo-white-c8f7a9c061.svg" alt="Springer Nature" loading="lazy" width="200" height="20"/>
    </a>
    <p class="c-footer__legal" data-test="copyright">&copy; 2026 Springer Nature Limited</p>
</div>

    </div>
    <div class="u-visually-hidden" aria-hidden="true">
    
    <svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><defs><path id="a" d="M0 .74h56.72v55.24H0z"/></defs><symbol id="icon-access" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M14 8a1 1 0 0 1 1 1v7h2.5a.5.5 0 0 1 .5.5V18H0v-1.5a.5.5 0 0 1 .5-.5H3V9a1 1 0 1 1 2 0v7h8V9a1 1 0 0 1 1-1M6 8l2 1v5l-2 1zm6 0v7l-2-1V9zM9.573.401l7.036 4.925A.92.92 0 0 1 16.081 7H1.92a.92.92 0 0 1-.528-1.674L8.427.401a1 1 0 0 1 1.146 0M9 2.441 5.345 5h7.31z"/></symbol><symbol id="icon-account" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M10.238 16.905a7.96 7.96 0 0 0 3.53-1.48c-.874-2.514-2.065-3.936-3.768-4.319V9.83a3.001 3.001 0 1 0-2 0v1.277c-1.703.383-2.894 1.805-3.767 4.319A7.96 7.96 0 0 0 9 17q.629 0 1.238-.095m4.342-2.172a8 8 0 1 0-11.16 0c.757-2.017 1.84-3.608 3.49-4.322a4 4 0 1 1 4.182 0c1.649.714 2.731 2.305 3.488 4.322M9 18A9 9 0 1 1 9 0a9 9 0 0 1 0 18"/></symbol><symbol id="icon-alert" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M4 10h2.5a.5.5 0 1 1 0 1H3.414l-1.121 1.121a1 1 0 0 0-.293.707V13h14v-.172a1 1 0 0 0-.293-.707L14 10.414V7A5 5 0 0 0 4 7zm3 4a2 2 0 1 0 4 0zm-5 0a1 1 0 0 1-1-1v-.172a2 2 0 0 1 .586-1.414L3 10V7a6 6 0 1 1 12 0v3l1.414 1.414A2 2 0 0 1 17 12.828V13a1 1 0 0 1-1 1h-4a3 3 0 0 1-6 0z"/></symbol><symbol id="icon-arrow-broad" viewBox="0 0 16 16"><path fill-rule="evenodd" d="M7.897 12.028v-7.69l-2.45 2.446c-.387.388-1.009.395-1.385.02a.986.986 0 0 1 0-1.397l4.123-4.118a.99.99 0 0 1 1.398 0l4.123 4.118a.976.976 0 0 1 .016 1.38.99.99 0 0 1-1.401-.002l-2.45-2.447v8.676c0 .541-.437.98-.985.982L.987 14a.987.987 0 1 1 0-1.972z"/></symbol><symbol id="icon-arrow-down" viewBox="0 0 16 16"><path fill-rule="evenodd" d="m3.283 11.53 4.031 4.176a.943.943 0 0 0 1.367 0l4.031-4.176c.378-.391.384-1.02.016-1.4a.94.94 0 0 0-1.37.003l-2.395 2.482V1L8.956.883C8.901.386 8.493 0 7.998 0s-.903.386-.959.883L7.033 1v11.615l-2.396-2.482c-.379-.393-.986-.4-1.354-.02a1.027 1.027 0 0 0 0 1.417"/></symbol><symbol id="icon-arrow-left" viewBox="0 0 16 16"><path fill-rule="evenodd" d="M4.47 3.283.294 7.314a.943.943 0 0 0 0 1.367l4.176 4.031c.391.378 1.02.384 1.4.016a.94.94 0 0 0-.003-1.37L3.385 8.963H15l.117-.007c.497-.055.883-.463.883-.958s-.386-.903-.883-.959L15 7.033H3.385l2.482-2.396c.393-.379.4-.986.02-1.354a1.027 1.027 0 0 0-1.417 0"/></symbol><symbol id="icon-arrow-right" viewBox="0 0 16 16"><path fill-rule="evenodd" d="m11.53 12.717 4.176-4.031a.943.943 0 0 0 0-1.367L11.53 3.288c-.391-.378-1.02-.384-1.4-.016a.94.94 0 0 0 .003 1.37l2.482 2.395H1l-.117.007C.386 7.099 0 7.507 0 8.002s.386.903.883.959L1 8.967h11.615l-2.482 2.396c-.393.379-.4.986-.02 1.354a1.027 1.027 0 0 0 1.417 0"/></symbol><symbol id="icon-arrow-sub" viewBox="0 0 16 16"><path fill-rule="evenodd" d="M7.897 4.972v7.69l-2.45-2.446c-.387-.388-1.009-.395-1.385-.02a.986.986 0 0 0 0 1.397l4.123 4.118a.99.99 0 0 0 1.398 0l4.123-4.118a.976.976 0 0 0 .016-1.38.99.99 0 0 0-1.401.002l-2.45 2.447V3.986a.98.98 0 0 0-.985-.982L.987 3a.987.987 0 1 0 0 1.972z"/></symbol><symbol id="icon-arrow-up" viewBox="0 0 16 16"><path fill-rule="evenodd" d="M12.717 4.47 8.686.294a.943.943 0 0 0-1.367 0L3.288 4.47c-.378.391-.384 1.02-.016 1.4a.94.94 0 0 0 1.37-.003l2.395-2.482V15l.007.117c.055.497.463.883.958.883s.903-.386.959-.883L8.967 15V3.385l2.396 2.482c.379.393.986.4 1.354.02a1.027 1.027 0 0 0 0-1.417"/></symbol><symbol id="icon-article" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M13 15V2.01q-.002-.011.001-.01H2v13.006c0 .548.446.994.994.994h10.274A2 2 0 0 1 13 15m-12 .006V2C1 1.445 1.447 1 1.999 1H13c.552 0 .999.452.999 1.01V5h3v9.991A2.003 2.003 0 0 1 15.006 17H2.994C1.894 17 1 16.107 1 15.006M14 6v9a1 1 0 0 0 2 0V6zM4 4h7v4H4zm1 1v2h5V5zM4 9h7v1H4zm0 2h7v1H4zm0 2h7v1H4z"/></symbol><symbol id="icon-audio" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M13.096 13.559a.503.503 0 0 1-.707 0 .493.493 0 0 1 0-.702A5.41 5.41 0 0 0 13.998 9a5.41 5.41 0 0 0-1.609-3.856.493.493 0 0 1 0-.701.503.503 0 0 1 .708 0A6.4 6.4 0 0 1 15 9a6.4 6.4 0 0 1-1.904 4.559m2.123 2.102a.503.503 0 0 1-.707 0 .493.493 0 0 1 0-.7A8.37 8.37 0 0 0 17 9a8.37 8.37 0 0 0-2.488-5.96c-.195-.193-.195-.507 0-.7s.513-.194.708 0A9.36 9.36 0 0 1 18 9a9.36 9.36 0 0 1-2.78 6.661M1 11.976c-.552 0-1-.444-1-.992V7.016a.996.996 0 0 1 1-.992h2l5.42-3.84a1.005 1.005 0 0 1 1.395.231c.122.169.187.37.187.577v12.016a.996.996 0 0 1-1 .992c-.209 0-.412-.065-.582-.185L3 11.975zm0-.992h2.321l5.68 4.024V2.992l-5.68 4.024h-2.32z"/></symbol><symbol id="icon-block" viewBox="0 0 24 24"><path fill-rule="evenodd" d="M0 0h24v24H0z"/></symbol><symbol id="icon-book" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M4 13V2h1v11h11V2H3a1 1 0 0 0-1 1v10.268A2 2 0 0 1 3 13zm12 1H3a1 1 0 0 0 0 2h13zm0 3H3a2 2 0 0 1-2-2V3a2 2 0 0 1 2-2h13a1 1 0 0 1 1 1v14a1 1 0 0 1-1 1M7.5 4h6a.5.5 0 1 1 0 1h-6a.5.5 0 0 1 0-1m1 2h4a.5.5 0 1 1 0 1h-4a.5.5 0 0 1 0-1"/></symbol><symbol id="icon-broad" viewBox="0 0 24 24"><path fill-rule="evenodd" d="M11 16.995v-7.8l-2.482 2.482c-.392.393-1.022.4-1.403.02a1 1 0 0 1 0-1.417l4.177-4.176a1 1 0 0 1 1.416 0l4.177 4.176a.99.99 0 0 1 .016 1.4 1 1 0 0 1-1.42-.003L13 9.195v8.8c0 .55-.443.995-.998.996L4 18.995a1 1 0 0 1 0-2z"/></symbol><symbol id="icon-calendar" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M12.5 0c.276 0 .5.215.5.49V1h2c1.107 0 2 .895 2 2v12c0 1.107-.895 2-2 2H3c-1.107 0-2-.895-2-2V3c0-1.107.895-2 2-2h1v1H3c-.554 0-1 .446-1 1v3h14V3c0-.554-.446-1-1-1h-2v1.51a.5.5 0 0 1-.5.49.49.49 0 0 1-.5-.49V.49a.5.5 0 0 1 .5-.49M16 7H2v8c0 .554.446 1 1 1h12c.554 0 1-.446 1-1zM5 13v1H4v-1zm3 0v1H7v-1zm3 0v1h-1v-1zm-6-2v1H4v-1zm3 0v1H7v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zM8 9v1H7V9zm6 0v1h-1V9zm-3 0v1h-1V9zM5.5 0c.276 0 .5.215.5.49V1h5v1H6v1.51a.5.5 0 0 1-.5.49.49.49 0 0 1-.5-.49V.49A.5.5 0 0 1 5.5 0"/></symbol><symbol id="icon-cart" viewBox="0 0 18 18"><path d="M5 14a2 2 0 1 1 0 4 2 2 0 0 1 0-4m10 0a2 2 0 1 1 0 4 2 2 0 0 1 0-4M5 15a1 1 0 1 0 0 2 1 1 0 0 0 0-2m10 0a1 1 0 1 0 0 2 1 1 0 0 0 0-2M2.18 0a1 1 0 0 1 .98.804L3.4 2H16.76a1 1 0 0 1 .978 1.21l-1.29 5.986c-.102.468-.544.804-1.058.804H5.143c-.592 0-1.072.448-1.072 1 0 .513.414.936.947.993l.125.007h10.36a.498.498 0 0 1 0 .996L5.142 13C3.959 13 3 12.105 3 11c0-.663.345-1.25.877-1.614l-1.638-8.19a1 1 0 0 1-.02-.195L.5 1a.5.5 0 1 1 0-1zm14.532 3H3.599l1.205 6.025A2 2 0 0 1 5.143 9h10.27z"/></symbol><symbol id="icon-chevron-less" viewBox="0 0 10 10"><path fill-rule="evenodd" d="m5 3.414 3.293 3.293a1 1 0 0 0 1.414-1.414l-4-4a1 1 0 0 0-1.414 0l-4 4a1 1 0 0 0 1.414 1.414z"/></symbol><symbol id="icon-chevron-more" viewBox="0 0 10 10"><path fill-rule="evenodd" d="m5 6.586 3.293-3.293a1 1 0 0 1 1.414 1.414l-4 4a1 1 0 0 1-1.414 0l-4-4a1 1 0 1 1 1.414-1.414z"/></symbol><symbol id="icon-chevron-right" viewBox="0 0 10 10"><path fill-rule="evenodd" d="M4.706 4.033 2.292 1.637A.953.953 0 0 1 2.273.283a.98.98 0 0 1 1.378 0l4.063 4.031c.381.378.381.99 0 1.367L3.651 9.712a.97.97 0 0 1-1.362.016.96.96 0 0 1 .003-1.37l2.414-2.395L5.693 5z"/></symbol><symbol id="icon-circle-fill" viewBox="0 0 16 16"><path fill-rule="evenodd" d="M8 14A6 6 0 1 1 8 2a6 6 0 0 1 0 12"/></symbol><symbol id="icon-circle" viewBox="0 0 16 16"><path fill-rule="evenodd" d="M8 12a4 4 0 1 0 0-8 4 4 0 0 0 0 8m0 2A6 6 0 1 1 8 2a6 6 0 0 1 0 12"/></symbol><symbol id="icon-citation" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M8.636 6a4 4 0 0 1 2.174 7.358 6.23 6.23 0 0 1 3.462 3.641h-1.077a5.22 5.22 0 0 0-2.769-2.718l-.79-.33v-1.023l.63-.41a3 3 0 1 0-3.26 0l.63.41v1.024l-.79.329a5.22 5.22 0 0 0-2.77 2.718H3a6.23 6.23 0 0 1 3.461-3.641A4 4 0 0 1 8.636 6m7.369-5C17.107 1 18 1.894 18 3.003v5.994A2 2 0 0 1 16.005 11L13 10.999v-1h3.005c.549 0 .995-.447.995-1.002V3.003A.997.997 0 0 0 16.005 2H1.995A1 1 0 0 0 1 3.003V9q0 1 1 1l2-.001v1H2c-1 0-2-1-2-2V3.004C0 1.897.893 1 1.995 1zM7.5 4a.5.5 0 1 1 0 1h-4a.5.5 0 0 1 0-1zm3 0a.5.5 0 1 1 0 1h-1a.5.5 0 0 1 0-1zm4 0a.5.5 0 1 1 0 1h-2a.5.5 0 0 1 0-1z"/></symbol><symbol id="icon-close" viewBox="0 0 16 16"><path fill-rule="evenodd" d="M2.297 12.277a1.007 1.007 0 0 0 0 1.427 1.006 1.006 0 0 0 1.426 0L8 9.425l4.277 4.277a1.007 1.007 0 0 0 1.427 0 1.006 1.006 0 0 0 0-1.426L9.425 8l4.277-4.277a1.007 1.007 0 0 0 0-1.427 1.006 1.006 0 0 0-1.426 0L8 6.575 3.723 2.297a1.007 1.007 0 0 0-1.427 0 1.006 1.006 0 0 0 0 1.426L6.575 8z"/></symbol><symbol id="icon-collections" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M15 4a2 2 0 0 1 2 2v9a2 2 0 0 1-2 2H7a2 2 0 0 1-2-2h1a1 1 0 0 0 .883.993L7 16h8a1 1 0 0 0 .993-.883L16 15V6a1 1 0 0 0-.883-.993L15 5h-1V4zm-4-3a2 2 0 0 1 2 2v9a2 2 0 0 1-2 2H3a2 2 0 0 1-2-2V3a2 2 0 0 1 2-2zm0 1H3a1 1 0 0 0-.993.883L2 3v9a1 1 0 0 0 .883.993L3 13h8a1 1 0 0 0 .993-.883L12 12V3a1 1 0 0 0-.883-.993zM9.5 9a.5.5 0 0 1 0 1h-5a.5.5 0 0 1 0-1zm0-2a.5.5 0 0 1 0 1h-5a.5.5 0 0 1 0-1zm0-2a.5.5 0 0 1 0 1h-5a.5.5 0 0 1 0-1z"/></symbol><symbol id="icon-compare" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M12 3a6 6 0 1 1-3 11.197A6 6 0 1 1 9 3.803a5.96 5.96 0 0 1 3-.803M6 4a5 5 0 1 0 2.085 9.546C6.808 12.446 6 10.817 6 9s.808-3.446 2.084-4.546A5 5 0 0 0 6 4m6 0c-.744 0-1.45.162-2.085.454C11.192 5.554 12 7.183 12 9s-.808 3.446-2.084 4.546A5 5 0 1 0 12 4m-1.416 7H7.416q.236.538.585 1.001h1.998q.35-.463.585-1M11 9H7q.001.515.1 1.001h3.8q.099-.486.1-1.001m-.416-2H7.416A5 5 0 0 0 7.1 8h3.8a5 5 0 0 0-.316-1M9.001 5l-.083.063A5 5 0 0 0 8 6h2a5 5 0 0 0-.999-1"/></symbol><symbol id="icon-download-file" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M10.005 0c.55 0 1.318.323 1.707.712l4.576 4.576c.393.393.712 1.168.712 1.714v8.99C17 17.1 16.105 18 15.006 18H2.994A1.994 1.994 0 0 1 1 16.005V1.995C1 .893 1.887 0 3 0zm0 1H3c-.557 0-1 .443-1 .995v14.01c0 .55.445.995.994.995h12.012c.546 0 .994-.45.994-1.009V7.002c0-.283-.215-.803-.419-1.007L11.005 1.42c-.204-.204-.719-.419-1-.419M8.5 5c.276 0 .5.216.5.492v6.148l1.746-1.78a.497.497 0 0 1 .7-.006.5.5 0 0 1-.002.702l-2.591 2.591a.5.5 0 0 1-.706 0l-2.59-2.59a.5.5 0 0 1-.004-.704.49.49 0 0 1 .7.007L8 11.64V5.492C8 5.22 8.232 5 8.5 5"/></symbol><symbol id="icon-download" viewBox="0 0 16 16"><path fill-rule="evenodd" d="M12.998 13a.999.999 0 1 1 0 2H3.002A1.006 1.006 0 0 1 2 14c0-.557.449-1 1.002-1zM8 1c.552 0 1 .445 1 .996v6.802l2.482-2.482c.392-.393 1.022-.401 1.403-.02a1 1 0 0 1 0 1.417l-4.177 4.178a1 1 0 0 1-1.416 0L3.115 7.713a.99.99 0 0 1-.016-1.4 1 1 0 0 1 1.42.002L7 8.798V1.996C7 1.446 7.444 1 8 1"/></symbol><symbol id="icon-editors" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M8.726 2.546A3 3 0 1 0 5.37 7.519l.63.409v1.024l-.79.329A5.22 5.22 0 0 0 2 14.099V15H1v-.901a6.22 6.22 0 0 1 3.825-5.741 4 4 0 1 1 4.976-6.213 5 5 0 0 0-1.075.4M6 17H5v-.901a6.22 6.22 0 0 1 3.825-5.741 4 4 0 1 1 4.349 0A6.22 6.22 0 0 1 17 16.099V17h-1v-.901a5.22 5.22 0 0 0-3.21-4.818l-.79-.33V9.929l.63-.409a3 3 0 1 0-3.26 0l.63.409v1.024l-.79.329A5.22 5.22 0 0 0 6 16.099z"/></symbol><symbol id="icon-email" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M16.005 2A2 2 0 0 1 18 4.006v9.988A2 2 0 0 1 16.005 16H1.995A2 2 0 0 1 0 13.994V4.006A2 2 0 0 1 1.995 2zm0 1H1.995A1 1 0 0 0 1 4.006v9.988A1 1 0 0 0 1.995 15h14.01A1 1 0 0 0 17 13.994V4.006A1 1 0 0 0 16.005 3M16 5.557V7l-7 4-7-4V5.557l7 4z"/></symbol><symbol id="icon-error" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M9 0a9 9 0 1 1 0 18A9 9 0 0 1 9 0m2.863 4.711L9 7.574 6.137 4.711a1.007 1.007 0 0 0-1.427 0 1.006 1.006 0 0 0 .001 1.426L7.574 9l-2.863 2.863a1.007 1.007 0 0 0 0 1.427 1.006 1.006 0 0 0 1.426-.001L9 10.426l2.863 2.863a1.007 1.007 0 0 0 1.427 0 1.006 1.006 0 0 0-.001-1.426L10.426 9l2.863-2.863a1.007 1.007 0 0 0 0-1.427 1.006 1.006 0 0 0-1.426.001"/></symbol><symbol id="icon-ethics" viewBox="0 0 18 18"><path fill-rule="evenodd" d="m6.764 1.414.833-.833a1.984 1.984 0 0 1 2.806 0l.833.833A2 2 0 0 0 12.65 2H14a2 2 0 0 1 2 2v1.35a2 2 0 0 0 .586 1.414l.833.833a1.984 1.984 0 0 1 0 2.806l-.833.833A2 2 0 0 0 16 12.65V14a2 2 0 0 1-2 2h-1.35a2 2 0 0 0-1.414.586l-.833.833a1.984 1.984 0 0 1-2.806 0l-.833-.833A2 2 0 0 0 5.35 16H4a2 2 0 0 1-2-2v-1.35a2 2 0 0 0-.586-1.414l-.833-.833a1.984 1.984 0 0 1 0-2.806l.833-.833A2 2 0 0 0 2 5.35V4a2 2 0 0 1 2-2h1.35a2 2 0 0 0 1.414-.586M5.35 3H4a1 1 0 0 0-1 1v1.35a3 3 0 0 1-.879 2.121l-.833.833a.984.984 0 0 0 0 1.392l.833.833A3 3 0 0 1 3 12.65V14a1 1 0 0 0 1 1h1.35a3 3 0 0 1 2.121.879l.833.833a.984.984 0 0 0 1.392 0l.833-.833A3 3 0 0 1 12.65 15H14a1 1 0 0 0 1-1v-1.35a3 3 0 0 1 .879-2.121l.833-.833a.984.984 0 0 0 0-1.392l-.833-.833A3 3 0 0 1 15 5.35V4a1 1 0 0 0-1-1h-1.35a3 3 0 0 1-2.121-.879l-.833-.833a.984.984 0 0 0-1.392 0l-.833.833A3 3 0 0 1 5.35 3m3.587 11.496a1 1 0 0 1-.064.003 5.5 5.5 0 0 1-2.759-.816.5.5 0 0 1 .526-.85 4.5 4.5 0 0 0 2.256.666q.026 0 .052.004L9 13.5a4.5 4.5 0 0 0 3.493-7.338.5.5 0 1 1 .775-.631A5.5 5.5 0 0 1 9 14.5zm1.58-10.784a.5.5 0 0 1-.276.961 4.5 4.5 0 0 0-1.156-.172C6.527 4.5 4.5 6.503 4.5 9c0 .627.128 1.235.373 1.796a.5.5 0 1 1-.917.4A5.5 5.5 0 0 1 3.5 9c0-3.052 2.477-5.5 5.594-5.5.486.009.963.08 1.422.212m-1.977 6.41 2.698-2.946a.5.5 0 0 1 .762.648l-3.016 3.343a.5.5 0 0 1-.693.047L6.36 9.592A.5.5 0 1 1 7 8.824z"/></symbol><symbol id="icon-expand"><path fill-rule="evenodd" d="M7.498 11.918a.997.997 0 0 0-.003-1.411.995.995 0 0 0-1.412-.003l-4.102 4.102v-3.51A1 1 0 0 0 .98 10.09.99.99 0 0 0 0 11.092V17c0 .554.448 1.002 1.002 1.002h5.907c.554 0 1.002-.45 1.002-1.003 0-.539-.45-.978-1.006-.978h-3.51zm3.005-5.835a.997.997 0 0 0 .003 1.412.995.995 0 0 0 1.411.003l4.103-4.103v3.51a1 1 0 0 0 1.001 1.006A.99.99 0 0 0 18 6.91V1.002A1 1 0 0 0 17 0h-5.907a1.003 1.003 0 0 0-1.002 1.003c0 .539.45.978 1.006.978h3.51z"/></symbol><symbol id="icon-explore" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M9 17A8 8 0 1 0 9 1a8 8 0 0 0 0 16m0 1A9 9 0 1 1 9 0a9 9 0 0 1 0 18m0-2.5a.5.5 0 1 1 0-1 5.5 5.5 0 0 0 5.497-5.317.5.5 0 1 1 1 .032A6.5 6.5 0 0 1 9 15.5M8.71 2.506a.5.5 0 1 1 .043 1A5.5 5.5 0 0 0 3.5 9a.5.5 0 0 1-1 0 6.5 6.5 0 0 1 6.21-6.494m1.137 8.048-1.2-1.2a.5.5 0 1 1 .707-.708l1.2 1.2 1.6-4-4.506 1.802-1.803 4.507zM13.95 4.05l-2.67 6.673a1 1 0 0 1-.557.557L4.05 13.95l2.67-6.673a1 1 0 0 1 .557-.557z"/></symbol><symbol id="icon-filter" viewBox="0 0 16 16"><path d="M14.974 0C15.54 0 16 .448 16 1c0 .242-.09.476-.254.658L10.052 8v5.5a1 1 0 0 1-.41.8L7.59 15.8a1.044 1.044 0 0 1-1.437-.2 1 1 0 0 1-.205-.6V8L.254 1.658A.98.98 0 0 1 .35.248C.537.087.778 0 1.026 0zM9.052 8.5H6.947v6.491l.012.007.02.002.02-.007 2.054-1.5zM1.026 1l-.015.002L6.843 7.5h2.313l5.836-6.499z"/></symbol><symbol id="icon-home" viewBox="0 0 18 18"><path fill-rule="evenodd" d="m9 5-6 6v5h4v-4h4v4h4v-5zm7 6.586V16a1 1 0 0 1-1 1h-5v-4H8v4H3a1 1 0 0 1-1-1v-4.414a1 1 0 0 1-.707-.293l-.586-.586a1 1 0 0 1 0-1.414L9 1l8.293 8.293a1 1 0 0 1 0 1.414l-.586.586a1 1 0 0 1-.707.293M9 2.414 1.414 10l.586.586 7-7 7 7 .586-.586z"/></symbol><symbol id="icon-image" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M10.005 0c.55 0 1.318.323 1.707.712l4.576 4.576c.393.393.712 1.168.712 1.714v8.99C17 17.1 16.105 18 15.006 18H2.994A1.994 1.994 0 0 1 1 16.005V1.995C1 .893 1.887 0 3 0zM6.508 10.175l-3.894 6.75a1 1 0 0 0 .38.075h10.603l-2.433-4.215-1.575 2.728zM15.006 17c.546 0 .994-.45.994-1.009V7.002c0-.283-.215-.803-.419-1.007L11.005 1.42c-.204-.204-.719-.419-1-.419H3c-.557 0-1 .443-1 .995v13.99l4.508-7.81 3.081 5.338 1.575-2.729L14.752 17zM12 6a2 2 0 1 1 0 4 2 2 0 0 1 0-4m0 1a1 1 0 1 0 0 2 1 1 0 0 0 0-2"/></symbol><symbol id="icon-info" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M9 0a9 9 0 1 1 0 18A9 9 0 0 1 9 0m0 7H7.5l-.117.007a1 1 0 0 0-.112 1.967l.112.02L7.5 9H8v3h-.5l-.117.007a1 1 0 0 0-.857.764l-.02.112L6.5 13l.007.117a1 1 0 0 0 .764.857l.112.02L7.5 14h3l.117-.007a1 1 0 0 0 .112-1.967l-.112-.02L10.5 12H10V8l-.007-.117a1 1 0 0 0-.764-.857l-.112-.02zm0-3.25a1.25 1.25 0 1 0 0 2.5 1.25 1.25 0 0 0 0-2.5"/></symbol><symbol id="icon-institution" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M7 17v-2h4v2h2v-3H5v3zM4 6.998H2.474a.5.5 0 0 1-.339-.868l1.232-1.132H1V17h3v-2H1v-1h3v-1h1V8.997H4zm10 0v2h-1V13h1v1h3v1h-3v2h3V4.999h-2.37l1.232 1.132a.5.5 0 0 1-.338.868zm3-3a1 1 0 0 1 1 1V18H0V4.998a1 1 0 0 1 1-1h3.455L8.66.131a.5.5 0 0 1 .677 0l4.205 3.865zm-4 3H5v1h8zm-2 6.001h1V9h-1zm-1 0V9H8v4zm-3 0V9H6v4zm8-4a1 1 0 0 1 1 1v2h-2v-2a1 1 0 0 1 1-1m-12 0a1 1 0 0 1 1 1v2H2v-2a1 1 0 0 1 1-1m5.999-7.82L3.757 5.998H14.24zM9 4.998a1 1 0 1 1 0-2 1 1 0 0 1 0 2M8 16v1h2v-1z"/></symbol><symbol id="icon-location" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M9.395 16.269a32 32 0 0 0 2.333-2.53c1.402-1.702 2.432-3.362 2.936-4.872C14.886 8.2 15 7.574 15 7a6 6 0 0 0-6-6C5.636 1 3 3.602 3 7c0 .574.114 1.199.336 1.867.504 1.51 1.534 3.17 2.936 4.872A32 32 0 0 0 9 16.65zM9 18S2 12 2 7c0-4 3.134-7 7-7a7 7 0 0 1 7 7c0 5-7 11-7 11m0-8a3 3 0 1 1 0-6 3 3 0 0 1 0 6m0-1a2 2 0 1 0 0-4 2 2 0 0 0 0 4"/></symbol><symbol id="icon-minus" viewBox="0 0 16 16"><path fill-rule="evenodd" d="M2 7h12c.552 0 1 .444 1 1 0 .552-.445 1-1 1H2c-.552 0-1-.444-1-1 0-.552.445-1 1-1"/></symbol><symbol id="icon-newsletter" viewBox="0 0 18 18"><path fill-rule="evenodd" d="m9 11.848 2-1.143V9H7v1.705zm-3-1.714V8h6v2.134l3-1.714V2H3v6.42zM16 4.75l1.53.956a1 1 0 0 1 .47.848V15a2 2 0 0 1-2 2H2a2 2 0 0 1-2-2V6.554a1 1 0 0 1 .47-.848L2 4.75V2a1 1 0 0 1 1-1h12a1 1 0 0 1 1 1zm0 1.18V9l-7 4-7-4V5.93l-1 .624V15a1 1 0 0 0 1 1h14a1 1 0 0 0 1-1V6.554zM6 4h6v1H6zM5 6h8v1H5z"/></symbol><symbol id="icon-orcid" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M9 1a8 8 0 1 1 0 16A8 8 0 0 1 9 1M6.099 6.273H4.68v7.171H6.1zm4.559.025H7.665v7.146h2.91q1.152 0 2.042-.445c.89-.445 1.051-.715 1.373-1.255q.484-.81.484-1.86 0-1.028-.481-1.852a3.3 3.3 0 0 0-1.35-1.278q-.87-.456-1.985-.456m-.19 1.08q1.182 0 1.88.67t.698 1.826q0 1.114-.693 1.803t-1.839.688H9.046V7.378zM5.382 3.667a.79.79 0 0 0-.577.253.8.8 0 0 0-.25.58q0 .336.25.59a.818.818 0 0 0 1.177.004.8.8 0 0 0 .25-.593q0-.351-.25-.593c-.25-.242-.366-.241-.6-.241"/></symbol><symbol id="icon-plus" viewBox="0 0 16 16"><path fill-rule="evenodd" d="M2 7h5V2c0-.552.444-1 1-1 .552 0 1 .445 1 1v5h5c.552 0 1 .444 1 1 0 .552-.445 1-1 1H9v5c0 .552-.444 1-1 1-.552 0-1-.445-1-1V9H2c-.552 0-1-.444-1-1 0-.552.445-1 1-1"/></symbol><symbol id="icon-print" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M16.005 5H1.995A.997.997 0 0 0 1 6v6c0 .557.443 1 .995 1H3v-3h12v3h1.005c.55 0 .995-.447.995-1V6c0-.557-.443-1-.995-1M14 4V1.998C14 1.45 13.548 1 12.991 1H5.01C4.452 1 4 1.45 4 1.998V4zm1 10v2.002A2.005 2.005 0 0 1 12.991 18H5.01A2 2 0 0 1 3 16.002V14H1.995A1.99 1.99 0 0 1 0 12V6c0-1.105.893-2 1.995-2H3V1.998C3 .894 3.902 0 5.009 0h7.982C14.101 0 15 .898 15 1.998V4h1.005C17.107 4 18 4.887 18 6v6c0 1.105-.893 2-1.995 2zm-1-3H4v5.002c0 .555.447.998 1.009.998h7.982c.557 0 1.009-.45 1.009-.998zm-9 1h8v1H5zm0 2h5v1H5zm9-5a1 1 0 1 1 0-2 1 1 0 0 1 0 2"/></symbol><symbol id="icon-search" viewBox="0 0 22 22"><path fill-rule="evenodd" d="M21.697 20.261a1.03 1.03 0 0 1 .01 1.448 1.034 1.034 0 0 1-1.448-.01l-4.267-4.267A9.812 9.812 0 0 1 0 9.812a9.812 9.811 0 1 1 17.43 6.182zM9.812 18.222A8.41 8.41 0 1 0 9.81 1.403a8.41 8.41 0 0 0 0 16.82z"/></symbol><symbol id="icon-social-facebook" viewBox="0 0 24 24"><path fill-rule="evenodd" d="M6.004 20A2 2 0 0 1 4 18.006V5.994C4 4.893 4.895 4 5.994 4h12.012C19.107 4 20 4.895 20 5.994v12.012A1.99 1.99 0 0 1 17.997 20H15.04v-6.196h2.08l.31-2.415h-2.39V9.848c0-.7.194-1.176 1.196-1.176h1.28v-2.16l-.235-.025c-.344-.032-.95-.07-1.63-.07-1.843 0-3.105 1.125-3.105 3.191v1.781h-2.085v2.415h2.085V20z"/></symbol><symbol id="icon-social-twitter" viewBox="0 0 24 24"><path fill-rule="evenodd" d="M18.877 6.874a3.77 3.77 0 0 0 1.625-2.096 7.2 7.2 0 0 1-2.347.917A3.64 3.64 0 0 0 15.463 4.5c-2.04 0-3.693 1.696-3.693 3.786q0 .448.094.862C8.8 8.99 6.076 7.483 4.254 5.191c-.317.56-.5 1.211-.5 1.905 0 1.314.653 2.472 1.643 3.152a3.65 3.65 0 0 1-1.672-.473v.045c0 1.834 1.273 3.366 2.964 3.713a3.5 3.5 0 0 1-.975.133c-.236 0-.471-.023-.694-.067.471 1.507 1.832 2.604 3.45 2.633a7.3 7.3 0 0 1-4.59 1.62q-.446 0-.88-.051A10.3 10.3 0 0 0 8.661 19.5c6.793 0 10.506-5.771 10.506-10.775l-.009-.49A7.5 7.5 0 0 0 21 6.275a7.3 7.3 0 0 1-2.122.596z"/></symbol><symbol id="icon-social-youtube" viewBox="0 0 24 24"><path fill-rule="evenodd" d="m10.142 14.397-.001-5.193 4.863 2.606zm9.963-7.927c-.685-.737-1.452-.74-1.804-.783-2.519-.187-6.297-.187-6.297-.187-.008 0-3.786 0-6.305.187-.352.043-1.119.046-1.804.783-.54.56-.715 1.834-.715 1.834S3 9.8 3 11.296v1.402c0 1.496.18 2.991.18 2.991s.176 1.274.715 1.835c.685.736 1.585.713 1.985.79 1.44.142 6.12.186 6.12.186s3.782-.006 6.301-.193c.352-.043 1.119-.047 1.804-.783.539-.561.715-1.835.715-1.835s.18-1.495.18-2.991v-1.402c0-1.496-.18-2.992-.18-2.992s-.176-1.273-.715-1.834"/></symbol><symbol id="icon-subject-medicine" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M12.5 8H6a3 3 0 0 0-3 3v1a3 3 0 0 0 3 3h1v-2h-.5a1.5 1.5 0 0 1 0-3H13a3 3 0 0 0 3-3V6a3 3 0 0 0-3-3h-2v2h1.5a1.5 1.5 0 0 1 0 3M7 7V6H3.5a2.5 2.5 0 0 1 0-5h1.028a3 3 0 0 1 1.342.317l1.133.567A2 2 0 0 1 11 2h2a4 4 0 0 1 4 4v1a4 4 0 0 1-4 4h-2v1h2a2 2 0 1 1 0 4h-2a2 2 0 1 1-4 0H6a4 4 0 0 1-4-4v-1a4 4 0 0 1 4-4zm0-2V2.943a2 2 0 0 1-.422-.154L5.422 2.21A2 2 0 0 0 4.528 2H3.5a1.5 1.5 0 0 0 0 3zm4 1v1h1.5a.5.5 0 1 0 0-1zm-1 1V2a1 1 0 1 0-2 0v5zm-2 4v5a1 1 0 0 0 2 0v-5zm3 2v2h2a1 1 0 0 0 0-2zm-4-1v-1h-.5a.5.5 0 1 0 0 1zM3.5 3h1a.5.5 0 0 1 0 1h-1a.5.5 0 0 1 0-1"/></symbol><symbol id="icon-success" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M9 0a9 9 0 1 1 0 18A9 9 0 0 1 9 0m3.486 4.982-4.718 5.506L5.14 8.465a.99.99 0 0 0-1.423.133 1.06 1.06 0 0 0 .13 1.463l3.407 2.733a1 1 0 0 0 1.387-.133l5.385-6.334a1.06 1.06 0 0 0-.116-1.464.99.99 0 0 0-1.424.119"/></symbol><symbol id="icon-table" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M16.005 2A2 2 0 0 1 18 4.006v9.988A2 2 0 0 1 16.005 16l-4.006-.001L12 16h-1l-.001-.001h-5L6 16H5l-.001-.001L1.995 16A2 2 0 0 1 0 13.994V4.006A2 2 0 0 1 1.995 2zM4.999 7H1v6.994A1 1 0 0 0 1.995 15H5zm6 0h-5v8h5zm5.006-4h-4.006v3H17v1h-5.001v7.999l4.006.001A1 1 0 0 0 17 13.994V4.006A1 1 0 0 0 16.005 3M3.5 12a.5.5 0 1 1 0 1h-1a.5.5 0 1 1 0-1zm12 0a.5.5 0 1 1 0 1h-2a.5.5 0 1 1 0-1zm-6 0a.5.5 0 1 1 0 1h-2a.5.5 0 1 1 0-1zm-6-2a.5.5 0 1 1 0 1h-1a.5.5 0 1 1 0-1zm12 0a.5.5 0 1 1 0 1h-2a.5.5 0 1 1 0-1zm-6 0a.5.5 0 1 1 0 1h-2a.5.5 0 1 1 0-1zm-6-2a.5.5 0 0 1 0 1h-1a.5.5 0 0 1 0-1zm12 0a.5.5 0 1 1 0 1h-2a.5.5 0 1 1 0-1zm-6 0a.5.5 0 0 1 0 1h-2a.5.5 0 0 1 0-1zm1.499-5h-5v3h5zm-6 0H1.995A1 1 0 0 0 1 4.006V6h3.999z"/></symbol><symbol id="icon-tick-circle" viewBox="0 0 24 24"><path fill-rule="evenodd" d="M12 2c5.523 0 10 4.477 10 10s-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2m0 1a9 9 0 1 0 0 18 9 9 0 0 0 0-18m4.22 5.366c.361-.437.999-.49 1.424-.119s.477 1.028.115 1.465l-6.093 6.944a1 1 0 0 1-1.405.097l-3.897-3.367c-.43-.368-.487-1.023-.13-1.464s.994-.5 1.423-.133l3.111 2.7z"/></symbol><symbol id="icon-tick" viewBox="0 0 16 16"><path fill-rule="evenodd" d="M6.768 9.211 3.657 6.628c-.429-.352-1.066-.295-1.423.127s-.3 1.049.13 1.4l3.915 3.24a1 1 0 0 0 1.375-.096l6.105-6.66a.984.984 0 0 0-.115-1.402 1.02 1.02 0 0 0-1.424.113z"/></symbol><symbol id="icon-update" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M1 13v1a1 1 0 0 0 1 1h14a1 1 0 0 0 1-1v-1h-1V3H2v10zm16-1h1v2a2 2 0 0 1-2 2H2a2 2 0 0 1-2-2v-2h1V3a1 1 0 0 1 1-1h14a1 1 0 0 1 1 1zm-1 0v1h-4.586l-1 1H7.586l-1-1H2v-1h5l1 1h2l1-1zM3 4h12v7H3zm1 1v5h10V5zm1 1h4v1H5zm0 2h4v1H5z"/></symbol><symbol id="icon-upload" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M10.005 0c.55 0 1.318.323 1.707.712l4.576 4.576c.393.393.712 1.168.712 1.714v8.99C17 17.1 16.105 18 15.006 18H2.994A1.994 1.994 0 0 1 1 16.005V1.995C1 .893 1.887 0 3 0zm0 1H3c-.557 0-1 .443-1 .995v14.01c0 .55.445.995.994.995h12.012c.546 0 .994-.45.994-1.009V7.002c0-.283-.215-.803-.419-1.007L11.005 1.42c-.204-.204-.719-.419-1-.419M8.149 5.146a.5.5 0 0 1 .705 0l2.591 2.59c.195.196.19.516.003.704a.49.49 0 0 1-.7-.007l-1.746-1.78V12.8a.501.501 0 0 1-1 0V6.653l-1.747 1.78a.497.497 0 0 1-.7.006.5.5 0 0 1 .003-.702z"/></symbol><symbol id="icon-video" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M16.005 2A2 2 0 0 1 18 4.006v9.988A2 2 0 0 1 16.005 16H1.995A2 2 0 0 1 0 13.994V4.006A2 2 0 0 1 1.995 2zm0 1H1.995A1 1 0 0 0 1 4.006v9.988A1 1 0 0 0 1.995 15h14.01A1 1 0 0 0 17 13.994V4.006A1 1 0 0 0 16.005 3m-8.31 2.25L12.3 7.99c.937.557.93 1.464 0 2.017l-4.604 2.74c-.937.557-1.696.165-1.696-.894v-5.71c0-1.05.767-1.446 1.696-.894m-.674.96v5.575c0 .3-.108.245.166.085l4.584-2.675c.305-.178.305-.216 0-.394L7.187 6.126c-.267-.156-.166-.207-.166.084"/></symbol><symbol id="icon-warning" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M9 11.75a1.25 1.25 0 1 1 0 2.5 1.25 1.25 0 0 1 0-2.5M9.413 4a1 1 0 0 1 1 1l-.003.083-.334 4A1 1 0 0 1 9.08 10h-.16a1 1 0 0 1-.996-.917l-.334-4a1 1 0 0 1 .914-1.08l.041-.002zM9 18A9 9 0 1 1 9 0a9 9 0 0 1 0 18"/></symbol><symbol id="icon-checklist-banner" viewBox="0 0 56.69 56.69"><path d="M0 0h56.69v56.69H0z" style="fill:none"/><clipPath id="b"><use xlink:href="#a" style="overflow:visible"/></clipPath><path d="M21.14 34.46c0-6.77 5.48-12.26 12.24-12.26s12.24 5.49 12.24 12.26-5.48 12.26-12.24 12.26c-6.76-.01-12.24-5.49-12.24-12.26zm19.33 10.66 10.23 9.22s1.21 1.09 2.3-.12l2.09-2.32s1.09-1.21-.12-2.3l-10.23-9.22m-19.29-5.92c0-4.38 3.55-7.94 7.93-7.94s7.93 3.55 7.93 7.94c0 4.38-3.55 7.94-7.93 7.94-4.38-.01-7.93-3.56-7.93-7.94zm17.58 12.99 4.14-4.81" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round"/><path d="M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5m14.42-5.2V4.86s0-2.93-2.93-2.93H4.13s-2.93 0-2.93 2.93v37.57s0 2.93 2.93 2.93h15.01M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round;stroke-linejoin:round"/></symbol><symbol id="icon-chevron-down" viewBox="0 0 16 16"><path fill-rule="evenodd" d="m8 6.586 3.293-3.293a1 1 0 0 1 1.414 1.414l-4 4a1 1 0 0 1-1.414 0l-4-4a1 1 0 0 1 1.414-1.414z"/></symbol><symbol id="icon-eds-i-arrow-right-medium" viewBox="0 0 24 24"><path d="m12.728 3.293 7.98 7.99a1 1 0 0 1 .281.561l.011.157c0 .32-.15.605-.384.788l-7.908 7.918a1 1 0 0 1-1.416-1.414L17.576 13H4a1 1 0 0 1 0-2h13.598l-6.285-6.293a1 1 0 0 1-.082-1.32l.083-.095a1 1 0 0 1 1.414.001"/></symbol><symbol id="icon-eds-i-check-circle-medium" viewBox="0 0 24 24"><path d="M12 1c6.075 0 11 4.925 11 11s-4.925 11-11 11S1 18.075 1 12 5.925 1 12 1m0 2a9 9 0 1 0 0 18 9 9 0 0 0 0-18m5.125 4.72a1 1 0 0 1 .156 1.405l-6 7.5a1 1 0 0 1-1.421.143l-3-2.5a1 1 0 0 1 1.28-1.536l2.217 1.846 5.362-6.703a1 1 0 0 1 1.406-.156Z"/></symbol><symbol id="icon-eds-i-chevron-down-medium" viewBox="0 0 16 16"><path fill-rule="evenodd" d="M2 7h5V2c0-.552.444-1 1-1 .552 0 1 .445 1 1v5h5c.552 0 1 .444 1 1 0 .552-.445 1-1 1H9v5c0 .552-.444 1-1 1-.552 0-1-.445-1-1V9H2c-.552 0-1-.444-1-1 0-.552.445-1 1-1"/></symbol><symbol id="icon-eds-i-chevron-down-small" viewBox="0 0 16 16"><path d="M13.692 5.278a1 1 0 0 1 .03 1.414L9.103 11.51a1.49 1.49 0 0 1-2.188.019L2.278 6.692a1 1 0 0 1 1.444-1.384L8 9.771l4.278-4.463a1 1 0 0 1 1.318-.111z"/></symbol><symbol id="icon-eds-i-chevron-right-medium" viewBox="0 0 10 10"><path fill-rule="evenodd" d="M4.706 4.033 2.292 1.637A.953.953 0 0 1 2.273.283a.98.98 0 0 1 1.378 0l4.063 4.031c.381.378.381.99 0 1.367L3.651 9.712a.97.97 0 0 1-1.362.016.96.96 0 0 1 .003-1.37l2.414-2.395L5.693 5z"/></symbol><symbol id="icon-eds-i-chevron-right-small" viewBox="0 0 10 10"><path fill-rule="evenodd" d="M4.706 4.033 2.292 1.637A.953.953 0 0 1 2.273.283a.98.98 0 0 1 1.378 0l4.063 4.031c.381.378.381.99 0 1.367L3.651 9.712a.97.97 0 0 1-1.362.016.96.96 0 0 1 .003-1.37l2.414-2.395L5.693 5z"/></symbol><symbol id="icon-eds-i-chevron-up-medium" viewBox="0 0 16 16"><path fill-rule="evenodd" d="M2 7h12c.552 0 1 .444 1 1 0 .552-.445 1-1 1H2c-.552 0-1-.444-1-1 0-.552.445-1 1-1"/></symbol><symbol id="icon-eds-i-close-medium" viewBox="0 0 24 24"><path d="M12 1c6.075 0 11 4.925 11 11s-4.925 11-11 11S1 18.075 1 12 5.925 1 12 1m0 2a9 9 0 1 0 0 18 9 9 0 0 0 0-18M8.707 7.293 12 10.585l3.293-3.292a1 1 0 0 1 1.414 1.414L13.415 12l3.292 3.293a1 1 0 0 1-1.414 1.414L12 13.415l-3.293 3.292a1 1 0 1 1-1.414-1.414L10.585 12 7.293 8.707a1 1 0 0 1 1.414-1.414"/></symbol><symbol id="icon-eds-i-copy-link" viewBox="0 0 24 24"><path fill-rule="evenodd" d="M19.46 8.57a1 1 0 0 1 0-1.414l.833-.833A1.946 1.946 0 0 0 17.54 3.57l-.833.833a1 1 0 0 1-1.414-1.414l.833-.833a3.946 3.946 0 1 1 5.581 5.58l-.833.834a1 1 0 0 1-1.415 0" clip-rule="evenodd"/><path fill-rule="evenodd" d="M18.094 5.906a1 1 0 0 1 0 1.414l-1.666 1.667a1 1 0 1 1-1.414-1.414l1.666-1.667a1 1 0 0 1 1.414 0" clip-rule="evenodd"/><path fill-rule="evenodd" d="M13.511 6.322a1 1 0 0 1 0 1.415l-.833.833a1.946 1.946 0 1 0 2.752 2.752l.834-.833a1 1 0 0 1 1.414 1.414l-.834.834a3.946 3.946 0 1 1-5.58-5.581l.833-.834a1 1 0 0 1 1.414 0" clip-rule="evenodd"/><path d="M8 20v2h11.462c.674 0 1.32-.269 1.796-.747A2.55 2.55 0 0 0 22 19.455V15a1 1 0 1 0-2 0v4.455a.55.55 0 0 1-.16.387.54.54 0 0 1-.378.158z"/><path d="M4 13H2v6.462c0 .674.269 1.32.747 1.796A2.55 2.55 0 0 0 4.545 22H9a1 1 0 1 0 0-2H4.545a.55.55 0 0 1-.387-.16.54.54 0 0 1-.158-.378zM4 13H2V4.538c0-.674.269-1.32.747-1.796A2.55 2.55 0 0 1 4.545 2H9a1 1 0 0 1 0 2H4.545a.55.55 0 0 0-.387.16.54.54 0 0 0-.158.378z"/></symbol><symbol id="icon-eds-i-download-medium" viewBox="0 0 16 16"><path fill-rule="evenodd" d="M12.998 13a.999.999 0 1 1 0 2H3.002A1.006 1.006 0 0 1 2 14c0-.557.449-1 1.002-1zM8 1c.552 0 1 .445 1 .996v6.802l2.482-2.482c.392-.393 1.022-.401 1.403-.02a1 1 0 0 1 0 1.417l-4.177 4.178a1 1 0 0 1-1.416 0L3.115 7.713a.99.99 0 0 1-.016-1.4 1 1 0 0 1 1.42.002L7 8.798V1.996C7 1.446 7.444 1 8 1"/></symbol><symbol id="icon-eds-i-info-filled-medium" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M9 0a9 9 0 1 1 0 18A9 9 0 0 1 9 0m0 7H7.5l-.117.007a1 1 0 0 0-.112 1.967l.112.02L7.5 9H8v3h-.5l-.117.007a1 1 0 0 0-.857.764l-.02.112L6.5 13l.007.117a1 1 0 0 0 .764.857l.112.02L7.5 14h3l.117-.007a1 1 0 0 0 .112-1.967l-.112-.02L10.5 12H10V8l-.007-.117a1 1 0 0 0-.764-.857l-.112-.02zm0-3.25a1.25 1.25 0 1 0 0 2.5 1.25 1.25 0 0 0 0-2.5"/></symbol><symbol id="icon-eds-i-institution-medium" viewBox="0 0 24 24"><path fill-rule="evenodd" d="M11.997 1c-.36 0-.718.09-1.036.265a1 1 0 0 0-.085.052L2.798 6.87a1.7 1.7 0 0 0-.72.897c-.13.389-.098.79.049 1.134C2.42 9.592 3.128 10 3.9 10H5v6h-.5A2.5 2.5 0 0 0 2 18.5v1A2.5 2.5 0 0 0 4.5 22h15a2.5 2.5 0 0 0 2.5-2.5v-1a2.5 2.5 0 0 0-2.5-2.5H19v-6h1.092c.773 0 1.48-.407 1.775-1.1.146-.344.178-.744.048-1.133a1.7 1.7 0 0 0-.72-.897l-8.078-5.553a1 1 0 0 0-.085-.052A2.15 2.15 0 0 0 11.997 1M4.684 8l7.263-4.992a.16.16 0 0 1 .1 0L19.308 8zM17 16v-6h-2v6zm-4 0v-6h-2v6zm-4 0v-6H7v6zm-5 2.5a.5.5 0 0 1 .5-.5h15a.5.5 0 0 1 .5.5v1a.5.5 0 0 1-.5.5h-15a.5.5 0 0 1-.5-.5z" clip-rule="evenodd"/></symbol><symbol id="icon-eds-i-mail-medium" viewBox="0 0 22 18"><path d="M19.462 0C20.875 0 22 1.184 22 2.619v12.762C22 16.816 20.875 18 19.462 18H2.538C1.125 18 0 16.816 0 15.381V2.619C0 1.184 1.125 0 2.538 0zM20 5.158l-7.378 6.258a2.55 2.55 0 0 1-3.253-.008L2 5.16v10.222c0 .353.253.619.538.619h16.924c.285 0 .538-.266.538-.619zM19.462 2H2.538c-.264 0-.5.228-.534.542l8.65 7.334c.2.165.492.165.684.007l8.656-7.342-.001-.025c-.044-.3-.274-.516-.531-.516"/></symbol><symbol id="icon-eds-i-marker-unfilled"><path d="M17.8 3.578c0-.248-.153-.4-.4-.4H6.5c-.248 0-.4.152-.4.4v17.046l5.325-3.737.135-.08a1 1 0 0 1 1.014.08l5.226 3.666zm2 17.527c0 .661-.347 1.231-.895 1.521a1.75 1.75 0 0 1-1.78-.102l-5.126-3.598-5.125 3.598-.06.039a1.84 1.84 0 0 1-1.73.084 1.7 1.7 0 0 1-.984-1.542V3.578c0-1.353 1.048-2.4 2.4-2.4h10.9c1.352 0 2.4 1.047 2.4 2.4z"/></symbol><symbol id="icon-eds-i-menu-medium" viewBox="0 0 24 24"><path d="M21 4a1 1 0 0 1 0 2H3a1 1 0 1 1 0-2zm-4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2zm4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2z"/></symbol><symbol id="icon-eds-i-search-medium" viewBox="0 0 24 24"><path d="M11 1c5.523 0 10 4.477 10 10 0 2.4-.846 4.604-2.256 6.328l3.963 3.965a1 1 0 0 1-1.414 1.414l-3.965-3.963A9.96 9.96 0 0 1 11 21C5.477 21 1 16.523 1 11S5.477 1 11 1m0 2a8 8 0 1 0 0 16 8 8 0 0 0 0-16"/></symbol><symbol id="icon-eds-i-user-single-medium" viewBox="0 0 24 24"><path d="M12 1a5 5 0 1 1 0 10 5 5 0 0 1 0-10m0 2a3 3 0 1 0 0 6 3 3 0 0 0 0-6m-.406 9.008a8.97 8.97 0 0 1 6.596 2.494A9.16 9.16 0 0 1 21 21.025V22a1 1 0 0 1-1 1H4a1 1 0 0 1-1-1v-.985c.05-4.825 3.815-8.777 8.594-9.007m.39 1.992-.299.006c-3.63.175-6.518 3.127-6.678 6.775L5 21h13.998l-.009-.268a7.16 7.16 0 0 0-1.97-4.573l-.214-.213A6.97 6.97 0 0 0 11.984 14"/></symbol><symbol id="icon-eds-i-warning-filled-medium" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M9 11.75a1.25 1.25 0 1 1 0 2.5 1.25 1.25 0 0 1 0-2.5M9.413 4a1 1 0 0 1 1 1l-.003.083-.334 4A1 1 0 0 1 9.08 10h-.16a1 1 0 0 1-.996-.917l-.334-4a1 1 0 0 1 .914-1.08l.041-.002zM9 18A9 9 0 1 1 9 0a9 9 0 0 1 0 18"/></symbol><symbol id="icon-expand-image" viewBox="0 0 18 18"><path fill-rule="evenodd" d="M7.498 11.918a.997.997 0 0 0-.003-1.411.995.995 0 0 0-1.412-.003l-4.102 4.102v-3.51A1 1 0 0 0 .98 10.09.99.99 0 0 0 0 11.092V17c0 .554.448 1.002 1.002 1.002h5.907c.554 0 1.002-.45 1.002-1.003 0-.539-.45-.978-1.006-.978h-3.51zm3.005-5.835a.997.997 0 0 0 .003 1.412.995.995 0 0 0 1.411.003l4.103-4.103v3.51a1 1 0 0 0 1.001 1.006A.99.99 0 0 0 18 6.91V1.002C18 .448 17.553 0 17 0h-5.907c-.554.001-1.002.45-1.002 1.003 0 .539.45.978 1.006.978h3.51z"/></symbol><symbol id="icon-github" viewBox="0 0 100 100"><path fill-rule="evenodd" d="M48.854 0C21.839 0 0 22 0 49.217c0 21.756 13.993 40.172 33.405 46.69 2.427.49 3.316-1.059 3.316-2.362 0-1.141-.08-5.052-.08-9.127-13.59 2.934-16.42-5.867-16.42-5.867-2.184-5.704-5.42-7.17-5.42-7.17-4.448-3.015.324-3.015.324-3.015 4.934.326 7.523 5.052 7.523 5.052 4.367 7.496 11.404 5.378 14.235 4.074.404-3.178 1.699-5.378 3.074-6.6-10.839-1.141-22.243-5.378-22.243-24.283 0-5.378 1.94-9.778 5.014-13.2-.485-1.222-2.184-6.275.486-13.038 0 0 4.125-1.304 13.426 5.052a47 47 0 0 1 12.214-1.63c4.125 0 8.33.571 12.213 1.63 9.302-6.356 13.427-5.052 13.427-5.052 2.67 6.763.97 11.816.485 13.038 3.155 3.422 5.015 7.822 5.015 13.2 0 18.905-11.404 23.06-22.324 24.283 1.78 1.548 3.316 4.481 3.316 9.126 0 6.6-.08 11.897-.08 13.526 0 1.304.89 2.853 3.316 2.364 19.412-6.52 33.405-24.935 33.405-46.691C97.707 22 75.788 0 48.854 0" clip-rule="evenodd"/></symbol><symbol id="icon-orcid-logo" viewBox="0 0 40 40"><path fill-rule="evenodd" d="M12.281 10.453c.875 0 1.578-.719 1.578-1.578s-.703-1.578-1.578-1.578-1.578.703-1.578 1.578c0 .86.703 1.578 1.578 1.578m-1.203 18.641h2.406V12.359h-2.406z"/><path fill-rule="evenodd" d="M17.016 12.36h6.5c6.187 0 8.906 4.421 8.906 8.374 0 4.297-3.36 8.375-8.875 8.375h-6.531zm6.234 14.578h-3.828V14.53h3.703c4.688 0 6.828 2.844 6.828 6.203 0 2.063-1.25 6.203-6.703 6.203Z" clip-rule="evenodd"/></symbol><symbol id="icon-springer-arrow-left"><path d="M15 7a1 1 0 0 0 0-2H3.385l2.482-2.482a.994.994 0 0 0 .02-1.403 1 1 0 0 0-1.417 0L.294 5.292a1 1 0 0 0 0 1.416l4.176 4.177a.99.99 0 0 0 1.4.016 1 1 0 0 0-.003-1.42L3.385 7z"/></symbol><symbol id="icon-springer-arrow-right"><path d="M1 7a1 1 0 0 1 0-2h11.615l-2.482-2.482a.994.994 0 0 1-.02-1.403 1 1 0 0 1 1.417 0l4.176 4.177a1 1 0 0 1 0 1.416l-4.176 4.177a.99.99 0 0 1-1.4.016 1 1 0 0 1 .003-1.42L12.615 7z"/></symbol><symbol id="icon-submit-open" viewBox="0 0 16 17"><path d="M12 0a2 2 0 0 1 2 2v5a.5.5 0 0 1-1 0V2a1 1 0 0 0-.883-.993L12 1H6v3a2 2 0 0 1-2 2H1v8a1 1 0 0 0 .883.993L2 15h6.5a.5.5 0 0 1 0 1H2a2 2 0 0 1-2-2V5.828a2 2 0 0 1 .586-1.414L4.414.586A2 2 0 0 1 5.828 0zm3.41 11.14c.25.25.25.66 0 .91a.636.636 0 0 1-.9-.01l-1.864-1.9.001 5.87a.64.64 0 0 1-.647.636.65.65 0 0 1-.647-.637l-.001-5.87L9.5 12.04a.627.627 0 0 1-.9.01.65.65 0 0 1 0-.91l2.942-2.951a.647.647 0 0 1 .914 0zM5 1.413 1.413 5H4a1 1 0 0 0 1-1zM11 3a.5.5 0 0 1 0 1H7.5a.5.5 0 0 1 0-1zm0 2a.5.5 0 0 1 0 1H7.5a.5.5 0 0 1 0-1z"/></symbol></svg>
</div>
</footer>




    

    

<div class="c-site-messages message u-hide u-hide-print c-site-messages--nature-briefing c-site-messages--nature-briefing-email-variant c-site-messages--nature-briefing-redesign-2020 sans-serif "
data-component-id="nature-briefing-banner"
data-component-expirydays="30"
data-component-trigger-scroll-percentage="15"
data-track="in-view"
data-track-action="in-view"
data-track-category="nature briefing"
data-track-label="Briefing banner visible: Flagship">

    
    <div class="c-site-messages__banner-large">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close"
        data-track="click"
        data-track-category="nature briefing"
        data-track-label="Briefing banner dismiss: Flagship">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__form-container">

            <div class="grid grid-12 last">
                <div class="grid grid-4">
                    <img alt="Nature Briefing" src="/static/images/logos/nature-briefing-logo-n150-white-afc2e6ccc7.svg" width="250" height="40">
                    <p class="c-site-messages--nature-briefing__strapline extra-tight-line-height">Sign up for the <em>Nature Briefing</em> newsletter — what matters in science, free to your inbox daily.</p>
                </div>
                <div class="grid grid-8 last">
                    <form action="https://www.nature.com/briefing/briefing" method="post" data-location="banner" data-track="signup_nature_briefing_banner" data-track-action="transmit-form" data-track-category="nature briefing" data-track-label="Briefing banner submit: Flagship">
                        <input id="briefing-banner-signup-form-input-track-originReferralPoint" type="hidden" name="track_originReferralPoint" value="MainBriefingBanner">
                        <input id="briefing-banner-signup-form-input-track-formType" type="hidden" name="track_formType" value="DirectEmailBanner">

                        <input type="hidden" value="false" name="gdpr_tick" id="gdpr_tick_banner">
                        <input type="hidden" value="false" name="marketing" id="marketing_input_banner">
                        <input type="hidden" value="false" name="marketing_tick" id="marketing_tick_banner">
                        <input type="hidden" value="MainBriefingBanner" name="brieferEntryPoint" id="brieferEntryPoint_banner">

                        <label class="nature-briefing-banner__email-label" for="emailAddress">Email address</label>

                        <div class="nature-briefing-banner__email-wrapper">
                            <input class="nature-briefing-banner__email-input box-sizing text14" type="email" id="emailAddress" name="emailAddress" value="" placeholder="e.g. jo.smith@university.ac.uk" required data-test-element="briefing-emailbanner-email-input">
                            
                            <input type="hidden" value="true" name="N:nature_briefing_daily" id="defaultNewsletter_banner">
                            <button type="submit" class="nature-briefing-banner__submit-button box-sizing text14" data-test-element="briefing-emailbanner-signup-button">Sign up</button>
                        </div>

                        <div class="nature-briefing-banner__checkbox-wrapper grid grid-12 last">
                            <input class="nature-briefing-banner__checkbox-checkbox" id="gdpr-briefing-banner-checkbox" type="checkbox" name="gdpr" value="true" data-test-element="briefing-emailbanner-gdpr-checkbox" required>
                            <label class="nature-briefing-banner__checkbox-label box-sizing text13 sans-serif block tighten-line-height" for="gdpr-briefing-banner-checkbox">I agree my information will be processed in accordance with the <em>Nature</em> and Springer Nature Limited <a href="https://www.nature.com/info/privacy">Privacy Policy</a>.</label>
                        </div>
                    </form>
                </div>
            </div>

        </div>

    </div>

    
    <div class="c-site-messages__banner-small">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close"
        data-track="click"
        data-track-category="nature briefing"
        data-track-label="Briefing banner dismiss: Flagship">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__content text14">
            <span class="c-site-messages--nature-briefing__strapline strong">Get the most important science stories of the day, free in your inbox.</span>
            <a class="nature-briefing__link text14 sans-serif"
                data-track="click"
                data-track-category="nature briefing"
                data-track-label="Small-screen banner CTA to site"
                data-test-element="briefing-banner-link"
                target="_blank"
                rel="noreferrer noopener"
                href="https://www.nature.com/briefing/signup/?brieferEntryPoint=MainBriefingBanner">Sign up for Nature Briefing
            </a>
        </div>

    </div>

</div>






<noscript>
    <img hidden src="https://verify.nature.com/verify/nature.png" width="0" height="0" style="display: none" alt="">
</noscript>




<script src="//content.readcube.com/ping?doi=10.1038/s41591-026-04206-y&amp;format=js&amp;last_modified=2026-02-19" async></script>
</body>
</html>